10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

xQuarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended September 30, 2012

oTransition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period From                    to                     .

Commission File Numbers: 001 — 34465 and 001 — 31441

SELECT MEDICAL HOLDINGS CORPORATION

SELECT MEDICAL CORPORATION

(Exact name of Registrants as specified in their charters)

Delaware Delaware
(State or other jurisdiction of
incorporation or organization) 20-1764048 23-2872718
(I.R.S. employer identification
number)

4714 Gettysburg Road, P.O. Box 2034, Mechanicsburg, Pennsylvania 17055

(Address of principal executive offices and zip code)

(717) 972-1100

(Registrants’ telephone number, including area code)

Indicate by check mark whether the Registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the Registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days.  YES x   NO o

Indicate by check mark whether the Registrants have submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrants were required to submit and post such files).   YES x   NO o

Indicate by check mark whether the Registrants are large accelerated filers, accelerated filers, non-accelerated filers, or smaller reporting companies.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer x
Non-accelerated filer o	Smaller reporting company o

Indicate by check mark whether the Registrants are shell companies (as defined in Rule 12b-2 of the Exchange Act). YES o NO x

As of October 31, 2012, Select Medical Holdings Corporation had outstanding 140,520,316 shares of common stock.

This Form 10-Q is a combined quarterly report being filed separately by two Registrants: Select Medical Holdings Corporation and Select Medical Corporation.  Unless the context indicates otherwise, any reference in this report to “Holdings” refers to Select Medical Holdings Corporation and any reference to “Select” refers to Select Medical Corporation, the wholly-owned operating subsidiary of Holdings.  References to the “Company,” “we,” “us,” and “our” refer collectively to Select Medical Holdings Corporation and Select Medical Corporation.

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	3
ITEM 1.	CONSOLIDATED FINANCIAL STATEMENTS
	Consolidated balance sheets	3
	Consolidated statements of operations	4
	Consolidated statements of changes in stockholders’ equity and income	6
	Consolidated statements of cash flows	7
	Notes to consolidated financial statements	8
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	28
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	54
ITEM 4.	CONTROLS AND PROCEDURES	54
PART II	OTHER INFORMATION	55
ITEM 1.	LEGAL PROCEEDINGS	55
ITEM 1A.	RISK FACTORS	56
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	56
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	56
ITEM 4.	MINE SAFETY DISCLOSURES	56
ITEM 5.	OTHER INFORMATION	56
ITEM 6.	EXHIBITS	57
SIGNATURES

2

PART I FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

	Select Medical Holdings Corporation				Select Medical Corporation
	December 31,		September 30,		December 31,		September 30,
	2011		2012		2011		2012
ASSETS
Current Assets:
Cash and cash equivalents	$	12,043	$	49,676	$	12,043	$	49,676
Accounts receivable, net of allowance for doubtful accounts of $47,469 and $45,719 in 2011 and 2012, respectively	413,743		392,647		413,743		392,647
Current deferred tax asset	18,305		17,978		18,305		17,978
Prepaid income taxes	9,497		1,410		9,497		1,410
Other current assets	29,822		31,620		29,822		31,620
Total Current Assets	483,410		493,331		483,410		493,331
Property and equipment, net	510,028		494,625		510,028		494,625
Goodwill	1,631,716		1,633,106		1,631,716		1,633,106
Other identifiable intangibles	72,123		71,783		72,123		71,783
Assets held for sale	2,742		2,742		2,742		2,742
Other assets	72,128		86,221		70,719		85,091
Total Assets	$	2,772,147	$	2,781,808	$	2,770,738	$	2,780,678
LIABILITIES AND EQUITY
Current Liabilities:
Bank overdrafts	$	16,609	$	13,598	$	16,609	$	13,598
Current portion of long-term debt and notes payable	10,848		11,084		10,848		11,084
Accounts payable	95,618		91,520		95,618		91,520
Accrued payroll	82,888		83,683		82,888		83,683
Accrued vacation	51,250		53,210		51,250		53,210
Accrued interest	15,096		13,921		11,980		13,413
Accrued restructuring	5,027		2,015		5,027		2,015
Accrued other	101,076		99,004		106,316		99,004
Due to third party payors	5,526		5,886		5,526		5,886
Total Current Liabilities	383,938		373,921		386,062		373,413
Long-term debt, net of current portion	1,385,950		1,330,549		1,218,650		1,163,249
Non-current deferred tax liability	82,028		84,118		82,028		84,118
Other non-current liabilities	64,905		70,502		64,905		70,502
Total Liabilities	1,916,821		1,859,090		1,751,645		1,691,282
Stockholders’ Equity:
Common stock of Holdings, $0.001 par value, 700,000,000 shares authorized, 145,268,190 shares and 139,991,156 shares issued and outstanding in 2011 and 2012, respectively	145		140		—		—
Common stock of Select, $0.01 par value, 100 shares issued and outstanding	—		—		0		0
Capital in excess of par	493,828		471,358		848,844		856,446
Retained earnings	328,882		418,071		137,778		199,801
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	822,855		889,569		986,622		1,056,247
Non-controlling interest	32,471		33,149		32,471		33,149
Total Equity	855,326		922,718		1,019,093		1,089,396
Total Liabilities and Equity	$	2,772,147	$	2,781,808	$	2,770,738	$	2,780,678

The accompanying notes are an integral part of these consolidated financial statements.

3

Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Three Months Ended September 30,						For the Three Months Ended September 30,
	2011			2012			2011			2012
Net operating revenues	$	694,131		$	713,669		$	694,131		$	713,669
Costs and expenses:
Cost of services	581,829			598,984			581,829			598,984
General and administrative	14,975			17,130			14,975			17,130
Bad debt expense	11,709			11,199			11,709			11,199
Depreciation and amortization	17,545			15,537			17,545			15,537
Total costs and expenses	626,058			642,850			626,058			642,850
Income from operations	68,073			70,819			68,073			70,819
Other income and expense:
Loss on early retirement of debt	—			(6,064		)	—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	1,653			1,167			1,653			1,167
Interest income	119			—			119			—
Interest expense	(24,134		)	(24,575		)	(21,526		)	(21,740		)
Income before income taxes	45,711			41,347			48,319			44,182
Income tax expense	19,330			16,189			20,243			17,181
Net income	26,381			25,158			28,076			27,001
Less: Net income attributable to non-controlling interests	785			1,048			785			1,048
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	25,596		$	24,110		$	27,291		$	25,953
Income per common share:
Basic	$	0.17		$	0.17
Diluted	$	0.17		$	0.17

The accompanying notes are an integral part of these consolidated financial statements.

4

Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Nine Months Ended September 30,						For the Nine Months Ended September 30,
	2011			2012			2011			2012
Net operating revenues	$	2,086,066		$	2,207,883		$	2,086,066		$	2,207,883
Costs and expenses:
Cost of services	1,708,911			1,823,272			1,708,911			1,823,272
General and administrative	47,656			49,908			47,656			49,908
Bad debt expense	40,002			31,603			40,002			31,603
Depreciation and amortization	52,766			47,164			52,766			47,164
Total costs and expenses	1,849,335			1,951,947			1,849,335			1,951,947
Income from operations	236,731			255,936			236,731			255,936
Other income and expense:
Loss on early retirement of debt	(31,018		)	(6,064		)	(20,385		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries	1,329			6,384			1,329			6,384
Interest income	286			—			286			—
Interest expense	(75,094		)	(72,295		)	(59,882		)	(63,947		)
Income before income taxes	132,234			183,961			158,079			192,309
Income tax expense	56,809			71,415			65,854			74,337
Net income	75,425			112,546			92,225			117,972
Less: Net income attributable to non-controlling interests	4,438			3,722			4,438			3,722
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	70,987		$	108,824		$	87,787		$	114,250
Income per common share:
Basic	$	0.46		$	0.77
Diluted	$	0.46		$	0.77

The accompanying notes are an integral part of these consolidated financial statements.

5

Select Medical Holdings Corporation

Consolidated Statement of Changes in Equity and Income

(unaudited)

(in thousands)

				Select Medical Holdings Corporation Stockholders
	Total			Common Stock Issued		Common Stock Par Value			Capital in Excess of Par			Retained Earnings			Non-controlling Interests
Balance at December 31, 2011	$	855,326		145,268		$	145		$	493,828		$	328,882		$	32,471
Net income	112,546											108,824			3,722
Issuance and vesting of restricted stock	3,085			232		0			3,085
Exercise of stock options	1,104			217		0			1,104
Stock option expense	905								905
Repurchase of common shares	(46,790		)	(5,726	)	(5		)	(27,150		)	(19,635		)
Distributions to non-controlling interests	(2,997		)												(2,997		)
Purchase of non-controlling interests	(477		)						(414		)				(63		)
Other	16														16
Balance at September 30, 2012	$	922,718		139,991		$	140		$	471,358		$	418,071		$	33,149

Select Medical Corporation

Consolidated Statement of Changes in Equity and Income

(unaudited)

(in thousands)

				Select Medical Corporation Stockholders
	Total			Common Stock Issued	Common Stock Par Value		Capital in Excess of Par			Retained Earnings			Non-controlling Interests
Balance at December 31, 2011	$	1,019,093		0	$	0	$	848,844		$	137,778		$	32,471
Net income	117,972									114,250			3,722
Federal tax benefit of losses contributed by Holdings	2,922						2,922
Additional investment by Holdings	1,104						1,104
Net change in dividends payable to Holdings	5,240									5,240
Dividends declared and paid to Holdings	(57,467		)							(57,467		)
Distributions to non-controlling interests	(2,997		)										(2,997		)
Purchase of non-controlling interests	(477		)				(414		)				(63		)
Other	16												16
Contribution related to restricted stock awards and stock option issuances by Holdings	3,990						3,990
Balance at September 30, 2012	$	1,089,396		0	$	0	$	856,446		$	199,801		$	33,149

The accompanying notes are an integral part of these consolidated financial statements.

6

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Nine Months Ended September 30,						For the Nine Months Ended September 30,
	2011			2012			2011			2012
Operating activities
Net income	$	75,425		$	112,546		$	92,225		$	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	52,766			47,164			52,766			47,164
Provision for bad debts	40,002			31,603			40,002			31,603
Loss on early retirement of debt	31,018			6,064			20,385			6,064
Gain from disposal or sale of assets	(5,182		)	(3,484		)	(5,182		)	(3,484		)
Non-cash stock compensation expense	2,698			3,990			2,698			3,990
Amortization of debt discount	1,271			1,123			412			1,123
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable	(81,466		)	(10,507		)	(81,466		)	(10,507		)
Other current assets	240			(1,849		)	240			(1,849		)
Other assets	1,072			(743		)	723			(1,022		)
Accounts payable	14,008			(4,098		)	14,008			(4,098		)
Due to third-party payors	(1,050		)	360			(1,050		)	360
Accrued expenses	(12,566		)	348			(3,650		)	2,956
Income and deferred taxes	25,678			11,559			34,723			14,481
Net cash provided by operating activities	143,914			194,076			166,834			204,753
Investing activities
Purchases of property and equipment	(32,094		)	(45,188		)	(32,094		)	(45,188		)
Proceeds from sale of assets	7,879			16,511			7,879			16,511
Investment in business, net of distributions	(13,514		)	(9,899		)	(13,514		)	(9,899		)
Acquisition of businesses, net of cash acquired	1,921			(1,547		)	1,921			(1,547		)
Net cash used in investing activities	(35,808		)	(40,123		)	(35,808		)	(40,123		)
Financing activities
Borrowings on revolving credit facilities	595,000			365,000			595,000			365,000
Payments on revolving credit facilities	(570,000		)	(405,000		)	(570,000		)	(405,000		)
Borrowings on 2011 credit facility term loans, net of discount	841,500			266,750			841,500			266,750
Payments on 2011 credit facility term loans	(2,125		)	(7,063		)	(2,125		)	(7,063		)
Payments on 2005 credit facility term loans, net of premium	(484,633		)	—			(484,633		)	—
Repurchase of 10% senior subordinated notes	(150,000		)	—			—			—
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(273,941		)	(278,495		)	(273,941		)	(278,495		)
Borrowings of other debt	5,496			5,835			5,496			5,835
Principal payments on other debt	(5,846		)	(7,417		)	(5,846		)	(7,417		)
Debt issuance costs	(18,556		)	(4,236		)	(18,556		)	(4,236		)
Dividends paid to Holdings	—			—			(204,561		)	(57,467		)
Repurchase of common stock	(31,641		)	(46,790		)	—			—
Proceeds from issuance of common stock	169			1,104			—			—
Equity investment by Holdings	—			—			169			1,104
Repayment of bank overdrafts	(4,174		)	(3,011		)	(4,174		)	(3,011		)
Distributions to non-controlling interests	(3,507		)	(2,997		)	(3,507		)	(2,997		)
Net cash used in financing activities	(102,258		)	(116,320		)	(125,178		)	(126,997		)
Net increase in cash and cash equivalents	5,848			37,633			5,848			37,633
Cash and cash equivalents at beginning of period	4,365			12,043			4,365			12,043
Cash and cash equivalents at end of period	$	10,213		$	49,676		$	10,213		$	49,676
Supplemental Cash Flow Information
Cash paid for interest	$	94,632		$	68,122		$	71,719		$	57,448
Cash paid for taxes	$	31,105		$	59,850		$	31,105		$	59,850

The accompanying notes are an integral part of these consolidated financial statements.

7

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1.Basis of Presentation

        Select Medical Corporation (“Select”) was formed in December 1996 and commenced operations during February 1997 upon the completion of its first acquisition. Select Medical Holdings Corporation (“Holdings”) was formed in October 2004 for the purpose of affecting a leveraged buyout of Select, which was a publicly traded entity.  On February 24, 2005, Select merged with a subsidiary of Holdings, which resulted in Select becoming a wholly-owned subsidiary of Holdings (the “Merger”). On September 30, 2009 Holdings completed its initial public offering of common stock.  Generally accepted accounting principles (“GAAP”) require that any amounts recorded or incurred (such as goodwill and compensation expense) by the parent as a result of the Merger or for the benefit of the subsidiary be “pushed down” and recorded in Select’s consolidated financial statements. Holdings and Select and their subsidiaries are collectively referred to as the “Company.” The consolidated financial statements of Holdings include the accounts of its wholly-owned subsidiary Select. Holdings conducts substantially all of its business through Select and its subsidiaries.

        The unaudited condensed consolidated financial statements of the Company as of September 30, 2012 and for the three and nine month periods ended September 30, 2011 and 2012 have been prepared in accordance with GAAP.  In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods.  All significant intercompany transactions and balances have been eliminated.  The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2012.

        Certain information and disclosures normally included in the notes to consolidated financial statements have been condensed or omitted consistent with the rules and regulations of the Securities and Exchange Commission (the “SEC”), although the Company believes the disclosure is adequate to make the information presented not misleading.  The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2011 contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2012.

2.Accounting Policies

Use of Estimates

        The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

8

Recent Accounting Pronouncements

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2012-02, “Intangibles — Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment,” (“Update 2012-02”). In accordance with Update 2012-02, an entity has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. If the entity determines that it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, the entity will be required to perform the quantitative impairment test. Update 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. However, early adoption is permitted. Update 2012-02 will not have a material impact on the Company’s consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05, “Comprehensive Income (Topic 220) — Presentation of Comprehensive Income” (“Update 2011-05”) that improves the comparability, consistency and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders’ equity. Update 2011-05 requires that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income (“OCI”) to net income, in both net income and OCI. Update 2011-05 does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, Update 2011-05 does not affect the calculation or reporting of earnings per share. Update 2011-05 was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 and is to be applied retrospectively. The Company adopted Update 2011-05 on January 1, 2012.  Update 2011-05 had no effect on the Company’s presentation of other comprehensive income for the three and nine months ended September 30, 2011 and 2012 because the Company did not have any items of other comprehensive income during these periods.

3.  Intangible Assets

The Company’s intangible assets consist of the following:

	As of September 30, 2012
	Gross Carrying Amount		Accumulated Amortization
	(in thousands)
Amortized intangible assets:
Non-compete agreements	$	25,909	$	(25,909	)
Indefinite-lived intangible assets:
Goodwill	$	1,633,106
Trademarks	57,709
Certificates of need	11,914
Accreditations	2,160
Total	$	1,704,889

9

The Company’s accreditations and trademarks have renewal terms. The costs to renew these intangibles are expensed as incurred. At September 30, 2012, the accreditations and trademarks have a weighted average time until next renewal of approximately 1.5 years and 7.7 years, respectively.

Amortization expense for the Company’s intangible assets with finite lives follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2011		2012		2011		2012
	(in thousands)				(in thousands)
Amortization expense	$	328	$	—	$	981	$	340

Amortization expense for the Company’s intangible assets primarily relates to the amortization of the value associated with the non-compete agreement entered into in connection with the acquisition of the outpatient rehabilitation division of HealthSouth Corporation. The useful life of the outpatient rehabilitation division of HealthSouth Corporation’s non-compete was five years.

The changes in the carrying amount of goodwill for the Company’s reportable segments for the nine months ended September 30, 2012 are as follows:

	Specialty Hospitals			Outpatient Rehabilitation		Total
	(in thousands)
Balance as of December 31, 2011	$	1,333,553		$	298,163	$	1,631,716
Goodwill acquired during the period	—			1,723		1,723
Other	(333		)	—		(333		)
Balance as of September 30, 2012	$	1,333,220		$	299,886	$	1,633,106

4.  Restructuring Reserves

In connection with the acquisition of substantially all of the outpatient rehabilitation division of HealthSouth Corporation, the Company recorded an estimated liability of $18.7 million in 2007 for business restructuring which was accounted for as additional purchase price. This reserve primarily included costs associated with workforce reductions and lease termination costs in accordance with the Company’s restructuring plan of which only lease termination costs remain.

In connection with the acquisition of all the issued and outstanding equity securities of Regency Hospital Company, L.L.C. (“Regency”), an operator of long term acute care hospitals, the Company recorded an estimated liability of $4.3 million in 2010 for business restructuring related to lease termination costs.

10

The following summarizes the Company’s restructuring activity:

	Lease Termination Costs
	(in thousands)
Balance as of December 31, 2011	$	5,027
Amounts paid in 2012	(1,169		)
Accretion expense	202
Revision of estimate	(2,045		)
Balance as of September 30, 2012	$	2,015

The Company expects to pay out the remaining lease termination costs through 2014 for the acquisition of the outpatient rehabilitation division of HealthSouth Corporation and through 2015 for the Regency acquisition.

5. Indebtedness

The components of long-term debt and notes payable are shown in the following tables:

	Holdings				Select
	December 31, 2011		September 30, 2012		December 31, 2011		September 30, 2012
	(in thousands)				(in thousands)
7 5/8 % senior subordinated notes	$	345,000	$	70,000	$	345,000	$	70,000
Senior secured credit facilities:
Revolving loan	40,000		—		40,000		—
Term loans (1)	837,974		1,098,784		837,974		1,098,784
Senior floating rate notes	167,300		167,300		—		—
Other debt	6,524		5,549		6,524		5,549
Total debt	1,396,798		1,341,633		1,229,498		1,174,333
Less: current maturities	10,848		11,084		10,848		11,084
Total long-term debt	$	1,385,950	$	1,330,549	$	1,218,650	$	1,163,249

(1)Includes unamortized discount of $7.8 million and $14.9 million at December 31, 2011 and September 30, 2012, respectively.

On August 13, 2012, Select, Holdings and the subsidiaries of Select named therein entered into an Additional Credit Extension Amendment (the “Extension Amendment”) to Select’s senior secured credit facility with a group of lenders and JPMorgan Chase Bank, N.A. as administrative agent.  Pursuant to the terms and conditions of the Extension Amendment, the lenders extended Series A Tranche B Term Loans in the aggregate principal amount of $275.0 million to Select at the same interest rate and with the same term as applies to other Tranche B Term Loan amounts borrowed by Select under the senior secured credit facility.  On September 12, 2012, Select used the proceeds of the Series A Tranche B Term Loans (other than amounts used for fees and expenses) and cash on hand to redeem an aggregate of $275.0 million principal amount of Select’s outstanding 7 5/8% senior subordinated notes due 2015 at a redemption price of 101.271% of the principal amount.  Select recognized a loss on early retirement of debt of $6.1 million for the three and nine months ended September 30, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

11

Maturities of Long-Term Debt and Notes Payable

Maturities of the Company’s long-term debt for the period from October 1, 2012 through December 31, 2012 and the years after 2012 are approximately as follows and are presented net of the discount on the senior secured credit facilities’ term loans:

	Holdings		Select
	(in thousands)		(in thousands)
October 1, 2012 – December 31, 2012	$	4,173	$	4,173
2013	9,652		9,652
2014	9,136		9,136
2015	246,345		79,045
2016	8,684		8,684
2017 and beyond	1,063,643		1,063,643

6.  Fair Value

Financial instruments include cash and cash equivalents, notes payable and long-term debt.  The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.

The carrying value of Select’s senior secured credit facility was $878.0 million and $1,098.8 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of Select’s senior secured credit facility was $823.3 million and $1,104.3 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of Select’s senior secured credit facility was based on quoted market prices for this debt in the syndicated loan market.

The carrying value of Select’s 7 5/8% senior subordinated notes was $345.0 million and $70.0 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of Select’s 7 5/8% senior subordinated notes was $326.4 million and $70.9 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of this registered debt was based on quoted market prices.

The carrying value of Holdings’ senior floating rate notes was $167.3 million at both December 31, 2011 and September 30, 2012.  The fair value of Holdings’ senior floating rate notes was $143.9 million and $167.3 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of this registered debt was based on quoted market prices.

The Company considers the inputs in the valuation process of its debt instruments to be Level 2 in the fair value hierarchy.  Level 2 in the fair value hierarchy is defined as inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.  These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

12

7.  Segment Information

The Company’s reportable segments consist of (i) specialty hospitals and (ii) outpatient rehabilitation. All other represents amounts associated with corporate activities and non-healthcare related services. The outpatient rehabilitation reportable segment has two operating segments: outpatient rehabilitation clinics and contract therapy. These operating segments are aggregated for reporting purposes as they have common economic characteristics and provide a similar service to a similar patient base. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries and other income (expense).

The following tables summarize selected financial data for the Company’s reportable segments for the three and nine months ended September 30, 2011 and 2012.  The segment results of Holdings are identical to those of Select with the exception of total assets:

	Three Months Ended September 30, 2011
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	521,085	$	173,030	$	16		$	694,131
Adjusted EBITDA	81,570		19,435		(14,469		)	86,536
Total assets:
Select Medical Corporation	2,191,493		468,551		89,568			2,749,612
Select Medical Holdings Corporation	2,191,493		468,551		91,066			2,751,110
Capital expenditures	4,957		3,160		281			8,398

	Three Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	531,409	$	182,246	$	14		$	713,669
Adjusted EBITDA	83,659		20,354		(16,266		)	87,747
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	12,281		3,073		1,900			17,254

13

	Nine Months Ended September 30, 2011
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	1,561,270	$	524,694	$	102		$	2,086,066
Adjusted EBITDA	273,004		65,308		(46,117		)	292,195
Total assets:
Select Medical Corporation	2,191,493		468,551		89,568			2,749,612
Select Medical Holdings Corporation	2,191,493		468,551		91,066			2,751,110
Capital expenditures	21,574		8,142		2,378			32,094

	Nine Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	1,641,577	$	566,195	$	111		$	2,207,883
Adjusted EBITDA	285,779		68,669		(47,358		)	307,090
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	31,963		9,786		3,439			45,188

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended September 30, 2011
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	81,570		$	19,435		$	(14,469	)
Depreciation and amortization	(12,828		)	(4,003		)	(714		)
Stock compensation expense	—			—			(918		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	68,742		$	15,432		$	(16,101	)	$	68,073		$	68,073
Equity in earnings of unconsolidated subsidiaries										1,653			1,653
Interest expense, net										(24,015		)	(21,407		)
Income before income taxes										$	45,711		$	48,319

14

	Three Months Ended September 30, 2012
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	83,659		$	20,354		$	(16,266	)
Depreciation and amortization	(11,553		)	(3,152		)	(832		)
Stock compensation expense	—			—			(1,391		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	72,106		$	17,202		$	(18,489	)	$	70,819		$	70,819
Loss on early retirement of debt										(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries										1,167			1,167
Interest expense, net										(24,575		)	(21,740		)
Income before income taxes										$	41,347		$	44,182

	Nine Months Ended September 30, 2011
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	273,004		$	65,308		$	(46,117	)
Depreciation and amortization	(37,921		)	(12,689		)	(2,156		)
Stock compensation expense	—			—			(2,698		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	235,083		$	52,619		$	(50,971	)	$	236,731		$	236,731
Loss on early retirement of debt										(31,018		)	(20,385		)
Equity in earnings of unconsolidated subsidiaries										1,329			1,329
Interest expense, net										(74,808		)	(59,596		)
Income before income taxes										$	132,234		$	158,079

15

	Nine Months Ended September 30, 2012
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	285,779		$	68,669		$	(47,358	)
Depreciation and amortization	(34,875		)	(10,034		)	(2,255		)
Stock compensation expense	—			—			(3,990		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	250,904		$	58,635		$	(53,603	)	$	255,936		$	255,936
Loss on early retirement of debt										(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries										6,384			6,384
Interest expense, net										(72,295		)	(63,947		)
Income before income taxes										$	183,961		$	192,309

8.  Income per Common Share

The Company applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings. Effective January 1, 2009 the Financial Accounting Standards Board (“FASB”) clarified that share based payment awards that have not yet vested meet the definition of a participating security provided the right to receive the dividend is non-forfeitable and non-contingent. Participating securities are defined as securities that participate in dividends with common stock according to a predetermined formula. These participating securities should be included in the computation of basic earnings per share under the two class method. Based upon the clarification made by FASB, the Company concluded that its non-vested restricted stock awards meet the definition of a participating security and should be included in the Company’s computation of basic earnings per share.

16

The following table sets forth for the periods indicated the calculation of net income per share in the Company’s consolidated statement of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2011		2012		2011		2012
	(in thousands, except per share data)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	25,596	$	24,110	$	70,987	$	108,824
Less: Earnings allocated to unvested restricted stockholders	278		407		763		1,759
Net income available to common stockholders	$	25,318	$	23,703	$	70,224	$	107,065
Denominator:
Weighted average shares — basic	151,470		137,551		152,299		139,138
Effect of dilutive securities:
Stock options	206		337		223		266
Weighted average shares — diluted	151,676		137,888		152,522		139,404
Basic income per common share	$	0.17	$	0.17	$	0.46	$	0.77
Diluted income per common share	$	0.17	$	0.17	$	0.46	$	0.77

The following share amounts are shown here for informational and comparative purposes only since their inclusion would be anti-dilutive:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2011	2012	2011	2012
	(in thousands)
Stock options	2,437	78	2,412	1,683

9. Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”) or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the

17

aggregate, have a material adverse effect on the Company’s business, financial position, results of operations and liquidity.

To address claims arising out of the operations of the Company’s specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

During April 2012, the Company’s long term acute care hospital in Evansville, Indiana (“SSH - Evansville”) received two subpoenas from the Office of Attorney General for the State of Indiana. One subpoena demanded certain patient medical records of SSH - Evansville. The second subpoena demanded reports and documents related to SSH - Evansville for various periods beginning in 2006, including certain financial, statistical, billing and quality reports; certain policies and procedures, joint venture board meeting minutes, and documents related to certain complaints and internal investigations. SSH — Evansville subsequently received a Request for Information or Assistance from the Office of Inspector General of the U.S. Department of Health and Human Services (Indianapolis, Indiana Field Office) covering the period beginning in 2007 seeking substantially the same records demanded by the Indiana Attorney General’s Office, additional patient medical records of SSH - Evansville and additional documents and information of SSH - Evansville, including documents concerning SSH - Evansville’s relationships with its joint venture partner and seven other identified persons and entities. During May 2012, the Evansville (Indiana) Police Department executed a search warrant at SSH - Evansville purporting to seek evidence pertaining to the crime of theft. At the Company’s request, the Vanderburgh (Indiana) Superior Court ordered the release of the probable cause affidavit supporting that search warrant. According to the affidavit, confidential informants, some of whom are purportedly current or former employees of SSH-Evansville, alleged, among other things, that a physician on the medical staff at SSH-Evansville improperly manipulated patient diagnoses to raise the diagnosis related group (DRG) and lengths-of-stay to enhance reimbursement and, on one occasion, discontinued treatments to a patient based on financial motivation and without regard to the patient’s end of life instructions resulting in the patient’s death, and that a second physician on the medical staff at SSH-Evansville performed bronchoscopes that were medically unnecessary and resulted in at least two patient deaths. The affidavit also makes allegations that imply that the Company may not have provided complete or accurate documents called for in the Indiana Attorney General’s Office subpoenas which were received during April 2012. In August 2012, the Company received a subpoena from the Office of Inspector General of the U.S. Department of Health and Human Services (Chicago Regional Office) (“OIG — Chicago”) demanding additional documents covering the period beginning in March 2007 relating to the Company and SSH — Evansville, including contracts with SSH — Evansville’s joint venture partner, contracts and other documents relating to financial relationships with

18

physicians practicing at SSH —Evansville, records of payments to and hours worked by physicians practicing at SSH — Evansville, documents relating to actual or expected physician referrals and admissions to SSH — Evansville, documents relating to billing for services furnished by the Company’s long term acute care hospitals (“LTCHs”), such as government program guidance and staff training materials, information relating to case manager duties and responsibilities at the Company’s LTCHs, reports on patient admissions, discharges, DRG, length-of-stay and transfers at SSH — Evansville, and documents relating to criteria used by the Company or SSH — Evansville for patient admissions, discharges and eligibility for service. In October 2012, the Company received an additional subpoena from OIG — Chicago seeking the medical records of 19 patients treated at SSH — Evansville between 2008 and 2012.  The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

Construction Commitments

At September 30, 2012, the Company had outstanding commitments under construction contracts related to new construction, improvements and renovations at the Company’s long term acute care properties and inpatient rehabilitation facilities totaling approximately $10.8 million.

10.Subsequent Events

On October 30, 2012, Holdings’ board of directors declared a special cash dividend of $1.50 per share, totaling approximately $210.8 million.  This special cash dividend will be paid on or about December 12, 2012 to all stockholders of record at the close of business on December 5, 2012. Select is entering into an amendment to its senior secured credit facility that provides Holdings and Select with additional flexibility to make certain restricted payments, including the payment of dividends.

11.Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select’s 7 5/8% Senior Subordinated Notes

Select’s 7 5/8% senior subordinated notes are fully and unconditionally guaranteed, except for customary limitations, on a senior subordinated basis by all of Select’s wholly-owned subsidiaries (the “Subsidiary Guarantors”). Certain of Select’s subsidiaries did not guarantee the 7 5/8% senior subordinated notes (the “Non-Guarantor Subsidiaries”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors and the Non-Guarantor Subsidiaries at December 31, 2011 and September 30, 2012 and for the three and nine months ended September 30, 2011 and 2012.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

19

Select Medical Corporation

Condensed Consolidating Balance Sheet

September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	45,069		$	3,535		$	1,072		$	—		$	49,676
Accounts receivable, net	—			334,826			57,821			—			392,647
Current deferred tax asset	11,673			2,698			3,607			—			17,978
Prepaid income taxes	1,410			—			—			—			1,410
Other current assets	5,158			21,497			4,965			—			31,620
Total Current Assets	63,310			362,556			67,465			—			493,331
Property and equipment, net	15,823			421,493			57,309			—			494,625
Investment in affiliates	2,889,285			80,859			—			(2,970,144		)(a) (b)	—
Goodwill	—			1,633,106			—			—			1,633,106
Other identifiable intangibles	—			71,783			—			—			71,783
Assets held for sale	2,742			—			—			—			2,742
Other assets	24,898			59,482			711			—			85,091
Total Assets	$	2,996,058		$	2,629,279		$	125,485		$	(2,970,144	)	$	2,780,678
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	13,598		$	—		$	—		$	—		$	13,598
Current portion of long-term debt and notes payable	9,062			585			1,437			—			11,084
Accounts payable	7,771			70,365			13,384			—			91,520
Intercompany accounts	1,058,973			(963,967		)	(95,006		)	—			—
Accrued payroll	72			83,293			318			—			83,683
Accrued vacation	4,120			42,565			6,525			—			53,210
Accrued interest	12,504			909			—			—			13,413
Accrued restructuring	—			2,015			—			—			2,015
Accrued other	50,778			40,287			7,939			—			99,004
Due to third party payors	—			2,705			3,181			—			5,886
Total Current Liabilities	1,156,878			(721,243		)	(62,222		)	—			373,413
Long-term debt, net of current portion	736,945			364,287			62,017			—			1,163,249
Non-current deferred tax liability	(4,715		)	80,258			8,575			—			84,118
Other non-current liabilities	50,703			19,546			253			—			70,502
Total Liabilities	1,939,811			(257,152		)	8,623			—			1,691,282
Stockholder’s Equity:
Common stock	0			—			—			—			0
Capital in excess of par	856,446			—			—			—			856,446
Retained earnings	199,801			752,267			24,428			(776,695		)(b)	199,801
Subsidiary investment	—			2,134,164			59,285			(2,193,449		)(a)	—
Total Select Medical Corporation Stockholder’s Equity	1,056,247			2,886,431			83,713			(2,970,144		)	1,056,247
Non-controlling interest	—			—			33,149			—			33,149
Total Equity	1,056,247			2,886,431			116,862			(2,970,144		)	1,089,396
Total Liabilities and Equity	$	2,996,058		$	2,629,279		$	125,485		$	(2,970,144	)	$	2,780,678

(a)  Elimination of investments in consolidated subsidiaries.

(b)  Elimination of investments in consolidated subsidiaries’ earnings.

20

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	14		$	616,610		$	97,045		$	—		$	713,669
Costs and expenses:
Cost of services	544			514,136			84,304			—			598,984
General and administrative	17,742			(612		)	—			—			17,130
Bad debt expense	—			9,525			1,674			—			11,199
Depreciation and amortization	832			12,372			2,333			—			15,537
Total costs and expenses	19,118			535,421			88,311			—			642,850
Income (loss) from operations	(19,104		)	81,189			8,734			—			70,819
Other income and expense:
Intercompany interest and royalty fees	(469		)	459			10			—			—
Intercompany management fees	34,811			(29,960		)	(4,851		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			1,146			21			—			1,167
Interest expense	(14,676		)	(6,010		)	(1,054		)	—			(21,740		)
Income (loss) from operations before income taxes	(5,502		)	46,824			2,860			—			44,182
Income tax expense (benefit)	(3,589		)	21,020			(250		)	—			17,181
Equity in earnings of subsidiaries	27,866			2,123			—			(29,989		)(a)	—
Net income	25,953			27,927			3,110			(29,989		)	27,001
Less: Net income attributable to non-controlling interests	—			—			1,048			—			1,048
Net income attributable to Select Medical Corporation	$	25,953		$	27,927		$	2,062		$	(29,989	)	$	25,953

(a) Elimination of equity in earnings of subsidiaries.

21

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	111		$	1,910,563		$	297,209		$	—		$	2,207,883
Costs and expenses:
Cost of services	1,554			1,567,080			254,638			—			1,823,272
General and administrative	51,197			(1,289		)	—			—			49,908
Bad debt expense	—			27,199			4,404			—			31,603
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Total costs and expenses	55,006			1,630,942			265,999			—			1,951,947
Income (loss) from operations	(54,895		)	279,621			31,210			—			255,936
Other income and expense:
Intercompany interest and royalty fees	(2,025		)	1,998			27			—			—
Intercompany management fees	91,940			(78,202		)	(13,738		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			6,340			44			—			6,384
Interest expense	(40,823		)	(19,920		)	(3,204		)	—			(63,947		)
Income (loss) from operations before income taxes	(11,867		)	189,837			14,339			—			192,309
Income tax expense (benefit)	(1,613		)	75,924			26			—			74,337
Equity in earnings of subsidiaries	124,504			11,234			—			(135,738		)(a)	—
Net income	114,250			125,147			14,313			(135,738		)	117,972
Less: Net income attributable to non-controlling interests	—			—			3,722			—			3,722
Net income attributable to Select Medical Corporation	$	114,250		$	125,147		$	10,591		$	(135,738	)	$	114,250

(a) Elimination of equity in earnings of subsidiaries.

22

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	114,250		$	125,147		$	14,313		$	(135,738	)(a)	$	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Provision for bad debts	—			27,199			4,404			—			31,603
Loss on early retirement of debt	6,064			—			—			—			6,064
Loss (gain) from disposal of assets	—			(3,501		)	17			—			(3,484		)
Non-cash stock compensation expense	3,990			—			—			—			3,990
Amortization of debt discount	1,123			—			—			—			1,123
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(124,504		)	(11,234		)	—			135,738		(a)	—
Intercompany	73,693			(65,471		)	(8,222		)	—			—
Accounts receivable	—			7,296			(17,803		)	—			(10,507		)
Other current assets	1,182			(2,141		)	(890		)	—			(1,849		)
Other assets	3,488			(4,652		)	142			—			(1,022		)
Accounts payable	418			(5,842		)	1,326			—			(4,098		)
Due to third-party payors	—			(10,928		)	11,288			—			360
Accrued expenses	3,870			(1,912		)	998			—			2,956
Income and deferred taxes	14,481			—			—			—			14,481
Net cash provided by operating activities	100,310			91,913			12,530			—			204,753
Investing activities
Purchases of property and equipment	(3,617		)	(31,978		)	(9,593		)	—			(45,188		)
Proceeds from sale of assets	—			16,511			—			—			16,511
Investment in business, net of distributions	—			(9,899		)	—			—			(9,899		)
Acquisition of businesses, net of cash acquired	—			(1,547		)	—			—			(1,547		)
Net cash used in investing activities	(3,617		)	(26,913		)	(9,593		)	—			(40,123		)
Financing activities
Borrowings on revolving credit facility	365,000			—			—			—			365,000
Payments on revolving credit facility	(405,000		)	—			—			—			(405,000		)
Borrowings on 2011 credit facility term loans, net of discount	266,750			—			—			—			266,750
Payments on 2011 credit facility term loans	(7,063		)	—			—			—			(7,063		)
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(278,495		)	—			—			—			(278,495		)
Borrowings of other debt	5,557			—			278			—			5,835
Principal payments on other debt	(6,667		)	(322		)	(428		)	—			(7,417		)
Debt issuance costs	(4,236		)	—			—			—			(4,236		)
Dividends paid to Holdings	(57,467		)	—			—			—			(57,467		)
Equity investment by Holdings	1,104			—			—			—			1,104
Repayment of bank overdrafts	(3,011		)	—			—			—			(3,011		)
Intercompany debt reallocation	60,477			(61,143		)	666			—			—
Distributions to non-controlling interests	—			—			(2,997		)	—			(2,997		)
Net cash used in financing activities	(63,051		)	(61,465		)	(2,481		)	—			(126,997		)
Net increase in cash and cash equivalents	33,642			3,535			456			—			37,633
Cash and cash equivalents at beginning of period	11,427			—			616			—			12,043
Cash and cash equivalents at end of period	$	45,069		$	3,535		$	1,072		$	—		$	49,676

(a)  Elimination of equity in earnings of consolidated subsidiaries.

23

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	11,427		$	—		$	616		$	—		$	12,043
Accounts receivable, net	—			369,321			44,422			—			413,743
Current deferred tax asset	11,415			3,221			3,669			—			18,305
Prepaid income taxes	9,497			—			—			—			9,497
Other current assets	6,340			19,407			4,075			—			29,822
Total Current Assets	38,679			391,949			52,782			—			483,410
Property and equipment, net	14,641			440,736			54,651			—			510,028
Investment in affiliates	2,751,776			83,772			—			(2,835,548		)(a) (b)	—
Goodwill	—			1,631,716			—			—			1,631,716
Other identifiable intangibles	—			72,123			—			—			72,123
Assets held for sale	2,742			—			—			—			2,742
Other assets	28,386			41,480			853			—			70,719
Total Assets	$	2,836,224		$	2,661,776		$	108,286		$	(2,835,548	)	$	2,770,738
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	16,609		$	—		$	—		$	—		$	16,609
Current portion of long-term debt and notes payable	8,853			390			1,605			—			10,848
Accounts payable	7,353			76,207			12,058			—			95,618
Intercompany accounts	975,809			(880,537		)	(95,272		)	—			—
Accrued payroll	229			82,518			141			—			82,888
Accrued vacation	3,703			41,305			6,242			—			51,250
Accrued interest	11,843			137			—			—			11,980
Accrued restructuring	—			5,027			—			—			5,027
Accrued other	47,829			51,086			7,401			—			106,316
Due to third party payors	—			13,633			(8,107		)	—			5,526
Total Current Liabilities	1,072,228			(610,234		)	(75,932		)	—			386,062
Long-term debt, net of current portion	733,328			425,315			60,007			—			1,218,650
Non-current deferred tax liability	(2,509		)	75,750			8,787			—			82,028
Other non-current liabilities	46,555			17,970			380			—			64,905
Total Liabilities	1,849,602			(91,199		)	(6,758		)	—			1,751,645
Stockholder’s Equity:
Common stock	0			—			—			—			0
Capital in excess of par	848,844			—			—			—			848,844
Retained earnings	137,778			627,120			23,154			(650,274		)(b)	137,778
Subsidiary investment	—			2,125,855			59,419			(2,185,274		)(a)	—
Total Select Medical Corporation Stockholder’s Equity	986,622			2,752,975			82,573			(2,835,548		)	986,622
Non-controlling interest	—			—			32,471			—			32,471
Total Equity	986,622			2,752,975			115,044			(2,835,548		)	1,019,093
Total Liabilities and Equity	$	2,836,224		$	2,661,776		$	108,286		$	(2,835,548	)	$	2,770,738

(a)  Elimination of investments in consolidated subsidiaries.

(b)  Elimination of investments in consolidated subsidiaries’ earnings.

24

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	16		$	603,737		$	90,378		$	—		$	694,131
Costs and expenses:
Cost of services	430			502,576			78,823			—			581,829
General and administrative	14,804			171			—			—			14,975
Bad debt expense	—			10,219			1,490			—			11,709
Depreciation and amortization	641			14,484			2,420			—			17,545
Total costs and expenses	15,875			527,450			82,733			—			626,058
Income (loss) from operations	(15,859		)	76,287			7,645			—			68,073
Other income and expense:
Intercompany interest and royalty fees	(659		)	655			4			—			—
Intercompany management fees	18,698			(14,320		)	(4,378		)	—			—
Equity in earnings of unconsolidated subsidiaries	—			1,633			20			—			1,653
Interest income	36			16			67			—			119
Interest expense	(12,556		)	(7,874		)	(1,096		)	—			(21,526		)
Income (loss) from operations before income taxes	(10,340		)	56,397			2,262			—			48,319
Income tax expense (benefit)	(1,502		)	21,215			530			—			20,243
Equity in earnings of subsidiaries	36,129			1,761			—			(37,890		)(a)	—
Net income	27,291			36,943			1,732			(37,890		)	28,076
Less: Net income attributable to non-controlling interests	—			—			785			—			785
Net income attributable to Select Medical Corporation	$	27,291		$	36,943		$	947		$	(37,890	)	$	27,291

(a) Elimination of equity in earnings of subsidiaries.

25

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	102		$	1,809,552		$	276,412		$	—		$	2,086,066
Costs and expenses:
Cost of services	1,262			1,476,857			230,792			—			1,708,911
General and administrative	47,298			358			—			—			47,656
Bad debt expense	—			35,128			4,874			—			40,002
Depreciation and amortization	1,941			43,939			6,886			—			52,766
Total costs and expenses	50,501			1,556,282			242,552			—			1,849,335
Income (loss) from operations	(50,399		)	253,270			33,860			—			236,731
Other income and expense:
Intercompany interest and royalty fees	(2,654		)	2,635			19			—			—
Intercompany management fees	86,561			(73,451		)	(13,110		)	—			—
Loss on early retirement of debt	(20,385		)	—			—			—			(20,385		)
Equity in earnings of unconsolidated subsidiaries	—			1,285			44			—			1,329
Interest income	101			117			68			—			286
Interest expense	(28,932		)	(27,193		)	(3,757		)	—			(59,882		)
Income (loss) from operations before income taxes	(15,708		)	156,663			17,124			—			158,079
Income tax expense (benefit)	(214		)	65,259			809			—			65,854
Equity in earnings of subsidiaries	103,281			12,342			—			(115,623		)(a)	—
Net income	87,787			103,746			16,315			(115,623		)	92,225
Less: Net income attributable to non-controlling interests	—			—			4,438			—			4,438
Net income attributable to Select Medical Corporation	$	87,787		$	103,746		$	11,877		$	(115,623	)	$	87,787

(a) Elimination of equity in earnings of subsidiaries.

26

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	87,787		$	103,746		$	16,315		$	(115,623	)(a)	$	92,225
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,941			43,939			6,886			—			52,766
Provision for bad debts	—			35,128			4,874			—			40,002
Loss on early retirement of debt	20,385			—			—			—			20,385
Loss (gain) from disposal of assets	13			(5,233		)	38			—			(5,182		)
Non-cash stock compensation expense	2,698			—			—			—			2,698
Amortization of debt discount	412			—			—			—			412
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(103,281		)	(12,342		)	—			115,623		(a)	—
Intercompany	60,188			(49,269		)	(10,919		)	—			—
Accounts receivable	—			(73,437		)	(8,029		)	—			(81,466		)
Other current assets	(455		)	412			283			—			240
Other assets	(8,306		)	8,826			203			—			723
Accounts payable	1,622			10,102			2,284			—			14,008
Due to third-party payors	—			2,710			(3,760		)	—			(1,050		)
Accrued expenses	(4,455		)	701			104			—			(3,650		)
Income and deferred taxes	34,723			—			—			—			34,723
Net cash provided by operating activities	93,272			65,283			8,279			—			166,834
Investing activities
Purchases of property and equipment	(2,384		)	(26,342		)	(3,368		)	—			(32,094		)
Investment in business	—			(13,514		)	—			—			(13,514		)
Acquisition of businesses, net of cash acquired	—			1,921			—			—			1,921
Proceeds from sale of assets	—			7,879			—			—			7,879
Net cash used in investing activities	(2,384		)	(30,056		)	(3,368		)	—			(35,808		)
Financing activities
Borrowings on revolving credit facility	595,000			—			—			—			595,000
Payments on revolving credit facility	(570,000		)	—			—			—			(570,000		)
Borrowings on 2011 credit facility term loans, net of discount	841,500			—			—			—			841,500
Payments on 2011 credit facility term loans	(2,125		)	—			—			—			(2,125		)
Payments on 2005 credit facility term loans, net of premium	(484,633		)	—			—			—			(484,633		)
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(273,941		)	—			—			—			(273,941		)
Borrowings of other debt	5,496			—			—			—			5,496
Principal payments on other debt	(4,326		)	(650		)	(870		)	—			(5,846		)
Debt issuance costs	(18,556		)	—			—			—			(18,556		)
Repayments of bank overdrafts	(4,174		)	—			—			—			(4,174		)
Equity investment by Holdings	169			—			—			—			169
Dividends paid to Holdings	(204,561		)	—			—			—			(204,561		)
Intercompany debt reallocation	38,082			(37,564		)	(518		)	—			—
Distributions to non-controlling interests	—			—			(3,507		)	—			(3,507		)
Net cash used in financing activities	(82,069		)	(38,214		)	(4,895		)	—			(125,178		)
Net increase (decrease) in cash and cash equivalents	8,819			(2,987		)	16			—			5,848
Cash and cash equivalents at beginning of period	149			3,567			649			—			4,365
Cash and cash equivalents at end of period	$	8,968		$	580		$	665		$	—		$	10,213

(a)  Elimination of equity in earnings of consolidated subsidiaries.

27

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with our unaudited consolidated financial statements and accompanying notes.

Forward-Looking Statements

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws.  Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements.  Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” “intend” and similar expressions.  These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance.  These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

·additional changes in government reimbursement for our services, including changes that will result from the expiration of the moratorium for long term acute care hospitals established by the Medicare, Medicaid, and SCHIP Extension Act of 2007, the American Recovery and Reinvestment Act, and the Patient Protection and Affordable Care Act may result in a reduction in net operating revenues, an increase in costs and a reduction in profitability;

·the failure of our specialty hospitals to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;

·the failure of our facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;

·a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

·acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources or expose us to unforeseen liabilities;

·private third-party payors for our services may undertake future cost containment initiatives that limit our future net operating revenues and profitability;

28

·the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;

·shortages in qualified nurses or therapists could increase our operating costs significantly;

·competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;

·the loss of key members of our management team could significantly disrupt our operations;

·the effect of claims asserted against us could subject us to substantial uninsured liabilities; and

·other factors discussed from time to time in our filings with the Securities and Exchange Commission (the “SEC”), including factors discussed under the heading “Risk Factors” for the year ended December 31, 2011 contained in our annual report on Form 10-K filed with the SEC on March 2, 2012.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise.  You should not place undue reliance on our forward-looking statements.  Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information.  Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report.  Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

Overview

We believe that we are one of the largest operators of both specialty hospitals and outpatient rehabilitation clinics in the United States based on number of facilities.  As of September 30, 2012, we operated 111 long term acute care hospitals and 12 acute medical rehabilitation hospitals in 28 states, and 965 outpatient rehabilitation clinics in 32 states and the District of Columbia. We also provide medical rehabilitation services on a contracted basis to nursing homes, hospitals, assisted living and senior care centers, schools and work sites.  We began operations in 1997 under the leadership of our current management team.  As of September 30, 2012, we had operations in 44 states and the District of Columbia.

We manage our Company through two business segments, our specialty hospital segment and our outpatient rehabilitation segment.  We had net operating revenues of $2,207.9 million for the nine months ended September 30, 2012.  Of this total, we earned approximately 74% of our net operating revenues from our specialty hospitals and approximately 26% from our outpatient rehabilitation business.  Our specialty hospital segment consists of hospitals designed to serve the needs of long term stay acute patients and hospitals designed to serve patients that require intensive medical rehabilitation care.  Patients are typically admitted to our specialty hospitals from general acute care hospitals.  These patients have specialized needs, and serious and often complex medical conditions such as respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders and cancer.  Our outpatient

29

rehabilitation segment consists of clinics and contract services that provide physical, occupational and speech rehabilitation services.  Our outpatient rehabilitation patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living.

Significant 2012 Events

Refinancing

On August 13, 2012, Select, Holdings and the subsidiaries of Select named therein entered into an Extension Amendment to Select’s senior secured credit facility with a group of lenders and JPMorgan Chase Bank, N.A. as administrative agent.  Pursuant to the terms and conditions of the Extension Amendment, the lenders extended Series A Tranche B Term Loans in the aggregate principal amount of $275.0 million to Select at the same interest rate and with the same term as applies to other Tranche B Term Loan amounts borrowed by Select under the senior secured credit facility.  On September 12, 2012, Select used the proceeds of the Series A Tranche B Term Loans (other than amounts used for fees and expenses) and cash on hand to redeem an aggregate of $275.0 million principal amount of Select’s outstanding 7 5/8% senior subordinated notes due 2015 at a redemption price of 101.271% of the principal amount.  Select recognized a loss on early retirement of debt of $6.1 million for the three and nine months ended September 30, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

Stock Repurchase Program

On February 22, 2012, the Company’s board of directors authorized an increase of $100.0 million in the capacity of its common stock repurchase program from $150.0 million to $250.0 million.  The program will remain in effect until March 31, 2013, unless extended by the board of directors.  Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as the Company deems appropriate.  The timing of purchases of stock will be based upon market conditions and other factors.  The Company is funding this program with cash on hand or borrowings under its revolving credit facility.  The Company did not repurchase any shares during the three months ended September 30, 2012.  The Company repurchased 5,725,782 shares at a cost of $46.8 million, which includes transaction costs, during the nine months ended September 30, 2012.  Since the inception of the program through September 30, 2012, the Company has repurchased 22,490,389 shares at a cost of $163.6 million, or $7.28 per share, which includes transaction costs.

Summary Financial Results

Three Months Ended September 30, 2012

For the three months ended September 30, 2012, our net operating revenues increased 2.8% to $713.7 million compared to $694.1 million for the three months ended September 30, 2011.  Our specialty hospital revenues increased $10.3 million or 2.0% and our outpatient rehabilitation revenues increased $9.2 million or 5.3%.  We had income from operations for the three months ended September 30, 2012 of $70.8 million compared to $68.1 million for the three months ended September 30, 2011.  We had net income attributable to Holdings for the three months ended September 30, 2012 of $24.1 million compared to $25.6 million for the three months ended September 30, 2011.  Our Adjusted EBITDA for the three months ended September 30, 2012 was $87.7 million compared to $86.5 million for the three months ended September 30, 2011.  See the section entitled “Results of Operations” for a reconciliation of net income to Adjusted EBITDA.  The increase in our income from operations and Adjusted EBITDA is principally due to increases in operating performance

30

in our specialty hospital segment. We were able to increase our specialty hospital income from operations $3.4 million or 4.9% and our specialty hospital Adjusted EBITDA $2.1 million or 2.6% for the three months ended September 30, 2012 compared to the same quarter prior year.  These increases principally occurred in our Regency hospitals, from management services fees and lower bad debt expense.

Net income attributable to Holdings decreased $1.5 million to $24.1 million for the three months ended September 30, 2012 compared to $25.6 million for the three months ended September 30, 2011.  The decrease resulted primarily from the loss on early retirement of debt related to the redemption of $275.0 million of our senior subordinated notes completed September 12, 2012, offset in part by an increase in income from operations.

Nine Months Ended September 30, 2012

For the nine months ended September 30, 2012, our net operating revenues increased 5.8% to $2,207.9 million compared to $2,086.1 million for the nine months ended September 30, 2011.  Our specialty hospital revenues increased $80.3 million or 5.1% and our outpatient rehabilitation revenues increased $41.5 million or 7.9%.  We had income from operations for the nine months ended September 30, 2012 of $255.9 million compared to $236.7 million for the nine months ended September 30, 2011.  We had net income attributable to Holdings for the nine months ended September 30, 2012 of $108.8 million compared to $71.0 million for the nine months ended September 30, 2011.  Our Adjusted EBITDA for the nine months ended September 30, 2012 was $307.1 million compared to $292.2 million for the nine months ended September 30, 2011.  See the section entitled “Results of Operations” for a reconciliation of net income to Adjusted EBITDA.  The increases in our income from operations and Adjusted EBITDA are principally due to increases in the operating performance of our specialty hospital segment. We were able to increase our specialty hospital income from operations $15.8 million or 6.7% and our specialty hospital Adjusted EBITDA $12.8 million or 4.7% for the nine months ended September 30, 2012 as compared to the nine months ended September 30, 2011.  These increases principally occurred due to the performance of our Regency hospitals.

Net income attributable to Holdings increased $37.8 million to $108.8 million for the nine months ended September 30, 2012 compared to $71.0 million for the nine months ended September 30, 2011. The increase resulted primarily from an increase in our income from operations described above, increases in our equity in earnings of unconsolidated subsidiaries principally related to our Baylor JV and a reduction of interest expense.  We also incurred losses on early retirement of debt related to the refinancing transactions completed June 1, 2011 that reduced our net income in the nine months ended September 30, 2011, and a debt redemption completed September 12, 2012 that reduced our net income in the nine months ended September 30, 2012.

Cash flow from operations provided $194.1 million of cash for the nine months ended September 30, 2012 for Holdings and $204.8 million of cash for the nine months ended September 30, 2012 for Select.  The difference in cash flow from operations between Holdings and Select primarily relates to interest payments on Holdings’ senior floating rate notes.

31

Regulatory Changes

In the past few years, there have been significant regulatory changes that have affected our net operating revenues and, in some cases, caused us to change our operating models and strategies.  The following is a discussion of recent regulatory changes that are affecting our results of operations in 2012 or may have an affect on our future results of operations.  Our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission (“SEC”) on March 2, 2012 contains a more detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations, and the information below should be read in connection with that more detailed discussion.

Healthcare Reform Legislation

Federal agencies, including the Centers for Medicare & Medicaid Services (“CMS”), continue to implement provisions of the Patient Protection and Affordable Care Act (“PPACA”).  The PPACA expands access to health insurance through subsidies, coverage mandates and other insurance market reforms.  In addition, PPACA makes dramatic changes to the Medicare and Medicaid programs by adopting numerous initiatives addressing, among other things, reductions in healthcare spending, patient safety incentives and protections against fraud and abuse of federal healthcare programs.  The PPACA adopts significant changes to the Medicare program that are particularly relevant to long term acute care hospitals (“LTCHs”), inpatient rehabilitation facilities (“IRFs”) and outpatient rehabilitation services.  As part of healthcare reform legislation, President Obama also signed the “Health Care and Education Affordability Reconciliation Act of 2010,” which made some limited but important changes to the PPACA.

A number of states attorneys general and other parties filed legal challenges to the PPACA seeking to block its implementation on constitutional grounds.  On June 28, 2012, the U.S. Supreme Court upheld the PPACA finding that the individual health insurance mandate does not violate the Constitution because it may be viewed as a permissible tax on individuals who do not obtain health insurance.  The only provision of the law that the Court invalidated is a Medicaid provision that threatened states with the loss of existing Medicaid funding if they decline to comply with the PPACA’s Medicaid coverage extension.

Federal and state agencies are expected to continue to implement provisions of the PPACA following the Court’s decision. However, the 2012 presidential election and pending efforts in the U.S. Congress to repeal, amend or retract funding for various aspects of the PPACA create additional uncertainty about the ultimate impact of the PPACA. As a result, the full impact of the PPACA, and healthcare reform efforts in general, may not be known for several years.

We have included in our Annual Report on Form 10-K for the year ended December 31, 2011 a discussion of the principal PPACA provisions that affect our business, as well as regulatory initiatives adopted by CMS in response to particular provisions of the PPACA.

Budget Control Act of 2011

Beginning in January 2013, the Budget Control Act of 2011 will automatically reduce federal spending by approximately $1.2 trillion split evenly between domestic and defense spending.  Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap.  Unless further legislation is enacted, we believe this will generally result in a 2% reduction to Medicare payments, beginning on February 1, 2013.

32

Medicare Payment of Long Term Acute Care Hospital Services

Medicare Payment of Long Term Acute Care Hospitals during Fiscal Year 2012

On August 18, 2011, CMS published the policies and payment rates for LTCH-PPS for fiscal year 2012 (affecting discharges and cost reporting periods beginning on or after October 1, 2011 through September 30, 2012).  The standard federal rate for fiscal year 2012 was $40,222, an increase from the fiscal year 2011 standard federal rate of $39,600.  The final rule established a fixed-loss amount for high cost outlier cases for fiscal year 2012 of $17,931, which was a decrease from the fixed-loss amount in the 2011 fiscal year of $18,785.

Medicare Payment of Long Term Acute Care Hospitals during Fiscal Year 2013

On August 1, 2012, CMS published the final rule updating the policies and payment rates for LTCH-PPS for fiscal year 2013 (affecting discharges and cost reporting periods beginning on or after October 1, 2012 through September 30, 2013).  Two different standard federal rates apply during fiscal year 2013.  The standard federal rate for discharges on or after October 1, 2012 through December 28, 2012 is set at $40,916, an increase from $40,222 applicable during fiscal year 2012. The standard federal rate for discharges on or after December 29, 2012 and the remainder of fiscal year 2013 is set at $40,398. The increase through December 28, 2012 is based on a market basket increase of 2.6% less a productivity adjustment of 0.7% and less an additional reduction of 0.1% mandated by the PPACA. The market basket increase for the period of December 29, 2012 through the remainder of fiscal 2013 is further reduced by a portion of the one-time budget neutrality adjustment, as discussed below.  The fixed loss amount for high cost outlier cases is set at $15,408, a decrease from the fixed loss amount in the 2012 fiscal year of $17,931.

Very Short Stay Outlier Policy

CMS established a different payment methodology for Medicare patients with a length of stay less than or equal to five-sixths of the geometric average length of stay for that particular MS-LTC-DRG, referred to as a short stay outlier, or “SSO.” The SSO rule was further revised adding a category referred to as a “very short stay outlier” for discharges occurring after July 1, 2007. For cases with a length of stay that is equal to or less than one standard deviation from the geometric average length of stay for the same MS-DRG under IPPS, referred to as the so-called “IPPS comparable threshold,” the rule lowers the LTCH payment to a rate based on the general acute care hospital IPPS per diem. SSO cases with covered lengths of stay that exceed the IPPS comparable threshold would continue to be paid under the SSO payment policy. The SCHIP Extension Act, as amended by the PPACA, prevented CMS from applying the very short-stay outlier policy before December 29, 2012. Under existing regulations Medicare payments for very short-stay cases will be generally lowered to a rate based on the general acute care hospital IPPS per diem beginning with discharges on or after December 29, 2012.

25 Percent Rule

The 25 Percent Rule is a downward payment adjustment that applies to Medicare patients discharged from LTCHs who were admitted from a co-located hospital or a non-co-located hospital and caused the LTCH to exceed the applicable percentage thresholds of discharged Medicare patients. The SCHIP Extension Act as amended by the American Recovery and Reinvestment Act, or “ARRA,” and the PPACA limited the full application of the Medicare percentage threshold and, in some cases, postponed application of the percentage threshold until cost reporting periods beginning on or after July 1, 2012 or October 1, 2012.

33

In the update to the Medicare policies and payment rates for fiscal year 2013, CMS adopted through regulations a one-year extension of relief granted by the SCHIP Extension Act from the full application of Medicare admission thresholds.  As a result, full implementation of the Medicare admission thresholds will not go into effect until cost reporting periods beginning on or after October 1, 2013, except for certain LTCHs with cost reporting periods that begin between July 1, 2012 and September 30, 2012.  Specifically, those freestanding facilities, grandfathered HIHs and grandfathered satellites with cost reporting periods beginning on or after July 1, 2012 and before October 1, 2012 were subject to a modified 25 Percent Rule for discharges occurring in a three month period between July 1, 2012 and September 30, 2012.

In the preamble to the proposed update to the Medicare policies and payment rates for fiscal year 2013, CMS indicated that “within the near future” it may recommend revisions to the payment policies addressing MedPAC’s recommendations for the development of patient-level and facility-level criteria.  CMS also indicated that these recommendations may render unnecessary the existing payment reductions for Medicare patients admitted from a general acute care hospital in excess of the applicable admission thresholds.

One-Time Budget Neutrality Adjustment

Congress required that the LTCH-PPS payment rates maintain budget neutrality during the first year of the prospective payment system with total expenditures that would have been made under the previous reasonable cost-based payment system. The LTCH-PPS regulations give CMS the ability to make a one-time adjustment to the standard federal rate to correct any “significant difference between actual payments and estimated payments for the first year” of LTCH-PPS. The SCHIP Extension Act, as amended by the PPACA, precluded CMS from implementing the one-time prospective adjustment to the LTCH standard federal rate before December 29, 2012.

In the update to the Medicare policies and payment rates for fiscal year 2013, CMS adopted a one-time budget neutrality adjustment that results in a permanent negative adjustment of 3.75% to the LTCH base rate.  CMS is implementing the adjustment over a three-year period by applying a factor of 0.98734 to the standard federal rate in fiscal years 2013, 2014 and 2015, except that the adjustment would not apply to payments for discharges occurring on or after October 1, 2012 through December 28, 2012.

Medicare Market Basket Adjustments for Long Term Acute Care Hospitals

In the update to the Medicare policies and payment rates for fiscal year 2013, CMS adopted for the first time an LTCH-specific market basket based entirely on Medicare cost report data from LTCHs.  The LTCH-specific market basket replaces the rehabilitation, psychiatric and long-term care hospital market basket previously used to determine the annual update to the LTCH-PPS.

Additionally, the PPACA instituted a market basket payment adjustment for LTCHs.  For fiscal years 2012 and 2013, the reduction was 0.1%.  For fiscal year 2014, the reduction is 0.3%.  For fiscal years 2015 and 2016, the reduction is 0.2%.  For fiscal years 2017 through fiscal year 2019, the reduction is 0.75%.

34

Medicare Payment of Inpatient Rehabilitation Facility Services

Medicare Payment of Inpatient Rehabilitation Facilities during Fiscal Year 2012

On August 5, 2011, CMS published the policies and payment rates for IRF-PPS for fiscal year 2012 (affecting discharges and cost reporting periods beginning on or after October 1, 2011 through September 30, 2012). The standard payment conversion factor for discharges for fiscal year 2012 was $14,076, an increase from the fiscal year 2011 standard payment conversion factor of $13,860.  CMS initially decreased the outlier threshold amount for fiscal year 2012 to $10,660 from $11,410 for fiscal year 2011.  In a notice published September 26, 2011, CMS corrected its calculation of the outlier threshold amount for fiscal year 2012 to $10,713.

Medicare Payment of Inpatient Rehabilitation Facilities during Fiscal Year 2013

On July 30, 2012, CMS published the policies and payment rates for IRF-PPS for fiscal year 2013 (affecting discharges and cost reporting periods beginning on or after October 1, 2012 through September 30, 2013).  The standard payment conversion factor for discharges for fiscal year 2013 is $14,343, an increase from the fiscal year 2012 standard payment conversion factor of $14,076.  The standard payment conversion factor for fiscal year 2013 includes a market basket increase of 2.7% less a productivity adjustment of 0.7% and less a reduction of 0.1% mandated by the PPACA.  The outlier threshold amount for fiscal year 2013 is set at $10,466, a decrease from the outlier threshold amount in the 2012 fiscal year of $10,713.

Medicare Market Basket Adjustments for Inpatient Rehabilitation Facilities

The PPACA instituted a market basket payment reduction adjustment for IRFs.  For fiscal years 2012 and 2013, the reduction was 0.1%.  For fiscal year 2014, the reduction is 0.3%.  For fiscal years 2015 and 2016, the reduction is 0.2%.  For fiscal years 2017 - 2019, the reduction is 0.75%.

Medicare Quality Reporting Program for LTCHs and IRFs

The PPACA requires that CMS establish new quality data reporting programs for LTCHs and IRFs by fiscal year 2014.  CMS has adopted a quality data reporting program requiring LTCHs to submit data from three quality measures in order to receive the full payment update in fiscal year 2014, including measures related to (1) catheter-associated urinary tract infections, (2) central line catheter-associated blood stream infection, and (3) pressure ulcers that are new or have worsened.  In addition to the foregoing measures, CMS has adopted the following quality measures for LTCH reporting beginning in fiscal year 2016: (1) percent of nursing home residents who were assessed and appropriately given the seasonal influenza vaccine and (2) influenza vaccination coverage among healthcare personnel.  CMS adopted a quality data reporting program requiring IRFs to submit data from two quality measures in order to receive the full payment update in fiscal year 2014, including measures related to (1) catheter-associated urinary tract infections and (2) pressure ulcers that are new or have worsened.  Under the PPACA and CMS regulations, if an LTCH or IRF fails to report on the selected quality measures, its reimbursement will be reduced by 2.0% of the annual market basket update.  The reduction can result in payment rates less than the prior year.  However, the reduction will not carry over into the subsequent fiscal years.

35

Medicare Payment of Outpatient Rehabilitation Services

Medicare Physician Fee Schedule and Sustainable Growth Rate Update

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule.  The Medicare physician fee schedule rates are automatically updated annually based on the sustainable growth rate (“SGR”) formula contained in legislation.  The SGR formula has resulted in automatic reductions in rates in every year since 2002; however, for each year through 2012 CMS or Congress has taken action to prevent the SGR formula reductions.  The Middle Class Tax Relief and Job Creation Act of 2012 froze Medicare physician fee schedule rates at 2011 levels through December 31, 2012, temporarily averting a scheduled 27.4% cut as a result of the SGR formula that would have taken effect on March 1, 2012.  In the proposed 2013 Medicare physician fee schedule rule, CMS has estimated a 27.0% reduction in the Medicare physician fee schedule payment rates beginning on January 1, 2013, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect.  This reduction would be in addition to any automatic spending reductions being enacted as a result of the Budget Control Act of 2011 which, as discussed above, would cut all Medicare spending by 2%.  If the 27.0% SGR reduction and 2% cut in all Medicare spending are averted by Congress, the projected impact of other changes in the proposed 2013 Medicare physician fee schedule rule on outpatient physical therapy services in aggregate would result in a 3% increase in 2013.  This positive change is primarily due to the phase in of the final year of the 4-year transition to the new practice expense relative value units based on data from the Physician Practice Information Survey.

On October 6, 2011, MedPAC recommended that Congress repeal and replace the statutory SGR formula.  The MedPAC proposal, which would require Congressional approval, would freeze current Medicare physician fee schedule rates for primary care services for 10 years, while other services would be subject to annual payment reductions of 5.9% for 3 years, followed by a freeze on payments for the next seven years. MedPAC offered a list of options for Congress to consider if it decides to offset SGR repeal costs (estimated at about $200 billion over 10 years) within the Medicare program.

In addition to the SGR proposal, MedPAC recommended that Congress direct CMS to collect data on provider service volume and work time to establish more accurate relative value unit payment rates and to identify and reduce overpriced fee schedule services.  Similarly, the PPACA requires CMS to identify and review potentially misvalued codes and make appropriate adjustments to the relative values of those services identified as being misvalued.  In the final update to the Medicare physician fee schedule for calendar year 2012, CMS identified several CPT codes used by physical therapists as codes they will review.

In the proposed 2013 Medicare physician fee schedule rule, CMS indicated that it will implement a claims-based data collection process to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes.  All practice settings that provide outpatient therapy services would be required to include this data on the claim form.  Beginning on January 1, 2013, therapists would be required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge.  For claims submitted after July 1, 2013, CMS proposes to return claims as unpaid if the required data is not included in the claim.

Several government agencies are expected to release reports on aspects of the Medicare payment system for therapy services.  In the final 2011 Medicare physician fee schedule rule, CMS indicated the agency is evaluating alternative payment methodologies that would provide appropriate payment for medically necessary and effective therapy services furnished to Medicare beneficiaries based on patient needs rather than the current therapy caps.  The Middle Class Tax Relief and Job Creation Act of 2012 directs MedPAC to submit a report to Congress by June 15, 2013 making recommendations on how to reform the payment system so that it is better

36

designed to reflect functional limitations, severity, and the therapy needs of the patient.  The MedPAC report is to include an examination of private sector initiatives to manage outpatient therapy benefits.  In September 2012, MedPAC presented analysis and information on spending, utilization, and data quality issues that affect the Medicare outpatient therapy benefit.  MedPAC presented potential policy options in three key areas for consideration:  1) improving management of the benefit, 2) collecting information on patients’ functional status, and 3) reforming the payment system for outpatient therapy services.  At its October 2012 meeting, MedPAC proposed two additional specific policy options:  An increase in the multiple procedure payment reduction from 25% to 50% in the practice expense component for the second and subsequent therapy services furnished by a provider to the same patient on the same day; and reducing the level of the therapy caps to a lower level while allowing manual medical review for requests that exceed the therapy cap.  In addition to the MedPAC report, the GAO is directed to issue a report no later than May 1, 2013 regarding implementation of the manual medical review process instituted by the Middle Class Tax Relief and Job Creation Act of 2012.  The report must detail the number of beneficiaries subject to the process, the number of reviews conducted, and the outcome of the reviews.

Therapy Caps

Beginning on January 1, 1999, the Balanced Budget Act of 1997 subjected certain outpatient therapy providers reimbursed under the Medicare physician fee schedule to annual limits for therapy expenses.  Effective January 1, 2012, the annual limit on outpatient therapy services is $1,880 for combined physical and speech language pathology services and $1,880 for occupational therapy services.  The per beneficiary caps were $1,870 for calendar year 2011.  The annual limits for therapy expenses do not apply to services furnished and billed by outpatient hospital departments.  However, beginning no later than October 1, 2012 and expiring on December 31, 2012, the Middle Class Tax Relief and Job Creation Act of 2012 will apply the annual limits on therapy expenses to hospital outpatient department settings.  The application of annual limits to hospital outpatient department settings will sunset at the end of 2012 unless extended by Congress. We operated 965 outpatient rehabilitation clinics at September 30, 2012, of which 139 are provider-based outpatient rehabilitation clinics operated as departments of the inpatient rehabilitation hospitals.

In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual limit for therapy expenses.  Under this process, a Medicare enrollee (or person acting on behalf of the Medicare enrollee) is able to request an exception from the therapy caps if the provision of therapy services was deemed to be medically necessary.  Therapy cap exceptions have been available automatically for certain conditions and on a case-by-case basis upon submission of documentation of medical necessity.  The Middle Class Tax Relief and Job Creation Act of 2012 extended the exceptions process for outpatient therapy caps through December 31, 2012.  Unless Congress extends the exceptions process, the therapy caps will apply to all outpatient therapy services beginning January 1, 2013, except those services furnished and billed by outpatient hospital departments.

The Middle Class Tax Relief and Job Creation Act of 2012 made several changes to the exceptions process to the annual limit for therapy expenses.  For any claim above the annual limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record.  Effective October 1, 2012, all claims exceeding $3,700 will be subject to a manual medical review process.  The $3,700 threshold will be applied separately to the combined physical therapy/speech therapy cap and the occupational therapy cap.  Effective October 1, 2012, all therapy claims, whether above or below the annual limit, must include the national provider identifier (NPI) of the physician responsible for certifying and periodically reviewing the plan of care.

37

Multiple Procedure Payment Reduction

CMS adopted a multiple procedure payment reduction for therapy services in the final update to the Medicare physician fee schedule for calendar year 2011.  Under the policy, the Medicare program pays 100% of the practice expense component of the therapy procedure or unit of service with the highest relative value unit and then reduces the payment for the practice expense component by 20% in office and other non-institutional settings and 25% in institutional settings for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions.  This multiple procedure payment reduction policy became effective January 1, 2011 and applies to all outpatient therapy services paid under Medicare Part B.  Furthermore, the multiple procedure payment reduction policy applies across all therapy disciplines — occupational therapy, physical therapy and speech language pathology.  Our outpatient rehabilitation therapy services are primarily offered in institutional settings and, as such, are subject to the applicable 25% payment reduction in the practice expense component for the second and subsequent therapy services furnished by us to the same patient on the same day.  In the 2012 Medicare physician fee schedule rule, CMS indicated that over the next year it will continue to review whether specific CPT codes billed under the fee schedule are overvalued or undervalued, including certain specific CPT codes used by physical therapists.

38

Operating Statistics

The following tables set forth operating statistics for our specialty hospitals and our outpatient rehabilitation clinics for each of the periods presented. The data in the tables reflect the changes in the number of specialty hospitals and outpatient rehabilitation clinics we operate that resulted from acquisitions, start-up activities, closures and sales. The operating statistics reflect data for the period of time these operations were managed by us.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2012			2011			2012
Specialty hospital data(1):
Number of hospitals owned - start of period	115			117			116			115
Number of hospitals acquired	—			—			1			1
Number of hospital start-ups	—			—			—			1
Number of hospitals closed/sold	—			—			(2		)	—
Number of hospitals owned - end of period	115			117			115			117
Number of hospitals managed - end of period	4			6			4			6
Total number of hospitals (all) - end of period	119			123			119			123
Long term acute care hospitals	110			111			110			111
Rehabilitation hospitals	9			12			9			12
Available licensed beds (2)	5,135			5,174			5,135			5,174
Admissions (2)	13,599			13,477			40,965			41,404
Patient days (2)	333,322			328,871			994,179			1,007,908
Average length of stay (days) (2)	25			25			24			24
Net revenue per patient day (2)(3)	$	1,474		$	1,517		$	1,498		$	1,532
Occupancy rate (2)	71		%	69		%	71		%	71		%
Percent patient days - Medicare (2)	65		%	64		%	65		%	64		%
Outpatient rehabilitation data:
Number of clinics owned - start of period	849			852			875			850
Number of clinics acquired	—			3			—			3
Number of clinic start-ups	7			6			22			24
Number of clinics closed/sold	(9		)	(3		)	(50		)	(19		)
Number of clinics owned - end of period	847			858			847			858
Number of clinics managed - end of period	105			107			105			107
Total number of clinics (all) - end of period	952			965			952			965
Number of visits (2)	1,099,342			1,129,015			3,381,896			3,447,774
Net revenue per visit (2)(4)	$	103		$	103		$	103		$	103

(1)Specialty hospitals consist of long term acute care hospitals and inpatient rehabilitation facilities.

(2)Data excludes specialty hospitals and outpatient clinics managed by the Company.

(3)Net revenue per patient day is calculated by dividing specialty hospital direct patient service revenues by the total number of patient days.

(4)Net revenue per visit is calculated by dividing outpatient rehabilitation clinic direct patient service revenue by the total number of visits. For purposes of this computation, outpatient rehabilitation clinic direct patient service revenue does not include managed clinics or contract services revenue.

39

Results of Operations

The following table outlines, for the periods indicated, selected operating data as a percentage of net operating revenues:

	Select Medical Holdings Corporation				Select Medical Corporation
	Three MonthsEnded September 30,				Three MonthsEnded September 30,
	2011		2012		2011		2012
Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services(1)	83.8		83.9		83.8		83.9
General and administrative	2.2		2.4		2.2		2.4
Bad debt expense	1.7		1.6		1.7		1.6
Depreciation and amortization	2.5		2.2		2.5		2.2
Income from operations	9.8		9.9		9.8		9.9
Loss on early retirement of debt	—		(0.9	)	—		(0.9	)
Equity in earnings of unconsolidated subsidiaries	0.2		0.2		0.2		0.2
Interest expense, net	(3.4	)	(3.3	)	(3.1	)	(3.0	)
Income before income taxes	6.6		5.9		6.9		6.2
Income tax expense	2.8		2.3		2.9		2.4
Net income	3.8		3.6		4.0		3.8
Net income attributable to non-controlling interest	0.1		0.2		0.1		0.2
Net income attributable to Holdings and Select	3.7	%	3.4	%	3.9	%	3.6	%

	Select Medical Holdings Corporation				Select Medical Corporation
	Nine MonthsEnded September 30,				Nine MonthsEnded September 30,
	2011		2012		2011		2012
Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services(1)	81.9		82.6		81.9		82.6
General and administrative	2.3		2.3		2.3		2.3
Bad debt expense	1.9		1.4		1.9		1.4
Depreciation and amortization	2.5		2.1		2.5		2.1
Income from operations	11.4		11.6		11.4		11.6
Loss on early retirement of debt	(1.5	)	(0.3	)	(0.9	)	(0.3	)
Equity in earnings of unconsolidated subsidiaries	0.0		0.3		0.0		0.3
Interest expense, net	(3.6	)	(3.3	)	(2.9	)	(2.8	)
Income before income taxes	6.3		8.3		7.6		8.8
Income tax expense	2.7		3.2		3.2		3.4
Net income	3.6		5.1		4.4		5.4
Net income attributable to non-controlling interest	0.2		0.2		0.2		0.2
Net income attributable to Holdings and Select	3.4	%	4.9	%	4.2	%	5.2	%

40

The following tables summarize selected financial data by business segment, for the periods indicated:

	Select Medical Holdings Corporation								Select Medical Corporation
	Three Months Ended September 30,								Three Months Ended September 30,
	2011			2012			% Change		2011			2012			% Change
	(in thousands)								(in thousands)
Net operating revenues:
Specialty hospitals	$	521,085		$	531,409		2.0	%	$	521,085		$	531,409		2.0	%
Outpatient rehabilitation	173,030			182,246			5.3		173,030			182,246			5.3
Other(2)	16			14			(12.5	)	16			14			(12.5	)
Total company	$	694,131		$	713,669		2.8	%	$	694,131		$	713,669		2.8	%
Income (loss) from operations:
Specialty hospitals	$	68,742		$	72,106		4.9	%	$	68,742		$	72,106		4.9	%
Outpatient rehabilitation	15,432			17,202			11.5		15,432			17,202			11.5
Other(2)	(16,101		)	(18,489		)	(14.8	)	(16,101		)	(18,489		)	(14.8	)
Total company	$	68,073		$	70,819		4.0	%	$	68,073		$	70,819		4.0	%
Adjusted EBITDA:(3)
Specialty hospitals	$	81,570		$	83,659		2.6	%	$	81,570		$	83,659		2.6	%
Outpatient rehabilitation	19,435			20,354			4.7		19,435			20,354			4.7
Other(2)	(14,469		)	(16,266		)	(12.4	)	(14,469		)	(16,266		)	(12.4	)
Total company	$	86,536		$	87,747		1.4	%	$	86,536		$	87,747		1.4	%
Adjusted EBITDA margins:(3)
Specialty hospitals	15.7		%	15.7		%			15.7		%	15.7		%
Outpatient rehabilitation	11.2			11.2					11.2			11.2
Other(2)	N/M			N/M					N/M			N/M
Total company	12.5		%	12.3		%			12.5		%	12.3		%
Total assets:
Specialty hospitals	$	2,191,493		$	2,165,248				$	2,191,493		$	2,165,248
Outpatient rehabilitation	468,551			431,310					468,551			431,310
Other(2)	91,066			185,250					89,568			184,120
Total company	$	2,751,110		$	2,781,808				$	2,749,612		$	2,780,678
Purchases of property and equipment:
Specialty hospitals	$	4,957		$	12,281				$	4,957		$	12,281
Outpatient rehabilitation	3,160			3,073					3,160			3,073
Other(2)	281			1,900					281			1,900
Total company	$	8,398		$	17,254				$	8,398		$	17,254

41

	Select Medical Holdings Corporation								Select Medical Corporation
	Nine Months Ended September 30,								Nine Months Ended September 30,
	2011			2012			% Change		2011			2012			% Change
	(in thousands)								(in thousands)
Net operating revenues:
Specialty hospitals	$	1,561,270		$	1,641,577		5.1	%	$	1,561,270		$	1,641,577		5.1	%
Outpatient rehabilitation	524,694			566,195			7.9		524,694			566,195			7.9
Other(2)	102			111			8.8		102			111			8.8
Total company	$	2,086,066		$	2,207,883		5.8	%	$	2,086,066		$	2,207,883		5.8	%
Income (loss) from operations:
Specialty hospitals	$	235,083		$	250,904		6.7	%	$	235,083		$	250,904		6.7	%
Outpatient rehabilitation	52,619			58,635			11.4		52,619			58,635			11.4
Other(2)	(50,971		)	(53,603		)	(5.2	)	(50,971		)	(53,603		)	(5.2	)
Total company	$	236,731		$	255,936		8.1	%	$	236,731		$	255,936		8.1	%
Adjusted EBITDA:(3)
Specialty hospitals	$	273,004		$	285,779		4.7	%	$	273,004		$	285,779		4.7	%
Outpatient rehabilitation	65,308			68,669			5.1		65,308			68,669			5.1
Other(2)	(46,117		)	(47,358		)	(2.7	)	(46,117		)	(47,358		)	(2.7	)
Total company	$	292,195		$	307,090		5.1	%	$	292,195		$	307,090		5.1	%
Adjusted EBITDA margins:(3)
Specialty hospitals	17.5		%	17.4		%			17.5		%	17.4		%
Outpatient rehabilitation	12.4			12.1					12.4			12.1
Other(2)	N/M			N/M					N/M			N/M
Total company	14.0		%	13.9		%			14.0		%	13.9		%
Total assets:
Specialty hospitals	$	2,191,493		$	2,165,248				$	2,191,493		$	2,165,248
Outpatient rehabilitation	468,551			431,310					468,551			431,310
Other(2)	91,066			185,250					89,568			184,120
Total company	$	2,751,110		$	2,781,808				$	2,749,612		$	2,780,678
Purchases of property and equipment:
Specialty hospitals	$	21,574		$	31,963				$	21,574		$	31,963
Outpatient rehabilitation	8,142			9,786					8,142			9,786
Other(2)	2,378			3,439					2,378			3,439
Total company	$	32,094		$	45,188				$	32,094		$	45,188

N/M — Not Meaningful.

(1)Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense and other operating costs.

(2)Other includes our general and administrative services and non-healthcare services.

42

(3)We define Adjusted EBITDA as net income before interest, income taxes, depreciation and amortization, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries, gain (loss) on early retirement of debt and other income (expense). We believe that the presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our operating units. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

Following is a reconciliation of net income to Adjusted EBITDA as utilized by us in reporting our segment performance:

	Select Medical Holdings Corporation						Select Medical Corporation
	Three Months Ended September 30,						Three Months Ended September 30,
	2011			2012			2011			2012
	(in thousands)						(in thousands)
Net income	$	26,381		$	25,158		$	28,076		$	27,001
Income tax expense	19,330			16,189			20,243			17,181
Interest expense, net of interest income	24,015			24,575			21,407			21,740
Loss on early retirement of debt	—			6,064			—			6,064
Equity in earnings of unconsolidated subsidiaries	(1,653		)	(1,167		)	(1,653		)	(1,167		)
Stock compensation expense:
Included in general and administrative	488			847			488			847
Included in cost of services	430			544			430			544
Depreciation and amortization	17,545			15,537			17,545			15,537
Adjusted EBITDA	$	86,536		$	87,747		$	86,536		$	87,747

	Select Medical Holdings Corporation						Select Medical Corporation
	Nine Months Ended September 30,						Nine Months Ended September 30,
	2011			2012			2011			2012
	(in thousands)						(in thousands)
Net income	$	75,425		$	112,546		$	92,225		$	117,972
Income tax expense	56,809			71,415			65,854			74,337
Interest expense, net of interest income	74,808			72,295			59,596			63,947
Loss on early retirement of debt	31,018			6,064			20,385			6,064
Equity in earnings of unconsolidated subsidiaries	(1,329		)	(6,384		)	(1,329		)	(6,384		)
Stock compensation expense:
Included in general and administrative	1,436			2,436			1,436			2,436
Included in cost of services	1,262			1,554			1,262			1,554
Depreciation and amortization	52,766			47,164			52,766			47,164
Adjusted EBITDA	$	292,195		$	307,090		$	292,195		$	307,090

43

Three Months Ended September 30, 2012 Compared to Three Months Ended September 30, 2011

In the following discussion, we address the results of operations of Select and Holdings.  With the exception of interest expense and income taxes, the results of operations of Holdings are identical to those of Select.  Therefore, the discussion related to net operating revenues, operating expenses, Adjusted EBITDA, income from operations, loss on early retirement of debt, equity in earnings of unconsolidated subsidiaries and non-controlling interest is identical for Holdings and Select.

Net Operating Revenues

Our net operating revenues increased by 2.8% to $713.7 million for the three months ended September 30, 2012 compared to $694.1 million for the three months ended September 30, 2011.

Specialty Hospitals.  Our specialty hospital net operating revenues increased 2.0% to $531.4 million for the three months ended September 30, 2012 compared to $521.1 million for the three months ended September 30, 2011.  The growth in net operating revenue primarily resulted from increases in net revenue per patient day, partially offset by a decline in patient volumes.  Our average net revenue per patient day was $1,517 for the three months ended September 30, 2012 compared to $1,474 for the three months ended September 30, 2011.  The 2.9% increase in our net revenue per patient day was principally due to increases in both our average Medicare and non-Medicare net revenue per patient day.  Our patient days declined 1.3% to 328,871 days for the three months ended September 30, 2012 compared to the three months ended September 30, 2011 due to a decline in Medicare volume.  Our specialty hospital occupancy declined to 69% for the three months ended September 30, 2012 compared to 71% for the three months ended September 30, 2011.

Outpatient Rehabilitation.  Our outpatient rehabilitation net operating revenues increased 5.3% to $182.2 million for the three months ended September 30, 2012 compared to $173.0 million for the three months ended September 30, 2011.  The net operating revenues generated by our outpatient rehabilitation clinics increased 1.0% to $137.8 million for the three months ended September 30, 2012 compared to $136.3 million for the three months ended September 30, 2011.  The increase was principally related to volume growth in our owned outpatient rehabilitation clinics offset by declines in fees earned from managed centers.  The number of patient visits in our owned outpatient rehabilitation clinics increased 2.7% for the three months ended September 30, 2012 to 1,129,015 visits compared to 1,099,342 visits for the three months ended September 30, 2011.  Net revenue per visit in our outpatient rehabilitation clinics was $103 for both the three months ended September 30, 2012 and 2011.  Our contract services business increased net operating revenues by 21.2% to $44.5 million for the three months ended September 30, 2012 compared to $36.7 million for the three months ended September 30, 2011, which primarily resulted from the addition of new contracts in the fourth quarter of 2011.

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense and bad debt expense.  Our operating expenses increased 3.1% to $627.3 million for the three months ended September 30, 2012 compared to $608.5 million for the three months ended September 30, 2011.  As a percentage of our net operating revenues, our operating expenses were 87.9% for the three months ended September 30, 2012 compared to 87.7% for the three months ended September 30, 2011.  Our cost of services, a major component of which is labor expense, were $599.0 million or 83.9% of net operating revenues for the three months ended September 30, 2012 compared to $581.8 million or 83.8% of net operating revenues for the three months ended September 30, 2011.  The increase in cost of services as a percentage of net operating revenues resulted from increased relative labor costs in both our specialty hospital segment and outpatient rehabilitation segment.  This increase in relative labor costs for the three months ended September 30, 2012 resulted from increased labor

44

costs associated with the Baylor JV services agreement, increased staffing costs in our hospitals, and lower productivity in our contract services business.  Facility rent expense, which is a component of cost of services, was $31.7 million for three months ended September 30, 2012 compared to $29.5 million for the three months ended September 30, 2011.  General and administrative expenses were 2.4% of net operating revenues or $17.1 million for the three months ended September 30, 2012 compared to 2.2% of net operating revenues or $15.0 million for the three months ended September 30, 2011.  The increase in our general and administrative expenses resulted from increased administrative costs principally related to executive compensation.  Our bad debt expense was $11.2 million or 1.6% of net operating revenues for the three months ended September 30, 2012 compared to $11.7 million or 1.7% of net operating revenues for the three months ended September 30, 2011.  The decline in our bad debt expense was attributable to our favorable collections experience of accounts receivable in both our operating segments for the three months ended September 30, 2012 as compared to the three months ended September 30, 2011.

Adjusted EBITDA

Specialty Hospitals.   Our Adjusted EBITDA for our specialty hospitals increased 2.6% to $83.7 million for the three months ended September 30, 2012 compared to $81.6 million for the three months ended September 30, 2011.  Our Adjusted EBITDA margins for the segment were 15.7% for both the three months ended September 30, 2012 and 2011.  The increase in the Adjusted EBITDA for our specialty hospitals was primarily the result of operating improvements in the Regency hospitals, increases in management services fees, and lower bad debt expense.

Outpatient Rehabilitation.   Our Adjusted EBITDA for our outpatient rehabilitation segment increased 4.7% to $20.4 million for the three months ended September 30, 2012 compared to $19.4 million for the three months ended September 30, 2011.  Our Adjusted EBITDA margins for the segment were 11.2% for both the three months ended September 30, 2012 and 2011.  The Adjusted EBITDA in our outpatient rehabilitation clinics increased by $0.7 million to $17.9 million and our Adjusted EBITDA margins in our outpatient rehabilitation clinics increased to 13.0% from 12.6% for the three months ended September 30, 2012 compared to the three months ended September 30, 2011.  The increase in our Adjusted EBITDA in our outpatient rehabilitation clinics was principally due to increased volumes and a reduction of bad debt expense, offset in part by increases in labor costs. The Adjusted EBITDA in our contract services business increased by $0.2 million to $2.5 million and the Adjusted EBITDA margins in our contract services business declined to 5.6% from 6.2% for the three months ended September 30, 2012 compared to the three months ended September 30, 2011.  The decline in Adjusted EBITDA margins in our contract services business was principally due to increased relative labor costs associated with lower productivity related to new business.

Other.   Our Adjusted EBITDA loss was $16.3 million for the three months ended September 30, 2012 compared to an Adjusted EBITDA loss of $14.5 million for the three months ended September 30, 2011 and is primarily related to higher general and administrative expenses, as described under “Operating Expenses.”

Income from Operations

For the three months ended September 30, 2012 we had income from operations of $70.8 million compared to $68.1 million for the three months ended September 30, 2011.  The increase in our income from operations resulted principally from increases in our operating performance of our specialty hospital and outpatient rehabilitation segments described above and a decline in depreciation and amortization expense, offset in part by an increase in general and administrative expenses.

45

Loss on Early Retirement of Debt

On September 12, 2012, we redeemed an aggregate of $275.0 million principal amount of Select’s 7 5/8% senior subordinated notes at a redemption price of 101.271% of the principal amount.  We recognized a loss on early retirement of debt of $6.1 million for the three months ended September 30, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and payment of the call premiums.

Equity in Earnings of Unconsolidated Subsidiaries

For the three months ended September 30, 2012, we had equity in earnings of unconsolidated subsidiaries of $1.2 million compared to equity in earnings of unconsolidated subsidiaries of $1.7 million for the three months ended September 30, 2011.  The decline in our equity in earnings of unconsolidated subsidiaries resulted principally from start-up losses incurred by companies that provide specialized technology and services to healthcare entities where we hold a minority equity investment.

Interest Expense

Select Medical Corporation.  Interest expense was $21.7 million for the three months ended September 30, 2012 compared to $21.5 million for the three months ended September 30, 2011.  The increase in interest expense for the three months ended September 30, 2012 is principally due to incremental borrowings associated with the $275.0 million incremental facility under our senior credit agreement completed on August 13, 2012.  The proceeds of which were not used to redeem $275.0 million of Select’s 7 5/8% senior subordinated notes until September 12, 2012.

Select Medical Holdings Corporation.  Interest expense was $24.6 million for the three months ended September 30, 2012 compared to $24.1 million for the three months ended September 30, 2011.  The increase in interest expense for the three months ended September 30, 2012 is principally due to incremental borrowings associated with the $275.0 million incremental facility under our senior credit agreement completed on August 13, 2012.  The proceeds of which were not used to redeem $275.0 million of Select’s 7 5/8% senior subordinated notes until September 12, 2012.

Income Taxes

Select Medical Corporation. We recorded income tax expense of $17.2 million for the three months ended September 30, 2012. The expense represented an effective tax rate of 38.9%.  We recorded income tax expense of $20.2 million for the three months ended September 30, 2011. The expense represented an effective tax rate of 41.9%.  Select Medical Corporation is part of the consolidated federal tax return for Select Medical Holdings Corporation.  We allocate income taxes between Select and Holdings for purposes of financial statement presentation.  Because Holdings is a passive investment company incorporated in Delaware, it does not incur any state income tax expense or benefit on its specific income or loss and, as such, receives a tax allocation equal to the federal statutory rate of 35% on its specific income or loss.  Based upon the relative size of Holdings’ income or loss, this can cause the effective tax rate for Select to differ from the effective tax rate for the consolidated company.

Select Medical Holdings Corporation.  We recorded income tax expense of $16.2 million for the three months ended September 30, 2012.  The expense represented an effective tax rate of 39.2%.  We recorded income tax expense of $19.3 million for the three months ended September 30, 2011.  The expense represented an effective tax rate of 42.3%.  The decline in our effective tax rate is primarily a consequence of the 2011 rate

46

having been impacted by a tax gain associated with a hospital exchange that occurred in 2011, a reduction in the provision for uncertain tax positions and a lower effective state tax rate.

Non-Controlling Interests

Non-controlling interests in consolidated earnings were $1.0 million for the three months ended September 30, 2012 and $0.8 million for the three months ended September 30, 2011.

Nine Months Ended September 30, 2012 Compared to Nine Months Ended September 30, 2011

In the following discussion, we address the results of operations of Select and Holdings.  With the exception of loss on early retirement of debt, interest expense, and income taxes, the results of operations of Holdings are identical to those of Select.  Therefore, the discussion related to net operating revenues, operating expenses, Adjusted EBITDA, income from operations, equity in earnings of unconsolidated subsidiaries and non-controlling interest is identical for Holdings and Select.

Net Operating Revenues

Our net operating revenues increased by 5.8% to $2,207.9 million for the nine months ended September 30, 2012 compared to $2,086.1 million for the nine months ended September 30, 2011.

Specialty Hospitals.  Our specialty hospital net operating revenues increased by 5.1% to $1,641.6 million for the nine months ended September 30, 2012 compared to $1,561.3 million for the nine months ended September 30, 2011.  The growth in net operating revenue primarily resulted from increases in patient volumes, increases in both Medicare and non-Medicare reimbursement rates and revenues that are generated from contracted labor services provided to the Baylor JV.  Our patient days increased 1.4% to 1,007,908 days for the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011.  Our specialty hospital occupancy was 71% for both the nine months ended September 30, 2012 and 2011.  Our average net revenue per patient day was $1,532 for the nine months ended September 30, 2012 compared to $1,498 for the nine months ended September 30, 2011.  The increase in our net revenue per patient day was principally due to increases in our average non-Medicare net revenue per patient day resulting from Medicaid bonus payments we received during the three months ended June 30, 2012, and from increases in management services fees.

Outpatient Rehabilitation.  Our outpatient rehabilitation net operating revenues increased 7.9% to $566.2 million for the nine months ended September 30, 2012 compared to $524.7 million for the nine months ended September 30, 2011.  The net operating revenues generated by our outpatient rehabilitation clinics for the nine months ended September 30, 2012 increased 3.0% to $421.7 million compared to $409.3 million for the nine months ended September 30, 2011.  The increase was primarily related to revenues we generated from contracted labor services provided to the Baylor JV and volume growth in our owned outpatient rehabilitation clinics.  The number of patient visits in our owned outpatient rehabilitation clinics increased 1.9% for the nine months ended September 30, 2012 to 3,447,774 visits compared to 3,381,896 visits for the nine months ended September 30, 2011.  Net revenue per visit in our outpatient rehabilitation clinics was $103 for both the nine months ended September 30, 2012 and 2011.  Our contract services business increased net operating revenues 25.2% to $144.5 million compared to $115.4 million for the nine months ended September 30, 2011, which primarily resulted from the addition of new contracts in the fourth quarter of 2011.

47

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense and bad debt expense.  Our operating expenses increased by 6.0% to $1,904.8 million for the nine months ended September 30, 2012 compared to $1,796.6 million for the nine months ended September 30, 2011.  As a percentage of our net operating revenues, our operating expenses were 86.3% for the nine months ended September 30, 2012 compared to 86.1% for the nine months ended September 30, 2011.  Our cost of services, a major component of which is labor expense, were $1,823.3 million or 82.6% of net operating revenues for the nine months ended September 30, 2012 compared to $1,708.9 million or 81.9% of net operating revenues for the nine months ended September 30, 2011.  The increase in cost of services as a percentage of net operating revenues resulted primarily from increased relative labor costs in both our specialty hospital and our outpatient rehabilitation segments.  Our specialty hospitals experienced an increase in relative labor costs due to the labor costs associated with the Baylor JV services agreement and increased staffing costs during the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011.  Our outpatient rehabilitation segment experienced an increase in relative labor costs associated with the Baylor JV services agreement and lower productivity in our contract services business.  Facility rent expense, which is a component of cost of services, was $93.3 million for the nine months ended September 30, 2012 compared to $89.1 million for the nine months ended September 30, 2011.  General and administrative expenses were $49.9 million for the nine months ended September 30, 2012 compared to $47.7 million for the nine months ended September 30, 2011 and represented 2.3% of net operating revenues in both periods.  This increase in general and administrative expense resulted principally from increases in executive compensation.  Our bad debt expense was $31.6 million or 1.4% of net operating revenues for the nine months ended September 30, 2012 compared to $40.0 million or 1.9% for the nine months ended September 30, 2011.  The decline in our bad debt expense was attributed to our favorable collections experience of accounts receivable in both our operating segments for the nine months ended September 30, 2012 as compared to the nine months ended September 30, 2011.

Adjusted EBITDA

Specialty Hospitals.   Our Adjusted EBITDA for our specialty hospitals increased by 4.7% to $285.8 million for the nine months ended September 30, 2012 compared to $273.0 million for the nine months ended September 30, 2011.  Our Adjusted EBITDA margins for the segment decreased to 17.4% for the nine months ended September 30, 2012 from 17.5% for the nine months ended September 30, 2011.  The increase in the Adjusted EBITDA for our specialty hospitals was primarily the result of increased volume discussed above under “Net Operating Revenues” and a reduction in bad debt expense discussed above under “Operating Expenses.”  The decrease in the Adjusted EBITDA margin is due to negative margin effect of the Baylor JV services agreement.

Outpatient Rehabilitation.   Our Adjusted EBITDA for our outpatient rehabilitation segment increased 5.1% to $68.7 million for the nine months ended September 30, 2012 compared to $65.3 million for the nine months ended September 30, 2011.  Our Adjusted EBITDA margins decreased to 12.1% for the nine months ended September 30, 2012 from 12.4% for the nine months ended September 30, 2011.  The Adjusted EBITDA in our outpatient rehabilitation clinics increased by $2.1 million to $58.2 million for the nine months ended September 30, 2012 compared to $56.1 million for the nine months ended September 30, 2011.  Our Adjusted EBITDA margins for our outpatient rehabilitation clinics increased to 13.8% for the nine months ended September 30, 2012 from 13.7% for the nine months ended September 30, 2011.  The increase in our Adjusted EBITDA margin in our outpatient rehabilitation clinics was principally due to a reduction in relative bad debt and operating expenses, offset in part by increases in relative labor costs.  The Adjusted EBITDA in our contract services business increased by $1.2 million to $10.4 million for the nine months ended September 30, 2012 compared to $9.2 million for the nine months ended September 30, 2011.  The Adjusted EBITDA margins for

48

our contract services business declined to 7.2% for the nine months ended September 30, 2012 compared to 8.0% for the nine months ended September 30, 2011.  The decline in Adjusted EBITDA margins for our contract services business was principally due to increased labor costs associated with new business and lower productivity resulting from regulatory changes that became effective on October 1, 2011.

Other.   Our Adjusted EBITDA loss was $47.4 million for the nine months ended September 30, 2012 compared to an Adjusted EBITDA loss of $46.1 million for the nine months ended September 30, 2011, and is principally related to increases in executive compensation.

Income from Operations

For the nine months ended September 30, 2012 we had income from operations of $255.9 million compared to $236.7 million for the nine months ended September 30, 2011.  The increase in our income from operations resulted principally from increases in our operating performance of our specialty hospital and outpatient rehabilitation segments described above and a decline in depreciation and amortization expense.

Loss on Early Retirement of Debt

Select Medical Corporation.  On September 12, 2012 we redeemed an aggregate of $275.0 million principal amount of Select’s 7 5/8% senior subordinated notes at a redemption price of 101.271% of the principal amount.  We recognized a loss on early retirement of debt of $6.1 million for the nine months ended September 30, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

On June 1, 2011, we refinanced our senior secured credit facility.  A portion of the proceeds from this transaction were used to repurchase and retire $266.5 million of Select’s 7 5/8% senior subordinated notes.  We recognized a loss on early retirement of debt of $20.4 million for the nine months ended September 30, 2011, which included the write-off of unamortized deferred financing costs and tender premiums.

Select Medical Holdings Corporation. On September 12, 2012 we redeemed an aggregate of $275.0 million principal amount of Select’s 7 5/8% senior subordinated notes at a redemption price of 101.271% of the principal amount.  We recognized a loss on early retirement of debt of $6.1 million for the nine months ended September 30, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

On June 1, 2011, we refinanced our senior secured credit facility.  A portion of the proceeds from this transaction were used to repurchase and retire $266.5 million of Select’s 7 5/8% senior subordinated notes and $150.0 million to repurchase and retire our 10% senior subordinated notes.  We recognized a loss on early retirement of debt of $31.0 million for the nine months ended September 30, 2011, which included the write-off of unamortized deferred financing costs, tender premiums and original issue discount.

Equity in Earnings of Unconsolidated Subsidiaries

For the nine months ended September 30, 2012, we had equity in earnings of unconsolidated subsidiaries of $6.4 million compared to equity in earnings of unconsolidated subsidiaries of $1.3 million for the nine months ended September 30, 2011.  The increase in our equity in earnings of unconsolidated subsidiaries resulted principally from an increase in the contribution from the Baylor JV.

49

Interest Expense

Select Medical Corporation.  Interest expense was $63.9 million for the nine months ended September 30, 2012 compared to $59.9 million for the nine months ended September 30, 2011.  The increase in interest expense resulted primarily from the refinancing of $150.0 million of Holdings’ debt, for which Select was not previously obligated, through indebtedness incurred by Select under the new senior secured credit facility on June 1, 2011.

Select Medical Holdings Corporation.  Interest expense was $72.3 million for the nine months ended September 30, 2012 compared to $75.1 million for the nine months ended September 30, 2011.  The decrease in interest expense resulted primarily from the lower interest rates on the portions of the debt that were refinanced on June 1, 2011 and reduced borrowings for the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011.

Income Taxes

Select Medical Corporation.  We recorded income tax expense of $74.3 million for the nine months ended September 30, 2012. The expense represented an effective tax rate of 38.7%.  We recorded income tax expense of $65.9 million for the nine months ended September 30, 2011. The expense represented an effective tax rate of 41.7%.  Select Medical Corporation is part of the consolidated federal tax return for Select Medical Holdings Corporation.  We allocate income taxes between Select and Holdings for purposes of financial statement presentation.  Because Holdings is a passive investment company incorporated in Delaware, it does not incur any state income tax expense or benefit on its specific income or loss and, as such, receives a tax allocation equal to the federal statutory rate of 35% on its specific income or loss.  Based upon the relative size of Holdings’ income or loss, this can cause the effective tax rate for Select to differ from the effective tax rate for the consolidated company.

Select Medical Holdings Corporation.  We recorded income tax expense of $71.4 million for the nine months ended September 30, 2012. The expense represented an effective tax rate of 38.8%.  We recorded income tax expense of $56.8 million for the nine months ended September 30, 2011. The expense represented an effective tax rate of 43.0%.  The decline in our effective tax rate is primarily a consequence of the 2011 rate having been impacted by a tax gain associated with a hospital exchange that occurred in 2011, a reduction in the provision for uncertain tax positions and a lower effective state tax rate.

Non-Controlling Interests

Non-controlling interests in consolidated earnings were $3.7 million for the nine months ended September 30, 2012 and $4.4 million for the nine months ended September 30, 2011.

50

Liquidity and Capital Resources

Cash Flows for the Nine Months Ended September 30, 2012 and Nine Months Ended September 30, 2011

	Select Medical Holdings Corporation						Select Medical Corporation
	Nine Months Ended September 30,						Nine MonthsEnded September 30,
	2011			2012			2011			2012
	(in thousands)						(in thousands)
Cash flows provided by operating activities	$	143,914		$	194,076		$	166,834		$	204,753
Cash flows used in investing activities	(35,808		)	(40,123		)	(35,808		)	(40,123		)
Cash flows used in financing activities	(102,258		)	(116,320		)	(125,178		)	(126,997		)
Net increase in cash and cash equivalents	5,848			37,633			5,848			37,633
Cash and cash equivalents at beginning of period	4,365			12,043			4,365			12,043
Cash and cash equivalents at end of period	$	10,213		$	49,676		$	10,213		$	49,676

Operating activities for Holdings provided $194.1 million and for Select provided $204.8 million of cash flows for the nine months ended September 30, 2012.  Operating activities for Holdings provided $143.9 million and for Select provided $166.8 million of cash flows for the nine months ended September 30, 2011.  The operating cash flows of Select exceeded the operating cash flows of Holdings by $10.7 million for the nine months ended September 30, 2012 and by $22.9 million for the nine months ended September 30, 2011.  The difference relates to interest payments on Holdings’ indebtedness.

Our days sales outstanding were 51 days at September 30, 2012 compared to 52 days at September 30, 2011 and 53 days at December 31, 2011.  The movement in our days sales outstanding is primarily affected by the timing of the periodic interim payments we receive from Medicare for the services provided at our specialty hospitals.

Investing activities used $40.1 million of cash flow for the nine months ended September 30, 2012.  The principal use of cash included $45.2 million related to the purchase of property and equipment, $9.9 million related primarily to an additional investment in the Baylor JV and $1.5 million used for acquisitions.  This use of cash was offset by $16.5 million in proceeds related to the sale of a building.  Investing activities used $35.8 million of cash flow for the nine months ended September 30, 2011.  The principal use of cash included $32.1 million related to the purchase of property and equipment and $13.5 million related to the purchase of the Baylor JV partnership units and working capital advances, offset by proceeds from the sale of assets of $7.9 million which was primarily related to the sale of a building we acquired in connection with the acquisition of Regency and $1.9 million from acquisition activities that includes the resolution of the Regency net working capital settlement with the seller.

Financing activities for Select used $127.0 million of cash flow for the nine months ended September 30, 2012.  The primary uses of cash related to repurchases and redemptions of its 7 5/8% senior subordinated notes of $278.5 million, net payments under our senior secured revolving credit facility of $40.0 million, senior secured credit facility term loan amortization payments of $7.1 million, dividends paid to Holdings to fund interest payments and stock repurchases of $57.5 million, principal payments of other debt of $7.4 million, debt issuance costs of $4.2 million, repayment of bank overdrafts of $3.0 million and distributions to non-controlling interests of $3.0

51

million.  These uses were offset, in part, by additional senior secured credit facility net term loan borrowings of $266.8 million, proceeds of $1.1 million from the issuance of common stock and borrowings of other debt of $5.8 million.  Financing activities for Select used $125.2 million of cash flow for the nine months ended September 30, 2011.  The primary use of cash related to dividends paid to Holdings of $204.6 million to fund interest payments and the repurchase of all $150.0 million principal amount of Holdings 10% senior subordinated notes, $18.6 million of debt issuance costs, repayment of bank overdrafts of $4.2 million and $3.5 million in distributions to non-controlling interests offset by net borrowings of debt of $105.5 million.

The difference in cash flows provided by financing activities of Holdings compared to Select of $10.7 million for the nine months ended September 30, 2012 and $22.9 million for the nine months ended September 30, 2011 related to dividends paid by Select to Holdings to service Holdings’ interest obligations related to indebtedness.

Capital Resources

Select Medical Corporation.  Select had net working capital of $119.9 million at September 30, 2012 compared to a net working capital of $97.3 million at December 31, 2011.

Select Medical Holdings Corporation.  Holdings had net working capital of $119.4 million at September 30, 2012 compared to a net working capital of $99.5 million at December 31, 2011.

On August 13, 2012, Select, Holdings and the subsidiaries of Select named therein entered into an Extension Amendment to Select’s senior secured credit facility with a group of lenders and JPMorgan Chase Bank, N.A. as administrative agent.  Pursuant to the terms and conditions of the Extension Amendment, the lenders extended Series A Tranche B Term Loans in the aggregate principal amount of $275.0 million to Select at the same interest rate and with the same term as applies to other Tranche B Term Loan amounts borrowed by Select under the senior secured credit facility.  On September 12, 2012, Select used the proceeds of the Series A Tranche B Term Loans (other than amounts used for fees and expenses) and cash on hand to redeem an aggregate of $275.0 million principal amount of Select’s outstanding 7 5/8% senior subordinated notes due 2015 at a redemption price of 101.271% of the principal amount.

At September 30, 2012, we had outstanding borrowings of $1,098.8 million (net of unamortized original issue discount of $14.9 million) under the term loans and no outstanding borrowings (excluding letters of credit) under the revolving loan portion of our senior secured credit facilities. Also, as of September 30, 2012, we had $265.9 million of availability under our revolving loan facility (after giving effect to $34.1 million of outstanding letters of credit).

The applicable margin percentage for borrowings under our term loans is (1) 2.75% for alternate base rate loans and (2) 3.75% for adjusted LIBO rate loans. The adjusted LIBO rate at no time shall be less than 1.75% when used in reference to borrowings under our term loans. The applicable margin percentage for borrowings under our revolving loan is subject to change based upon the ratio of Select’s leverage ratio (as defined in the credit agreement). The applicable margin percentage for revolving loans is currently (1) 2.25% for alternate base rate loans and (2) 3.25% for adjusted LIBO rate loans.

Our senior secured credit facility requires Select to maintain certain leverage ratios (as defined in our senior secured credit facility). For the four consecutive fiscal quarters ended September 30, 2012, Select was required to maintain its leverage ratio (its ratio of total indebtedness to consolidated EBITDA) at less than 5.00 to 1.00. Select’s leverage ratio was 2.86 to 1.00 as of September 30, 2012.

52

Holdings’ board of directors authorized a program to repurchase up to $250.0 million worth of shares of our common stock.  The program will remain in effect until March 31, 2013, unless extended by the board of directors. During the nine months ended September 30, 2012, Holdings has repurchased 5,725,782 shares at a cost of $46.8 million and since the inception of the program has repurchased 22,490,389 shares under the program at a cost of $163.6 million, which includes related transaction costs. We anticipate funding this program through available operating cash flow and borrowings under our senior secured credit facility.

We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise.  Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.  The amounts involved may be material.

We believe our internally generated cash flows and borrowing capacity under our senior secured credit facility will be sufficient to finance operations over the next twelve months.

We routinely pursue opportunities to develop new joint venture relationships with significant health systems, and from time to time we may also develop new inpatient rehabilitation hospitals. With the expiration of the moratorium on new LTCHs and new LTCH beds set to expire on December 28, 2012, we are evaluating the addition of LTCH beds at certain of our hospitals.  We also intend to open new outpatient rehabilitation clinics in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth.  In addition to our development activities, we may grow our network of specialty hospitals through opportunistic acquisitions.

Special Cash Dividend

On October 30, 2012, our board of directors declared a special cash dividend of $1.50 per share to be paid on or about December 12, 2012 to all common stockholders of record (including holders of shares of restricted stock) on December 5, 2012.  Cash for the dividend will come from cash on hand and borrowings under Select’s senior secured revolving credit facility.

Recent Accounting Pronouncements

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2012-02, “Intangibles — Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment,” (“Update 2012-02”). In accordance with Update 2012-02, an entity has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. If the entity determines that it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, the entity will be required to perform the quantitative impairment test. Update 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. However, early adoption is permitted. Update 2012-02 will not have a material impact on our consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05, “Comprehensive Income (Topic 220) — Presentation of Comprehensive Income” (“Update 2011-05”) that improves the comparability, consistency and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders’ equity. Update 2011-05 requires that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive

53

statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income (“OCI”) to net income, in both net income and OCI. Update 2011-05 does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, Update 2011-05 does not affect the calculation or reporting of earnings per share. Update 2011-05 was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 and is to be applied retrospectively. We adopted Update 2011-05 on January 1, 2012.  Update 2011-05 had no effect on our presentation of other comprehensive income for the three and nine months ended September 30, 2011 and 2012 because we did not have any items of other comprehensive income during these periods.

ITEM 3.                QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Quantitative and Qualitative Disclosures About Market Risk

We are subject to interest rate risk in connection with our long-term indebtedness.  Our principal interest rate exposure relates to the loans outstanding under Select’s senior secured credit facility and Holdings’ senior floating rate notes. As of September 30, 2012, we had $1,113.7 million (excluding unamortized original issue discount) in term loans outstanding under our senior secured credit facility and $167.3 million in senior floating rate notes outstanding, which bear interest at variable rates. Each eighth point change in interest rates on the variable rate portion of our long-term indebtedness would result in a $1.6 million annual change in interest expense.  However, because the variable interest rate for our $1,113.7 million in term loans is subject to an Adjusted LIBO Rate floor of 1.75% until the Adjusted LIBO Rate exceeds 1.75%, our interest rate on this indebtedness is effectively fixed at 5.50%.

ITEM 4.                CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective as of September 30, 2012 to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized and reported within the time periods specified in the relevant SEC rules and forms.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the third quarter ended September 30, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

54

Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met.  In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events.  Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

PART II                OTHER INFORMATION

ITEM 1.                LEGAL PROCEEDINGS

The Company is a party to various legal actions, proceedings and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”) or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations and liquidity.

To address claims arising out of the operations of the Company’s specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

During April 2012, the Company’s long term acute care hospital in Evansville, Indiana (“SSH - Evansville”) received two subpoenas from the Office of Attorney General for the State of Indiana. One subpoena demanded certain patient medical records of SSH - Evansville. The second subpoena demanded reports and documents related to SSH - Evansville for various periods beginning in 2006, including certain financial, statistical, billing and quality reports; certain policies and procedures, joint venture board meeting minutes, and documents related to certain complaints and internal investigations. SSH — Evansville subsequently received a Request for Information or Assistance from the Office of Inspector General of the U.S. Department of Health and Human Services (Indianapolis, Indiana Field Office) covering the period beginning in 2007 seeking substantially the same records demanded by the Indiana Attorney General’s Office, additional

55

patient medical records of SSH - Evansville and additional documents and information of SSH - Evansville, including documents concerning SSH - Evansville’s relationships with its joint venture partner and seven other identified persons and entities. During May 2012, the Evansville (Indiana) Police Department executed a search warrant at SSH - Evansville purporting to seek evidence pertaining to the crime of theft. At the Company’s request, the Vanderburgh (Indiana) Superior Court ordered the release of the probable cause affidavit supporting that search warrant. According to the affidavit, confidential informants, some of whom are purportedly current or former employees of SSH-Evansville, alleged, among other things, that a physician on the medical staff at SSH-Evansville improperly manipulated patient diagnoses to raise the diagnosis related group (DRG) and lengths-of-stay to enhance reimbursement and, on one occasion, discontinued treatments to a patient based on financial motivation and without regard to the patient’s end of life instructions resulting in the patient’s death, and that a second physician on the medical staff at SSH-Evansville performed bronchoscopes that were medically unnecessary and resulted in at least two patient deaths. The affidavit also makes allegations that imply that the Company may not have provided complete or accurate documents called for in the Indiana Attorney General’s Office subpoenas which were received during April 2012. In August 2012, the Company received a subpoena from the Office of Inspector General of the U.S. Department of Health and Human Services (Chicago Regional Office)  (“OIG—Chicago”) demanding additional documents covering the period beginning in March 2007 relating to the Company and SSH - Evansville, including contracts with SSH - Evansville’s joint venture partner, contracts and other documents relating to financial relationships with physicians practicing at SSH - Evansville, records of payments to and hours worked by physicians practicing at SSH - Evansville, documents relating to actual or expected physician referrals and admissions to SSH - Evansville, documents relating to billing for services furnished by the Company’s long term acute care hospitals (“LTCHs”), such as government program guidance and staff training materials, information relating to case manager duties and responsibilities at the Company’s LTCHs, reports on patient admissions, discharges, DRG, length-of-stay and transfers at SSH - Evansville, and documents relating to criteria used by the Company or SSH - Evansville for patient admissions, discharges and eligibility for service. In October 2012, the Company received an additional subpoena from OIG—Chicago seeking the medical records of 19 patients treated at SSH — Evansville between 2008 and 2012. The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

ITEM 1A.RISK FACTORS.

There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2011.

ITEM 2.                UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.                DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.                MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.                OTHER INFORMATION

None.

56

ITEM 6.                EXHIBITS

The exhibits to this report are listed in the Exhibit Index appearing on page 58 hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SELECT MEDICAL CORPORATION
	By:	/s/ Martin F. Jackson
		Martin F. Jackson
		Executive Vice President and Chief Financial Officer
		(Duly Authorized Officer)
	By:	/s/ Scott A. Romberger
		Scott A. Romberger
		Senior Vice President, Chief Accounting Officer and Controller
		(Principal Accounting Officer)
Dated: November 1, 2012
	SELECT MEDICAL HOLDINGS CORPORATION
	By:	/s/ Martin F. Jackson
		Martin F. Jackson
		Executive Vice President and Chief Financial Officer
		(Duly Authorized Officer)
	By:	/s/ Scott A. Romberger
		Scott A. Romberger
		Senior Vice President, Chief Accounting Officer and Controller
		(Principal Accounting Officer)
Dated:  November 1, 2012

57

EXHIBIT INDEX

Exhibit	Description
10.1	Additional Credit Extension Amendment, dated as of August 13, 2012, among Select Medical Holdings Corporation, Select Medical Corporation, the subsidiaries of Select Medical Corporation named therein and the financial institutions party thereto, incorporated herein by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on August 14, 2012 (Reg. Nos. 001-34465 and 001-31441).
10.2	Amendment No. 1 to the Credit Agreement, dated as of August 8, 2012, among Select Medical Holdings Corporation, Select Medical Corporation and JPMorgan Chase Bank, N.A., incorporated herein by reference to Exhibit 10.2 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select Medical Corporation filed on August 14, 2012 (Reg. Nos. 001-34465 and 001-31441).
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Operations for the three and nine months ended September 30, 2012 and 2011, (ii) Consolidated Balance Sheets as of September 30, 2012 and December 31, 2011, (iii) Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 and 2011, (iv) Consolidated Statements of Changes in Equity and Income for the nine months ended September 30, 2012 and (v) Notes to Consolidated Financial Statements.*

*  XBRL information is furnished and not filed herewith, is not part of a registration statement or prospectus for purposes of section 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

58

EX-31.1

EXHIBIT 31.1

SELECT MEDICAL HOLDINGS CORPORATION AND
SELECT MEDICAL CORPORATION
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Robert A. Ortenzio, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the

registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2012	/s/ Robert A. Ortenzio
	Robert A. Ortenzio
	Chief Executive Officer

EX-31.2

EXHIBIT 31.2

SELECT MEDICAL HOLDINGS CORPORATION AND
SELECT MEDICAL CORPORATION
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Martin F. Jackson, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the

registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2012	/s/ Martin F. Jackson
	Martin F. Jackson
	Executive Vice President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation and Select Medical Corporation (the “Company”) for the period ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Robert A. Ortenzio and Martin F. Jackson, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

November 1, 2012

/s/ Robert A. Ortenzio

Robert A. Ortenzio

Chief Executive Officer

/s/ Martin F. Jackson

Martin F. Jackson

Executive Vice President and Chief Financial Officer

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes (Details 3) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Condensed Consolidating Statement of Operations
Net operating revenues	$ 713,669	$ 694,131	$ 2,207,883	$ 2,086,066
Costs and expenses:
Cost of services	598,984	581,829	1,823,272	1,708,911
General and administrative	17,130	14,975	49,908	47,656
Bad debt expense	11,199	11,709	31,603	40,002
Depreciation and amortization	15,537	17,545	47,164	52,766
Total costs and expenses	642,850	626,058	1,951,947	1,849,335
Income from operations	70,819	68,073	255,936	236,731
Other income and expense:
Intercompany interest and royalty fees	0	0		0
Intercompany management fees	0	0		0
Loss on early retirement of debt	(6,064)		(6,064)	(31,018)
Equity in earnings of unconsolidated subsidiaries	1,167	1,653	6,384	1,329
Interest income		119		286
Interest expense	(24,575)	(24,134)	(72,295)	(75,094)
Income before income taxes	41,347	45,711	183,961	132,234
Income tax expense (benefit)	16,189	19,330	71,415	56,809
Net income	25,158	26,381	112,546	75,425
Less: Net income attributable to non-controlling interests	1,048	785	3,722	4,438
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	24,110	25,596	108,824	70,987
Select Medical Corporation
Condensed Consolidating Statement of Operations
Net operating revenues	713,669	694,131	2,207,883	2,086,066
Costs and expenses:
Cost of services	598,984	581,829	1,823,272	1,708,911
General and administrative	17,130	14,975	49,908	47,656
Bad debt expense	11,199	11,709	31,603	40,002
Depreciation and amortization	15,537	17,545	47,164	52,766
Total costs and expenses	642,850	626,058	1,951,947	1,849,335
Income from operations	70,819	68,073	255,936	236,731
Other income and expense:
Loss on early retirement of debt	(6,064)		(6,064)	(20,385)
Equity in earnings of unconsolidated subsidiaries	1,167	1,653	6,384	1,329
Interest income		119		286
Interest expense	(21,740)	(21,526)	(63,947)	(59,882)
Income before income taxes	44,182	48,319	192,309	158,079
Income tax expense (benefit)	17,181	20,243	74,337	65,854
Net income	27,001	28,076	117,972	92,225
Less: Net income attributable to non-controlling interests	1,048	785	3,722	4,438
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	25,953	27,291	114,250	87,787
Select Medical Corporation | Select Medical Corporation (Parent Company Only)
Condensed Consolidating Statement of Operations
Net operating revenues	14	16	111	102
Costs and expenses:
Cost of services	544	430	1,554	1,262
General and administrative	17,742	14,804	51,197	47,298
Depreciation and amortization	832	641	2,255	1,941
Total costs and expenses	19,118	15,875	55,006	50,501
Income from operations	(19,104)	(15,859)	(54,895)	(50,399)
Other income and expense:
Intercompany interest and royalty fees	(469)	(659)	(2,025)	(2,654)
Intercompany management fees	34,811	18,698	91,940	86,561
Loss on early retirement of debt	(6,064)		(6,064)	(20,385)
Interest income		36		101
Interest expense	(14,676)	(12,556)	(40,823)	(28,932)
Income before income taxes	(5,502)	(10,340)	(11,867)	(15,708)
Income tax expense (benefit)	(3,589)	(1,502)	(1,613)	(214)
Equity in earnings of subsidiaries	27,866	36,129	124,504	103,281
Net income	25,953	27,291	114,250	87,787
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	25,953	27,291	114,250	87,787
Select Medical Corporation | Subsidiary Guarantors
Condensed Consolidating Statement of Operations
Net operating revenues	616,610	603,737	1,910,563	1,809,552
Costs and expenses:
Cost of services	514,136	502,576	1,567,080	1,476,857
General and administrative	(612)	171	(1,289)	358
Bad debt expense	9,525	10,219	27,199	35,128
Depreciation and amortization	12,372	14,484	37,952	43,939
Total costs and expenses	535,421	527,450	1,630,942	1,556,282
Income from operations	81,189	76,287	279,621	253,270
Other income and expense:
Intercompany interest and royalty fees	459	655	1,998	2,635
Intercompany management fees	(29,960)	(14,320)	(78,202)	(73,451)
Equity in earnings of unconsolidated subsidiaries	1,146	1,633	6,340	1,285
Interest income		16		117
Interest expense	(6,010)	(7,874)	(19,920)	(27,193)
Income before income taxes	46,824	56,397	189,837	156,663
Income tax expense (benefit)	21,020	21,215	75,924	65,259
Equity in earnings of subsidiaries	2,123	1,761	11,234	12,342
Net income	27,927	36,943	125,147	103,746
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	27,927	36,943	125,147	103,746
Select Medical Corporation | Non-Guarantor Subsidiaries
Condensed Consolidating Statement of Operations
Net operating revenues	97,045	90,378	297,209	276,412
Costs and expenses:
Cost of services	84,304	78,823	254,638	230,792
Bad debt expense	1,674	1,490	4,404	4,874
Depreciation and amortization	2,333	2,420	6,957	6,886
Total costs and expenses	88,311	82,733	265,999	242,552
Income from operations	8,734	7,645	31,210	33,860
Other income and expense:
Intercompany interest and royalty fees	10	4	27	19
Intercompany management fees	(4,851)	(4,378)	(13,738)	(13,110)
Equity in earnings of unconsolidated subsidiaries	21	20	44	44
Interest income		67		68
Interest expense	(1,054)	(1,096)	(3,204)	(3,757)
Income before income taxes	2,860	2,262	14,339	17,124
Income tax expense (benefit)	(250)	530	26	809
Net income	3,110	1,732	14,313	16,315
Less: Net income attributable to non-controlling interests	1,048	785	3,722	4,438
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	2,062	947	10,591	11,877
Select Medical Corporation | Eliminations
Other income and expense:
Equity in earnings of subsidiaries	(29,989)	(37,890)	(135,738)	(115,623)
Net income	(29,989)	(37,890)	(135,738)	(115,623)
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ (29,989)	$ (37,890)	$ (135,738)	$ (115,623)

XML

Segment Information (Details 2) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Segment Information
Adjusted EBITDA	$ 87,747	$ 86,536	$ 307,090	$ 292,195
Depreciation and amortization	(15,537)	(17,545)	(47,164)	(52,766)
Income (loss) from operations	70,819	68,073	255,936	236,731
Loss on early retirement of debt	(6,064)		(6,064)	(31,018)
Equity in earnings of unconsolidated subsidiaries	1,167	1,653	6,384	1,329
Interest expense, net	(24,575)	(24,015)	(72,295)	(74,808)
Income before income taxes	41,347	45,711	183,961	132,234
Select Medical Corporation
Segment Information
Adjusted EBITDA	87,747	86,536	307,090	292,195
Depreciation and amortization	(15,537)	(17,545)	(47,164)	(52,766)
Income (loss) from operations	70,819	68,073	255,936	236,731
Loss on early retirement of debt	(6,064)		(6,064)	(20,385)
Equity in earnings of unconsolidated subsidiaries	1,167	1,653	6,384	1,329
Interest expense, net	(21,740)	(21,407)	(63,947)	(59,596)
Income before income taxes	44,182	48,319	192,309	158,079
Specialty Hospitals
Segment Information
Adjusted EBITDA	83,659	81,570	285,779	273,004
Depreciation and amortization	(11,553)	(12,828)	(34,875)	(37,921)
Income (loss) from operations	72,106	68,742	250,904	235,083
Outpatient Rehabilitation
Segment Information
Adjusted EBITDA	20,354	19,435	68,669	65,308
Depreciation and amortization	(3,152)	(4,003)	(10,034)	(12,689)
Income (loss) from operations	17,202	15,432	58,635	52,619
All Other
Segment Information
Adjusted EBITDA	(16,266)	(14,469)	(47,358)	(46,117)
Depreciation and amortization	(832)	(714)	(2,255)	(2,156)
Stock compensation expense	(1,391)	(918)	(3,990)	(2,698)
Income (loss) from operations	$ (18,489)	$ (16,101)	$ (53,603)	$ (50,971)

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes (Tables)

9 Months Ended

Sep. 30, 2012

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes

Schedule of Condensed Consolidating Balance Sheet

Select Medical Corporation

Condensed Consolidating Balance Sheet

September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	45,069		$	3,535		$	1,072		$	—		$	49,676
Accounts receivable, net	—			334,826			57,821			—			392,647
Current deferred tax asset	11,673			2,698			3,607			—			17,978
Prepaid income taxes	1,410			—			—			—			1,410
Other current assets	5,158			21,497			4,965			—			31,620
Total Current Assets	63,310			362,556			67,465			—			493,331
Property and equipment, net	15,823			421,493			57,309			—			494,625
Investment in affiliates	2,889,285			80,859			—			(2,970,144		)(a) (b)	—
Goodwill	—			1,633,106			—			—			1,633,106
Other identifiable intangibles	—			71,783			—			—			71,783
Assets held for sale	2,742			—			—			—			2,742
Other assets	24,898			59,482			711			—			85,091
Total Assets	$	2,996,058		$	2,629,279		$	125,485		$	(2,970,144	)	$	2,780,678
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	13,598		$	—		$	—		$	—		$	13,598
Current portion of long-term debt and notes payable	9,062			585			1,437			—			11,084
Accounts payable	7,771			70,365			13,384			—			91,520
Intercompany accounts	1,058,973			(963,967		)	(95,006		)	—			—
Accrued payroll	72			83,293			318			—			83,683
Accrued vacation	4,120			42,565			6,525			—			53,210
Accrued interest	12,504			909			—			—			13,413
Accrued restructuring	—			2,015			—			—			2,015
Accrued other	50,778			40,287			7,939			—			99,004
Due to third party payors	—			2,705			3,181			—			5,886
Total Current Liabilities	1,156,878			(721,243		)	(62,222		)	—			373,413
Long-term debt, net of current portion	736,945			364,287			62,017			—			1,163,249
Non-current deferred tax liability	(4,715		)	80,258			8,575			—			84,118
Other non-current liabilities	50,703			19,546			253			—			70,502
Total Liabilities	1,939,811			(257,152		)	8,623			—			1,691,282
Stockholder’s Equity:
Common stock	0			—			—			—			0
Capital in excess of par	856,446			—			—			—			856,446
Retained earnings	199,801			752,267			24,428			(776,695		)(b)	199,801
Subsidiary investment	—			2,134,164			59,285			(2,193,449		)(a)	—
Total Select Medical Corporation Stockholder’s Equity	1,056,247			2,886,431			83,713			(2,970,144		)	1,056,247
Non-controlling interest	—			—			33,149			—			33,149
Total Equity	1,056,247			2,886,431			116,862			(2,970,144		)	1,089,396
Total Liabilities and Equity	$	2,996,058		$	2,629,279		$	125,485		$	(2,970,144	)	$	2,780,678

(a)  Elimination of investments in consolidated subsidiaries.

(b)  Elimination of investments in consolidated subsidiaries’ earnings.

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	11,427		$	—		$	616		$	—		$	12,043
Accounts receivable, net	—			369,321			44,422			—			413,743
Current deferred tax asset	11,415			3,221			3,669			—			18,305
Prepaid income taxes	9,497			—			—			—			9,497
Other current assets	6,340			19,407			4,075			—			29,822
Total Current Assets	38,679			391,949			52,782			—			483,410
Property and equipment, net	14,641			440,736			54,651			—			510,028
Investment in affiliates	2,751,776			83,772			—			(2,835,548		)(a) (b)	—
Goodwill	—			1,631,716			—			—			1,631,716
Other identifiable intangibles	—			72,123			—			—			72,123
Assets held for sale	2,742			—			—			—			2,742
Other assets	28,386			41,480			853			—			70,719
Total Assets	$	2,836,224		$	2,661,776		$	108,286		$	(2,835,548	)	$	2,770,738
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	16,609		$	—		$	—		$	—		$	16,609
Current portion of long-term debt and notes payable	8,853			390			1,605			—			10,848
Accounts payable	7,353			76,207			12,058			—			95,618
Intercompany accounts	975,809			(880,537		)	(95,272		)	—			—
Accrued payroll	229			82,518			141			—			82,888
Accrued vacation	3,703			41,305			6,242			—			51,250
Accrued interest	11,843			137			—			—			11,980
Accrued restructuring	—			5,027			—			—			5,027
Accrued other	47,829			51,086			7,401			—			106,316
Due to third party payors	—			13,633			(8,107		)	—			5,526
Total Current Liabilities	1,072,228			(610,234		)	(75,932		)	—			386,062
Long-term debt, net of current portion	733,328			425,315			60,007			—			1,218,650
Non-current deferred tax liability	(2,509		)	75,750			8,787			—			82,028
Other non-current liabilities	46,555			17,970			380			—			64,905
Total Liabilities	1,849,602			(91,199		)	(6,758		)	—			1,751,645
Stockholder’s Equity:
Common stock	0			—			—			—			0
Capital in excess of par	848,844			—			—			—			848,844
Retained earnings	137,778			627,120			23,154			(650,274		)(b)	137,778
Subsidiary investment	—			2,125,855			59,419			(2,185,274		)(a)	—
Total Select Medical Corporation Stockholder’s Equity	986,622			2,752,975			82,573			(2,835,548		)	986,622
Non-controlling interest	—			—			32,471			—			32,471
Total Equity	986,622			2,752,975			115,044			(2,835,548		)	1,019,093
Total Liabilities and Equity	$	2,836,224		$	2,661,776		$	108,286		$	(2,835,548	)	$	2,770,738

(a)  Elimination of investments in consolidated subsidiaries.

(b)  Elimination of investments in consolidated subsidiaries’ earnings.

Schedule of Condensed Consolidating Statement of Operations

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	14		$	616,610		$	97,045		$	—		$	713,669
Costs and expenses:
Cost of services	544			514,136			84,304			—			598,984
General and administrative	17,742			(612		)	—			—			17,130
Bad debt expense	—			9,525			1,674			—			11,199
Depreciation and amortization	832			12,372			2,333			—			15,537
Total costs and expenses	19,118			535,421			88,311			—			642,850
Income (loss) from operations	(19,104		)	81,189			8,734			—			70,819
Other income and expense:
Intercompany interest and royalty fees	(469		)	459			10			—			—
Intercompany management fees	34,811			(29,960		)	(4,851		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			1,146			21			—			1,167
Interest expense	(14,676		)	(6,010		)	(1,054		)	—			(21,740		)
Income (loss) from operations before income taxes	(5,502		)	46,824			2,860			—			44,182
Income tax expense (benefit)	(3,589		)	21,020			(250		)	—			17,181
Equity in earnings of subsidiaries	27,866			2,123			—			(29,989		)(a)	—
Net income	25,953			27,927			3,110			(29,989		)	27,001
Less: Net income attributable to non-controlling interests	—			—			1,048			—			1,048
Net income attributable to Select Medical Corporation	$	25,953		$	27,927		$	2,062		$	(29,989	)	$	25,953

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	111		$	1,910,563		$	297,209		$	—		$	2,207,883
Costs and expenses:
Cost of services	1,554			1,567,080			254,638			—			1,823,272
General and administrative	51,197			(1,289		)	—			—			49,908
Bad debt expense	—			27,199			4,404			—			31,603
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Total costs and expenses	55,006			1,630,942			265,999			—			1,951,947
Income (loss) from operations	(54,895		)	279,621			31,210			—			255,936
Other income and expense:
Intercompany interest and royalty fees	(2,025		)	1,998			27			—			—
Intercompany management fees	91,940			(78,202		)	(13,738		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			6,340			44			—			6,384
Interest expense	(40,823		)	(19,920		)	(3,204		)	—			(63,947		)
Income (loss) from operations before income taxes	(11,867		)	189,837			14,339			—			192,309
Income tax expense (benefit)	(1,613		)	75,924			26			—			74,337
Equity in earnings of subsidiaries	124,504			11,234			—			(135,738		)(a)	—
Net income	114,250			125,147			14,313			(135,738		)	117,972
Less: Net income attributable to non-controlling interests	—			—			3,722			—			3,722
Net income attributable to Select Medical Corporation	$	114,250		$	125,147		$	10,591		$	(135,738	)	$	114,250

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	16		$	603,737		$	90,378		$	—		$	694,131
Costs and expenses:
Cost of services	430			502,576			78,823			—			581,829
General and administrative	14,804			171			—			—			14,975
Bad debt expense	—			10,219			1,490			—			11,709
Depreciation and amortization	641			14,484			2,420			—			17,545
Total costs and expenses	15,875			527,450			82,733			—			626,058
Income (loss) from operations	(15,859		)	76,287			7,645			—			68,073
Other income and expense:
Intercompany interest and royalty fees	(659		)	655			4			—			—
Intercompany management fees	18,698			(14,320		)	(4,378		)	—			—
Equity in earnings of unconsolidated subsidiaries	—			1,633			20			—			1,653
Interest income	36			16			67			—			119
Interest expense	(12,556		)	(7,874		)	(1,096		)	—			(21,526		)
Income (loss) from operations before income taxes	(10,340		)	56,397			2,262			—			48,319
Income tax expense (benefit)	(1,502		)	21,215			530			—			20,243
Equity in earnings of subsidiaries	36,129			1,761			—			(37,890		)(a)	—
Net income	27,291			36,943			1,732			(37,890		)	28,076
Less: Net income attributable to non-controlling interests	—			—			785			—			785
Net income attributable to Select Medical Corporation	$	27,291		$	36,943		$	947		$	(37,890	)	$	27,291

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	102		$	1,809,552		$	276,412		$	—		$	2,086,066
Costs and expenses:
Cost of services	1,262			1,476,857			230,792			—			1,708,911
General and administrative	47,298			358			—			—			47,656
Bad debt expense	—			35,128			4,874			—			40,002
Depreciation and amortization	1,941			43,939			6,886			—			52,766
Total costs and expenses	50,501			1,556,282			242,552			—			1,849,335
Income (loss) from operations	(50,399		)	253,270			33,860			—			236,731
Other income and expense:
Intercompany interest and royalty fees	(2,654		)	2,635			19			—			—
Intercompany management fees	86,561			(73,451		)	(13,110		)	—			—
Loss on early retirement of debt	(20,385		)	—			—			—			(20,385		)
Equity in earnings of unconsolidated subsidiaries	—			1,285			44			—			1,329
Interest income	101			117			68			—			286
Interest expense	(28,932		)	(27,193		)	(3,757		)	—			(59,882		)
Income (loss) from operations before income taxes	(15,708		)	156,663			17,124			—			158,079
Income tax expense (benefit)	(214		)	65,259			809			—			65,854
Equity in earnings of subsidiaries	103,281			12,342			—			(115,623		)(a)	—
Net income	87,787			103,746			16,315			(115,623		)	92,225
Less: Net income attributable to non-controlling interests	—			—			4,438			—			4,438
Net income attributable to Select Medical Corporation	$	87,787		$	103,746		$	11,877		$	(115,623	)	$	87,787

(a) Elimination of equity in earnings of subsidiaries.

Schedule of Condensed Consolidating Statement of Cash Flows

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	114,250		$	125,147		$	14,313		$	(135,738	)(a)	$	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Provision for bad debts	—			27,199			4,404			—			31,603
Loss on early retirement of debt	6,064			—			—			—			6,064
Loss (gain) from disposal of assets	—			(3,501		)	17			—			(3,484		)
Non-cash stock compensation expense	3,990			—			—			—			3,990
Amortization of debt discount	1,123			—			—			—			1,123
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(124,504		)	(11,234		)	—			135,738		(a)	—
Intercompany	73,693			(65,471		)	(8,222		)	—			—
Accounts receivable	—			7,296			(17,803		)	—			(10,507		)
Other current assets	1,182			(2,141		)	(890		)	—			(1,849		)
Other assets	3,488			(4,652		)	142			—			(1,022		)
Accounts payable	418			(5,842		)	1,326			—			(4,098		)
Due to third-party payors	—			(10,928		)	11,288			—			360
Accrued expenses	3,870			(1,912		)	998			—			2,956
Income and deferred taxes	14,481			—			—			—			14,481
Net cash provided by operating activities	100,310			91,913			12,530			—			204,753
Investing activities
Purchases of property and equipment	(3,617		)	(31,978		)	(9,593		)	—			(45,188		)
Proceeds from sale of assets	—			16,511			—			—			16,511
Investment in business, net of distributions	—			(9,899		)	—			—			(9,899		)
Acquisition of businesses, net of cash acquired	—			(1,547		)	—			—			(1,547		)
Net cash used in investing activities	(3,617		)	(26,913		)	(9,593		)	—			(40,123		)
Financing activities
Borrowings on revolving credit facility	365,000			—			—			—			365,000
Payments on revolving credit facility	(405,000		)	—			—			—			(405,000		)
Borrowings on 2011 credit facility term loans, net of discount	266,750			—			—			—			266,750
Payments on 2011 credit facility term loans	(7,063		)	—			—			—			(7,063		)
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(278,495		)	—			—			—			(278,495		)
Borrowings of other debt	5,557			—			278			—			5,835
Principal payments on other debt	(6,667		)	(322		)	(428		)	—			(7,417		)
Debt issuance costs	(4,236		)	—			—			—			(4,236		)
Dividends paid to Holdings	(57,467		)	—			—			—			(57,467		)
Equity investment by Holdings	1,104			—			—			—			1,104
Repayment of bank overdrafts	(3,011		)	—			—			—			(3,011		)
Intercompany debt reallocation	60,477			(61,143		)	666			—			—
Distributions to non-controlling interests	—			—			(2,997		)	—			(2,997		)
Net cash used in financing activities	(63,051		)	(61,465		)	(2,481		)	—			(126,997		)
Net increase in cash and cash equivalents	33,642			3,535			456			—			37,633
Cash and cash equivalents at beginning of period	11,427			—			616			—			12,043
Cash and cash equivalents at end of period	$	45,069		$	3,535		$	1,072		$	—		$	49,676

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	87,787		$	103,746		$	16,315		$	(115,623	)(a)	$	92,225
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,941			43,939			6,886			—			52,766
Provision for bad debts	—			35,128			4,874			—			40,002
Loss on early retirement of debt	20,385			—			—			—			20,385
Loss (gain) from disposal of assets	13			(5,233		)	38			—			(5,182		)
Non-cash stock compensation expense	2,698			—			—			—			2,698
Amortization of debt discount	412			—			—			—			412
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(103,281		)	(12,342		)	—			115,623		(a)	—
Intercompany	60,188			(49,269		)	(10,919		)	—			—
Accounts receivable	—			(73,437		)	(8,029		)	—			(81,466		)
Other current assets	(455		)	412			283			—			240
Other assets	(8,306		)	8,826			203			—			723
Accounts payable	1,622			10,102			2,284			—			14,008
Due to third-party payors	—			2,710			(3,760		)	—			(1,050		)
Accrued expenses	(4,455		)	701			104			—			(3,650		)
Income and deferred taxes	34,723			—			—			—			34,723
Net cash provided by operating activities	93,272			65,283			8,279			—			166,834
Investing activities
Purchases of property and equipment	(2,384		)	(26,342		)	(3,368		)	—			(32,094		)
Investment in business	—			(13,514		)	—			—			(13,514		)
Acquisition of businesses, net of cash acquired	—			1,921			—			—			1,921
Proceeds from sale of assets	—			7,879			—			—			7,879
Net cash used in investing activities	(2,384		)	(30,056		)	(3,368		)	—			(35,808		)
Financing activities
Borrowings on revolving credit facility	595,000			—			—			—			595,000
Payments on revolving credit facility	(570,000		)	—			—			—			(570,000		)
Borrowings on 2011 credit facility term loans, net of discount	841,500			—			—			—			841,500
Payments on 2011 credit facility term loans	(2,125		)	—			—			—			(2,125		)
Payments on 2005 credit facility term loans, net of premium	(484,633		)	—			—			—			(484,633		)
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(273,941		)	—			—			—			(273,941		)
Borrowings of other debt	5,496			—			—			—			5,496
Principal payments on other debt	(4,326		)	(650		)	(870		)	—			(5,846		)
Debt issuance costs	(18,556		)	—			—			—			(18,556		)
Repayments of bank overdrafts	(4,174		)	—			—			—			(4,174		)
Equity investment by Holdings	169			—			—			—			169
Dividends paid to Holdings	(204,561		)	—			—			—			(204,561		)
Intercompany debt reallocation	38,082			(37,564		)	(518		)	—			—
Distributions to non-controlling interests	—			—			(3,507		)	—			(3,507		)
Net cash used in financing activities	(82,069		)	(38,214		)	(4,895		)	—			(125,178		)
Net increase (decrease) in cash and cash equivalents	8,819			(2,987		)	16			—			5,848
Cash and cash equivalents at beginning of period	149			3,567			649			—			4,365
Cash and cash equivalents at end of period	$	8,968		$	580		$	665		$	—		$	10,213

(a)  Elimination of equity in earnings of consolidated subsidiaries.

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes (Details) (7 5/8% senior subordinated notes)	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011
Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes
Interest rate of debt (as a percent)	7.625%	7.625%	7.625%
Select
Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes
Interest rate of debt (as a percent)	7.625%	7.625%	7.625%

XML

Accounting Policies

9 Months Ended

Sep. 30, 2012

Accounting Policies

Accounting Policies

2.Accounting Policies

Use of Estimates

        The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Recent Accounting Pronouncements

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2012-02, “Intangibles — Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment,” (“Update 2012-02”). In accordance with Update 2012-02, an entity has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. If the entity determines that it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, the entity will be required to perform the quantitative impairment test. Update 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. However, early adoption is permitted. Update 2012-02 will not have a material impact on the Company’s consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05, “Comprehensive Income (Topic 220) — Presentation of Comprehensive Income” (“Update 2011-05”) that improves the comparability, consistency and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders’ equity. Update 2011-05 requires that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income (“OCI”) to net income, in both net income and OCI. Update 2011-05 does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, Update 2011-05 does not affect the calculation or reporting of earnings per share. Update 2011-05 was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 and is to be applied retrospectively. The Company adopted Update 2011-05 on January 1, 2012.  Update 2011-05 had no effect on the Company’s presentation of other comprehensive income for the three and nine months ended September 30, 2011 and 2012 because the Company did not have any items of other comprehensive income during these periods.

XML

Restructuring Reserves (Details) (USD $) In Thousands, unless otherwise specified			9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012 Lease Termination Costs	Dec. 31, 2007 Outpatient rehabilitation division of HealthSouth Corporation Workforce reductions and lease termination costs	Dec. 31, 2010 Regency Lease Termination Costs
Changes in restructuring activity
Balance at the beginning of the period	$ 2,015	$ 5,027	$ 5,027	$ 18,700	$ 4,300
Amounts paid in 2012			(1,169)
Accretion expense			202
Revision of estimate			(2,045)
Balance at the end of the period	$ 2,015	$ 5,027	$ 2,015	$ 18,700	$ 4,300

XML

Intangible Assets (Details 3) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012
Goodwill
Balance at the beginning of the period	$ 1,631,716
Goodwill acquired during the period	1,723
Other	(333)
Balance at the end of the period	1,633,106
Specialty Hospitals
Goodwill
Balance at the beginning of the period	1,333,553
Other	(333)
Balance at the end of the period	1,333,220
Outpatient Rehabilitation
Goodwill
Balance at the beginning of the period	298,163
Goodwill acquired during the period	1,723
Balance at the end of the period	$ 299,886

XML

Indebtedness (Details) (USD $)	3 Months Ended	9 Months Ended			3 Months Ended	9 Months Ended			0 Months Ended														0 Months Ended
	Sep. 30, 2012	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2012 Select	Sep. 30, 2012 Select	Sep. 30, 2011 Select	Dec. 31, 2011 Select	Sep. 12, 2012 7 5/8% senior subordinated notes	Sep. 30, 2012 7 5/8% senior subordinated notes	Dec. 31, 2011 7 5/8% senior subordinated notes	Sep. 30, 2011 7 5/8% senior subordinated notes	Sep. 30, 2012 7 5/8% senior subordinated notes Select	Sep. 12, 2012 7 5/8% senior subordinated notes Select	Dec. 31, 2011 7 5/8% senior subordinated notes Select	Sep. 30, 2011 7 5/8% senior subordinated notes Select	Dec. 31, 2011 2011 - senior secured credit facilities: Revolving loan	Dec. 31, 2011 2011 - senior secured credit facilities: Revolving loan Select	Sep. 30, 2012 2011 - senior secured credit facilities: Term loans	Dec. 31, 2011 2011 - senior secured credit facilities: Term loans	Sep. 30, 2012 2011 - senior secured credit facilities: Term loans Select	Dec. 31, 2011 2011 - senior secured credit facilities: Term loans Select	Aug. 13, 2012 Series A Tranche B Term Loans Select	Sep. 30, 2012 Senior floating rate notes	Dec. 31, 2011 Senior floating rate notes	Sep. 30, 2012 Other debt	Dec. 31, 2011 Other debt	Sep. 30, 2012 Other debt Select	Dec. 31, 2011 Other debt Select
Components of long-term debt and notes payable
Interest rate of debt (as a percent)										7.625%	7.625%	7.625%	7.625%		7.625%	7.625%
Total debt	$ 1,341,633,000	$ 1,341,633,000		$ 1,396,798,000	$ 1,174,333,000	$ 1,174,333,000		$ 1,229,498,000		$ 70,000,000	$ 345,000,000		$ 70,000,000		$ 345,000,000		$ 40,000,000	$ 40,000,000	$ 1,098,784,000	$ 837,974,000	$ 1,098,784,000	$ 837,974,000		$ 167,300,000	$ 167,300,000	$ 5,549,000	$ 6,524,000	$ 5,549,000	$ 6,524,000
Less: current maturities	11,084,000	11,084,000		10,848,000	11,084,000	11,084,000		10,848,000
Long-term debt, net of current portion	1,330,549,000	1,330,549,000		1,385,950,000	1,163,249,000	1,163,249,000		1,218,650,000
Unamortized discount	14,900,000	14,900,000		7,800,000																	14,900,000	7,800,000
Aggregate principal amount drawn																							275,000,000
Redemption price as percentage of principal amount									101.27%
Debt instrument repurchased amount														275,000,000
Loss on early retirement of debt	6,064,000	6,064,000	31,018,000		6,064,000	6,064,000	20,385,000
Maturities of Long-Term Debt and Notes Payable
October 1, 2012 - December 31, 2012	4,173,000	4,173,000			4,173,000	4,173,000
2013	9,652,000	9,652,000			9,652,000	9,652,000
2014	9,136,000	9,136,000			9,136,000	9,136,000
2015	246,345,000	246,345,000			79,045,000	79,045,000
2016	8,684,000	8,684,000			8,684,000	8,684,000
2017 and beyond	$ 1,063,643,000	$ 1,063,643,000			$ 1,063,643,000	$ 1,063,643,000

XML

Fair Value (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011
Fair Value
Total debt	$ 1,341,633,000	$ 1,396,798,000
Select
Fair Value
Total debt	1,174,333,000	1,229,498,000
Senior secured credit facility | Select
Fair Value
Total debt	1,098,800,000	878,000,000
Fair value	1,104,300,000	823,300,000
7 5/8% senior subordinated notes
Fair Value
Total debt	70,000,000	345,000,000
Interest rate of debt (as a percent)	7.625%	7.625%	7.625%
7 5/8% senior subordinated notes | Select
Fair Value
Total debt	70,000,000	345,000,000
Fair value	70,900,000	326,400,000
Interest rate of debt (as a percent)	7.625%	7.625%	7.625%
Senior floating rate notes
Fair Value
Total debt	167,300,000	167,300,000
Senior floating rate notes | Holdings
Fair Value
Fair value	$ 167,300,000	$ 143,900,000

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2012

Basis of Presentation

Basis of Presentation

1.Basis of Presentation

        Select Medical Corporation (“Select”) was formed in December 1996 and commenced operations during February 1997 upon the completion of its first acquisition. Select Medical Holdings Corporation (“Holdings”) was formed in October 2004 for the purpose of affecting a leveraged buyout of Select, which was a publicly traded entity.  On February 24, 2005, Select merged with a subsidiary of Holdings, which resulted in Select becoming a wholly-owned subsidiary of Holdings (the “Merger”). On September 30, 2009 Holdings completed its initial public offering of common stock.  Generally accepted accounting principles (“GAAP”) require that any amounts recorded or incurred (such as goodwill and compensation expense) by the parent as a result of the Merger or for the benefit of the subsidiary be “pushed down” and recorded in Select’s consolidated financial statements. Holdings and Select and their subsidiaries are collectively referred to as the “Company.” The consolidated financial statements of Holdings include the accounts of its wholly-owned subsidiary Select. Holdings conducts substantially all of its business through Select and its subsidiaries.

        The unaudited condensed consolidated financial statements of the Company as of September 30, 2012 and for the three and nine month periods ended September 30, 2011 and 2012 have been prepared in accordance with GAAP.  In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods.  All significant intercompany transactions and balances have been eliminated.  The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2012.

        Certain information and disclosures normally included in the notes to consolidated financial statements have been condensed or omitted consistent with the rules and regulations of the Securities and Exchange Commission (the “SEC”), although the Company believes the disclosure is adequate to make the information presented not misleading.  The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2011 contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2012.

XML

Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Segment Information
Net operating revenue	$ 713,669	$ 694,131	$ 2,207,883	$ 2,086,066
Adjusted EBITDA	87,747	86,536	307,090	292,195
Total assets:	2,781,808	2,751,110	2,781,808	2,751,110	2,772,147
Capital expenditures	17,254	8,398	45,188	32,094
Select Medical Corporation
Segment Information
Net operating revenue	713,669	694,131	2,207,883	2,086,066
Adjusted EBITDA	87,747	86,536	307,090	292,195
Total assets:	2,780,678	2,749,612	2,780,678	2,749,612	2,770,738
Capital expenditures	17,254	8,398	45,188	32,094
Specialty Hospitals
Segment Information
Net operating revenue	531,409	521,085	1,641,577	1,561,270
Adjusted EBITDA	83,659	81,570	285,779	273,004
Total assets:	2,165,248	2,191,493	2,165,248	2,191,493
Capital expenditures	12,281	4,957	31,963	21,574
Specialty Hospitals | Select Medical Corporation
Segment Information
Total assets:	2,165,248	2,191,493	2,165,248	2,191,493
Outpatient Rehabilitation
Segment Information
Number of operating segments			2
Net operating revenue	182,246	173,030	566,195	524,694
Adjusted EBITDA	20,354	19,435	68,669	65,308
Total assets:	431,310	468,551	431,310	468,551
Capital expenditures	3,073	3,160	9,786	8,142
Outpatient Rehabilitation | Select Medical Corporation
Segment Information
Total assets:	431,310	468,551	431,310	468,551
All Other
Segment Information
Net operating revenue	14	16	111	102
Adjusted EBITDA	(16,266)	(14,469)	(47,358)	(46,117)
Total assets:	185,250	91,066	185,250	91,066
Capital expenditures	1,900	281	3,439	2,378
All Other | Select Medical Corporation
Segment Information
Total assets:	$ 184,120	$ 89,568	$ 184,120	$ 89,568

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes (Details 4) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended					3 Months Ended		9 Months Ended					3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 7 5/8% senior subordinated notes	Dec. 31, 2011 7 5/8% senior subordinated notes	Sep. 30, 2011 7 5/8% senior subordinated notes	Sep. 30, 2012 Select Medical Corporation	Sep. 30, 2011 Select Medical Corporation	Sep. 30, 2012 Select Medical Corporation	Sep. 30, 2011 Select Medical Corporation	Sep. 30, 2012 Select Medical Corporation 7 5/8% senior subordinated notes	Dec. 31, 2011 Select Medical Corporation 7 5/8% senior subordinated notes	Sep. 30, 2011 Select Medical Corporation 7 5/8% senior subordinated notes	Sep. 30, 2012 Select Medical Corporation Select Medical Corporation (Parent Company Only)	Sep. 30, 2011 Select Medical Corporation Select Medical Corporation (Parent Company Only)	Sep. 30, 2012 Select Medical Corporation Select Medical Corporation (Parent Company Only)	Sep. 30, 2011 Select Medical Corporation Select Medical Corporation (Parent Company Only)	Sep. 30, 2012 Select Medical Corporation Subsidiary Guarantors	Sep. 30, 2011 Select Medical Corporation Subsidiary Guarantors	Sep. 30, 2012 Select Medical Corporation Subsidiary Guarantors	Sep. 30, 2011 Select Medical Corporation Subsidiary Guarantors	Sep. 30, 2012 Select Medical Corporation Non-Guarantor Subsidiaries	Sep. 30, 2011 Select Medical Corporation Non-Guarantor Subsidiaries	Sep. 30, 2012 Select Medical Corporation Non-Guarantor Subsidiaries	Sep. 30, 2011 Select Medical Corporation Non-Guarantor Subsidiaries	Sep. 30, 2012 Select Medical Corporation Eliminations	Sep. 30, 2011 Select Medical Corporation Eliminations	Sep. 30, 2012 Select Medical Corporation Eliminations	Sep. 30, 2011 Select Medical Corporation Eliminations
Operating activities
Net income	$ 25,158	$ 26,381	$ 112,546	$ 75,425				$ 27,001	$ 28,076	$ 117,972	$ 92,225				$ 25,953	$ 27,291	$ 114,250	$ 87,787	$ 27,927	$ 36,943	$ 125,147	$ 103,746	$ 3,110	$ 1,732	$ 14,313	$ 16,315	$ (29,989)	$ (37,890)	$ (135,738)	$ (115,623)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	15,537	17,545	47,164	52,766				15,537	17,545	47,164	52,766				832	641	2,255	1,941	12,372	14,484	37,952	43,939	2,333	2,420	6,957	6,886
Provision for bad debts	11,199	11,709	31,603	40,002				11,199	11,709	31,603	40,002								9,525	10,219	27,199	35,128	1,674	1,490	4,404	4,874
Loss on early retirement of debt	6,064		6,064	31,018				6,064		6,064	20,385				6,064		6,064	20,385
Loss (gain) from disposal of assets			(3,484)	(5,182)						(3,484)	(5,182)							13			(3,501)	(5,233)			17	38
Non-cash stock compensation expense			3,990	2,698						3,990	2,698						3,990	2,698
Amortization of debt discount			1,123	1,271						1,123	412						1,123	412
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries															(27,866)	(36,129)	(124,504)	(103,281)	(2,123)	(1,761)	(11,234)	(12,342)					29,989	37,890	135,738	115,623
Intercompany																	73,693	60,188			(65,471)	(49,269)			(8,222)	(10,919)
Accounts receivable			(10,507)	(81,466)						(10,507)	(81,466)										7,296	(73,437)			(17,803)	(8,029)
Other current assets			(1,849)	240						(1,849)	240						1,182	(455)			(2,141)	412			(890)	283
Other assets			(743)	1,072						(1,022)	723						3,488	(8,306)			(4,652)	8,826			142	203
Accounts payable			(4,098)	14,008						(4,098)	14,008						418	1,622			(5,842)	10,102			1,326	2,284
Due to third-party payors			360	(1,050)						360	(1,050)										(10,928)	2,710			11,288	(3,760)
Accrued expenses			348	(12,566)						2,956	(3,650)						3,870	(4,455)			(1,912)	701			998	104
Income and deferred taxes			11,559	25,678						14,481	34,723						14,481	34,723
Net cash provided by operating activities			194,076	143,914						204,753	166,834						100,310	93,272			91,913	65,283			12,530	8,279
Investing activities
Purchases of property and equipment	(17,254)	(8,398)	(45,188)	(32,094)				(17,254)	(8,398)	(45,188)	(32,094)						(3,617)	(2,384)			(31,978)	(26,342)			(9,593)	(3,368)
Investment in businesses			(9,899)	(13,514)						(9,899)	(13,514)										(9,899)	(13,514)
Acquisition of businesses, net of cash acquired			(1,547)	1,921						(1,547)	1,921										(1,547)	1,921
Proceeds from sale of assets			16,511	7,879						16,511	7,879										16,511	7,879
Net cash used in investing activities			(40,123)	(35,808)						(40,123)	(35,808)						(3,617)	(2,384)			(26,913)	(30,056)			(9,593)	(3,368)
Financing activities
Borrowings on revolving credit facility			365,000	595,000						365,000	595,000						365,000	595,000
Payments on revolving credit facility			(405,000)	(570,000)						(405,000)	(570,000)						(405,000)	(570,000)
Borrowings on 2011 credit facility term loans, net of discount			266,750	841,500						266,750	841,500						266,750	841,500
Payments on 2011 credit facility term loans			(7,063)	(2,125)						(7,063)	(2,125)						(7,063)	(2,125)
Payments on 2005 credit facility term loans, net of premium				(484,633)							(484,633)							(484,633)
Repurchase of 7 5/8% senior subordinated notes, net of premiums			(278,495)	(273,941)						(278,495)	(273,941)						(278,495)	(273,941)
Interest rate of debt (as a percent)					7.625%	7.625%	7.625%					7.625%	7.625%	7.625%
Borrowings of other debt			5,835	5,496						5,835	5,496						5,557	5,496							278
Principal payments on other debt			(7,417)	(5,846)						(7,417)	(5,846)						(6,667)	(4,326)			(322)	(650)			(428)	(870)
Debt issuance costs			(4,236)	(18,556)						(4,236)	(18,556)						(4,236)	(18,556)
Proceeds (Repayments) of bank overdrafts			(3,011)	(4,174)						(3,011)	(4,174)						(3,011)	(4,174)
Equity investment by Holdings										1,104	169						1,104	169
Dividends paid to Holdings										(57,467)	(204,561)						(57,467)	(204,561)
Intercompany debt reallocation																	60,477	38,082			(61,143)	(37,564)			666	(518)
Distributions to non-controlling interests			(2,997)	(3,507)						(2,997)	(3,507)														(2,997)	(3,507)
Net cash used in financing activities			(116,320)	(102,258)						(126,997)	(125,178)						(63,051)	(82,069)			(61,465)	(38,214)			(2,481)	(4,895)
Net increase in cash and cash equivalents			37,633	5,848						37,633	5,848						33,642	8,819			3,535	(2,987)			456	16
Cash and cash equivalents at beginning of period			12,043	4,365						12,043	4,365						11,427	149				3,567			616	649
Cash and cash equivalents at end of period	$ 49,676	$ 10,213	$ 49,676	$ 10,213				$ 49,676	$ 10,213	$ 49,676	$ 10,213				$ 45,069	$ 8,968	$ 45,069	$ 8,968	$ 3,535	$ 580	$ 3,535	$ 580	$ 1,072	$ 665	$ 1,072	$ 665

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Dec. 31, 2010
Current Assets:
Cash and cash equivalents	$ 49,676	$ 12,043	$ 10,213	$ 4,365
Accounts receivable, net of allowance for doubtful accounts of $47,469 and $45,719 in 2011 and 2012, respectively	392,647	413,743
Current deferred tax asset	17,978	18,305
Prepaid income taxes	1,410	9,497
Other current assets	31,620	29,822
Total Current Assets	493,331	483,410
Property and equipment, net	494,625	510,028
Goodwill	1,633,106	1,631,716
Other identifiable intangibles	71,783	72,123
Assets held for sale	2,742	2,742
Other assets	86,221	72,128
Total Assets	2,781,808	2,772,147	2,751,110
Current Liabilities:
Bank overdrafts	13,598	16,609
Current portion of long-term debt and notes payable	11,084	10,848
Accounts payable	91,520	95,618
Accrued payroll	83,683	82,888
Accrued vacation	53,210	51,250
Accrued interest	13,921	15,096
Accrued restructuring	2,015	5,027
Accrued other	99,004	101,076
Due to third party payors	5,886	5,526
Total Current Liabilities	373,921	383,938
Long-term debt, net of current portion	1,330,549	1,385,950
Non-current deferred tax liability	84,118	82,028
Other non-current liabilities	70,502	64,905
Total Liabilities	1,859,090	1,916,821
Stockholders' Equity:
Common stock	140	145
Capital in excess of par	471,358	493,828
Retained earnings	418,071	328,882
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	889,569	822,855
Non-controlling interest	33,149	32,471
Total Equity	922,718	855,326
Total Liabilities and Equity	2,781,808	2,772,147
Select
Current Assets:
Cash and cash equivalents	49,676	12,043	10,213	4,365
Accounts receivable, net of allowance for doubtful accounts of $47,469 and $45,719 in 2011 and 2012, respectively	392,647	413,743
Current deferred tax asset	17,978	18,305
Prepaid income taxes	1,410	9,497
Other current assets	31,620	29,822
Total Current Assets	493,331	483,410
Property and equipment, net	494,625	510,028
Goodwill	1,633,106	1,631,716
Other identifiable intangibles	71,783	72,123
Assets held for sale	2,742	2,742
Other assets	85,091	70,719
Total Assets	2,780,678	2,770,738	2,749,612
Current Liabilities:
Bank overdrafts	13,598	16,609
Current portion of long-term debt and notes payable	11,084	10,848
Accounts payable	91,520	95,618
Accrued payroll	83,683	82,888
Accrued vacation	53,210	51,250
Accrued interest	13,413	11,980
Accrued restructuring	2,015	5,027
Accrued other	99,004	106,316
Due to third party payors	5,886	5,526
Total Current Liabilities	373,413	386,062
Long-term debt, net of current portion	1,163,249	1,218,650
Non-current deferred tax liability	84,118	82,028
Other non-current liabilities	70,502	64,905
Total Liabilities	1,691,282	1,751,645
Stockholders' Equity:
Common stock	0
Capital in excess of par	856,446	848,844
Retained earnings	199,801	137,778
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	1,056,247	986,622
Non-controlling interest	33,149	32,471
Total Equity	1,089,396	1,019,093
Total Liabilities and Equity	$ 2,780,678	$ 2,770,738

XML

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Operating activities
Net income	$ 112,546	$ 75,425
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	47,164	52,766
Provision for bad debts	31,603	40,002
Loss on early retirement of debt	6,064	31,018
Gain from disposal or sale of assets	(3,484)	(5,182)
Non-cash stock compensation expense	3,990	2,698
Amortization of debt discount	1,123	1,271
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable	(10,507)	(81,466)
Other current assets	(1,849)	240
Other assets	(743)	1,072
Accounts payable	(4,098)	14,008
Due to third-party payors	360	(1,050)
Accrued expenses	348	(12,566)
Income and deferred taxes	11,559	25,678
Net cash provided by operating activities	194,076	143,914
Investing activities
Purchases of property and equipment	(45,188)	(32,094)
Proceeds from sale of assets	16,511	7,879
Investment in business, net of distributions	(9,899)	(13,514)
Acquisition of businesses, net of cash acquired	(1,547)	1,921
Net cash used in investing activities	(40,123)	(35,808)
Financing activities
Borrowings on revolving credit facilities	365,000	595,000
Payments on revolving credit facilities	(405,000)	(570,000)
Borrowings on 2011 credit facility term loans, net of discount	266,750	841,500
Payments on 2011 credit facility term loans	(7,063)	(2,125)
Payments on 2005 credit facility term loans, net of premium		(484,633)
Repurchase of 10% senior subordinated notes		(150,000)
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(278,495)	(273,941)
Borrowings of other debt	5,835	5,496
Principal payments on other debt	(7,417)	(5,846)
Debt issuance costs	(4,236)	(18,556)
Repurchase of common stock	(46,790)	(31,641)
Proceeds from issuance of common stock	1,104	169
Repayment of bank overdrafts	(3,011)	(4,174)
Distributions to non-controlling interests	(2,997)	(3,507)
Net cash used in financing activities	(116,320)	(102,258)
Net increase in cash and cash equivalents	37,633	5,848
Cash and cash equivalents at beginning of period	12,043	4,365
Cash and cash equivalents at end of period	49,676	10,213
Supplemental Cash Flow Information
Cash paid for interest	68,122	94,632
Cash paid for taxes	59,850	31,105
Select
Operating activities
Net income	117,972	92,225
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	47,164	52,766
Provision for bad debts	31,603	40,002
Loss on early retirement of debt	6,064	20,385
Gain from disposal or sale of assets	(3,484)	(5,182)
Non-cash stock compensation expense	3,990	2,698
Amortization of debt discount	1,123	412
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Accounts receivable	(10,507)	(81,466)
Other current assets	(1,849)	240
Other assets	(1,022)	723
Accounts payable	(4,098)	14,008
Due to third-party payors	360	(1,050)
Accrued expenses	2,956	(3,650)
Income and deferred taxes	14,481	34,723
Net cash provided by operating activities	204,753	166,834
Investing activities
Purchases of property and equipment	(45,188)	(32,094)
Proceeds from sale of assets	16,511	7,879
Investment in business, net of distributions	(9,899)	(13,514)
Acquisition of businesses, net of cash acquired	(1,547)	1,921
Net cash used in investing activities	(40,123)	(35,808)
Financing activities
Borrowings on revolving credit facilities	365,000	595,000
Payments on revolving credit facilities	(405,000)	(570,000)
Borrowings on 2011 credit facility term loans, net of discount	266,750	841,500
Payments on 2011 credit facility term loans	(7,063)	(2,125)
Payments on 2005 credit facility term loans, net of premium		(484,633)
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(278,495)	(273,941)
Borrowings of other debt	5,835	5,496
Principal payments on other debt	(7,417)	(5,846)
Debt issuance costs	(4,236)	(18,556)
Dividends paid to Holdings	(57,467)	(204,561)
Equity investment by Holdings	1,104	169
Repayment of bank overdrafts	(3,011)	(4,174)
Distributions to non-controlling interests	(2,997)	(3,507)
Net cash used in financing activities	(126,997)	(125,178)
Net increase in cash and cash equivalents	37,633	5,848
Cash and cash equivalents at beginning of period	12,043	4,365
Cash and cash equivalents at end of period	49,676	10,213
Supplemental Cash Flow Information
Cash paid for interest	57,448	71,719
Cash paid for taxes	$ 59,850	$ 31,105

XML

Commitments and Contingencies (Details) (USD $) In Millions, unless otherwise specified		1 Months Ended				9 Months Ended
	Sep. 30, 2012	Oct. 31, 2012 SSH-Evansville Subpoena received from the Office of Attorney General in the State of Indiana item	Apr. 30, 2012 SSH-Evansville Subpoena received from the Office of Attorney General in the State of Indiana item	May 31, 2012 SSH-Evansville Probable cause affidavit item	May 31, 2012 SSH-Evansville Probable cause affidavit Minimum item	Sep. 30, 2012 Professional liability claims	Sep. 30, 2012 General liability claims
Commitments and Contingencies
Liability insurance per medical incident or per occurrence						$ 2.0	$ 2.0
Number of subpoenas received from the Office of Attorney General in the State of Indiana			2
Number of identified persons and entities included in request for information or assistance			7
Number of alleged occasions of discontinued treatment				1
Number of patient deaths					2
Number of patient medical records for which the Company was subpoenaed		19
Construction Commitments
Outstanding commitments under construction contracts	$ 10.8

XML

Indebtedness (Tables)

9 Months Ended

Sep. 30, 2012

Indebtedness

Schedule of components of long-term debt and notes payable

	Holdings				Select
	December 31, 2011		September 30, 2012		December 31, 2011		September 30, 2012
	(in thousands)				(in thousands)
7 5/8 % senior subordinated notes	$	345,000	$	70,000	$	345,000	$	70,000
Senior secured credit facilities:
Revolving loan	40,000		—		40,000		—
Term loans (1)	837,974		1,098,784		837,974		1,098,784
Senior floating rate notes	167,300		167,300		—		—
Other debt	6,524		5,549		6,524		5,549
Total debt	1,396,798		1,341,633		1,229,498		1,174,333
Less: current maturities	10,848		11,084		10,848		11,084
Total long-term debt	$	1,385,950	$	1,330,549	$	1,218,650	$	1,163,249

Schedule of maturities of the Company's long-term debt presented net of the discount on 2011 Senior Secured Credit Facilities' term loan

	Holdings		Select
	(in thousands)		(in thousands)
October 1, 2012 – December 31, 2012	$	4,173	$	4,173
2013	9,652		9,652
2014	9,136		9,136
2015	246,345		79,045
2016	8,684		8,684
2017 and beyond	1,063,643		1,063,643

XML

Subsequent Events (Details) (Subsequent Events, USD $) In Thousands, except Per Share data, unless otherwise specified	0 Months Ended
	Oct. 30, 2012
Subsequent Events
Subsequent Events
Special cash dividend declared (in dollars per share)	$ 1.50
Special cash dividend declared	$ 210,800

XML

Income per Common Share (Tables)

9 Months Ended

Sep. 30, 2012

Income per Common Share

Schedule of calculation of net income per share

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2011		2012		2011		2012
	(in thousands, except per share data)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	25,596	$	24,110	$	70,987	$	108,824
Less: Earnings allocated to unvested restricted stockholders	278		407		763		1,759
Net income available to common stockholders	$	25,318	$	23,703	$	70,224	$	107,065
Denominator:
Weighted average shares — basic	151,470		137,551		152,299		139,138
Effect of dilutive securities:
Stock options	206		337		223		266
Weighted average shares — diluted	151,676		137,888		152,522		139,404
Basic income per common share	$	0.17	$	0.17	$	0.46	$	0.77
Diluted income per common share	$	0.17	$	0.17	$	0.46	$	0.77

Schedule of anti-dilutive shares excluded from computation

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2011	2012	2011	2012
	(in thousands)
Stock options	2,437	78	2,412	1,683

XML

Consolidated Statements of Cash Flows (Parenthetical)	Sep. 30, 2012	Dec. 31, 2011
7 5/8% senior subordinated notes
Senior subordinated notes
Interest rate of debt (as a percent)	7.625%	7.625%
10% senior subordinated notes
Senior subordinated notes
Interest rate of debt (as a percent)	10.00%	10.00%

XML

Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 45,719	$ 47,469
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	700,000,000	700,000,000
Common stock, shares issued	139,991,156	145,268,190
Common stock, shares outstanding	139,991,156	145,268,190
Select
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 45,719	$ 47,469
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued	100	100
Common stock, shares outstanding	100	100

XML

Subsequent Events

9 Months Ended

Sep. 30, 2012

Subsequent Events

Subsequent Events

10.Subsequent Events

On October 30, 2012, Holdings' board of directors declared a special cash dividend of $1.50 per share, totaling approximately $210.8 million.  This special cash dividend will be paid on or about December 12, 2012 to all stockholders of record at the close of business on December 5, 2012.  Select is entering into an amendment to its senior secured credit facility that provides Holdings and Select with additional flexibility to make certain restricted payments, including the payment of dividends.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2012	Oct. 31, 2012
Document and Entity Information
Entity Registrant Name	SELECT MEDICAL HOLDINGS CORP
Entity Central Index Key	0001320414
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		140,520,316
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes

9 Months Ended

Sep. 30, 2012

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes

11.Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select’s 7 5/8% Senior Subordinated Notes

Select’s 7 5/8% senior subordinated notes are fully and unconditionally guaranteed, except for customary limitations, on a senior subordinated basis by all of Select’s wholly-owned subsidiaries (the “Subsidiary Guarantors”). Certain of Select’s subsidiaries did not guarantee the 7 5/8% senior subordinated notes (the “Non-Guarantor Subsidiaries”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors and the Non-Guarantor Subsidiaries at December 31, 2011 and September 30, 2012 and for the three and nine months ended September 30, 2011 and 2012.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

Select Medical Corporation

Condensed Consolidating Balance Sheet

September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	45,069		$	3,535		$	1,072		$	—		$	49,676
Accounts receivable, net	—			334,826			57,821			—			392,647
Current deferred tax asset	11,673			2,698			3,607			—			17,978
Prepaid income taxes	1,410			—			—			—			1,410
Other current assets	5,158			21,497			4,965			—			31,620
Total Current Assets	63,310			362,556			67,465			—			493,331
Property and equipment, net	15,823			421,493			57,309			—			494,625
Investment in affiliates	2,889,285			80,859			—			(2,970,144		)(a) (b)	—
Goodwill	—			1,633,106			—			—			1,633,106
Other identifiable intangibles	—			71,783			—			—			71,783
Assets held for sale	2,742			—			—			—			2,742
Other assets	24,898			59,482			711			—			85,091
Total Assets	$	2,996,058		$	2,629,279		$	125,485		$	(2,970,144	)	$	2,780,678
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	13,598		$	—		$	—		$	—		$	13,598
Current portion of long-term debt and notes payable	9,062			585			1,437			—			11,084
Accounts payable	7,771			70,365			13,384			—			91,520
Intercompany accounts	1,058,973			(963,967		)	(95,006		)	—			—
Accrued payroll	72			83,293			318			—			83,683
Accrued vacation	4,120			42,565			6,525			—			53,210
Accrued interest	12,504			909			—			—			13,413
Accrued restructuring	—			2,015			—			—			2,015
Accrued other	50,778			40,287			7,939			—			99,004
Due to third party payors	—			2,705			3,181			—			5,886
Total Current Liabilities	1,156,878			(721,243		)	(62,222		)	—			373,413
Long-term debt, net of current portion	736,945			364,287			62,017			—			1,163,249
Non-current deferred tax liability	(4,715		)	80,258			8,575			—			84,118
Other non-current liabilities	50,703			19,546			253			—			70,502
Total Liabilities	1,939,811			(257,152		)	8,623			—			1,691,282
Stockholder’s Equity:
Common stock	0			—			—			—			0
Capital in excess of par	856,446			—			—			—			856,446
Retained earnings	199,801			752,267			24,428			(776,695		)(b)	199,801
Subsidiary investment	—			2,134,164			59,285			(2,193,449		)(a)	—
Total Select Medical Corporation Stockholder’s Equity	1,056,247			2,886,431			83,713			(2,970,144		)	1,056,247
Non-controlling interest	—			—			33,149			—			33,149
Total Equity	1,056,247			2,886,431			116,862			(2,970,144		)	1,089,396
Total Liabilities and Equity	$	2,996,058		$	2,629,279		$	125,485		$	(2,970,144	)	$	2,780,678

(a)  Elimination of investments in consolidated subsidiaries.

(b)  Elimination of investments in consolidated subsidiaries’ earnings.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	14		$	616,610		$	97,045		$	—		$	713,669
Costs and expenses:
Cost of services	544			514,136			84,304			—			598,984
General and administrative	17,742			(612		)	—			—			17,130
Bad debt expense	—			9,525			1,674			—			11,199
Depreciation and amortization	832			12,372			2,333			—			15,537
Total costs and expenses	19,118			535,421			88,311			—			642,850
Income (loss) from operations	(19,104		)	81,189			8,734			—			70,819
Other income and expense:
Intercompany interest and royalty fees	(469		)	459			10			—			—
Intercompany management fees	34,811			(29,960		)	(4,851		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			1,146			21			—			1,167
Interest expense	(14,676		)	(6,010		)	(1,054		)	—			(21,740		)
Income (loss) from operations before income taxes	(5,502		)	46,824			2,860			—			44,182
Income tax expense (benefit)	(3,589		)	21,020			(250		)	—			17,181
Equity in earnings of subsidiaries	27,866			2,123			—			(29,989		)(a)	—
Net income	25,953			27,927			3,110			(29,989		)	27,001
Less: Net income attributable to non-controlling interests	—			—			1,048			—			1,048
Net income attributable to Select Medical Corporation	$	25,953		$	27,927		$	2,062		$	(29,989	)	$	25,953

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	111		$	1,910,563		$	297,209		$	—		$	2,207,883
Costs and expenses:
Cost of services	1,554			1,567,080			254,638			—			1,823,272
General and administrative	51,197			(1,289		)	—			—			49,908
Bad debt expense	—			27,199			4,404			—			31,603
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Total costs and expenses	55,006			1,630,942			265,999			—			1,951,947
Income (loss) from operations	(54,895		)	279,621			31,210			—			255,936
Other income and expense:
Intercompany interest and royalty fees	(2,025		)	1,998			27			—			—
Intercompany management fees	91,940			(78,202		)	(13,738		)	—			—
Loss on early retirement of debt	(6,064		)	—			—			—			(6,064		)
Equity in earnings of unconsolidated subsidiaries	—			6,340			44			—			6,384
Interest expense	(40,823		)	(19,920		)	(3,204		)	—			(63,947		)
Income (loss) from operations before income taxes	(11,867		)	189,837			14,339			—			192,309
Income tax expense (benefit)	(1,613		)	75,924			26			—			74,337
Equity in earnings of subsidiaries	124,504			11,234			—			(135,738		)(a)	—
Net income	114,250			125,147			14,313			(135,738		)	117,972
Less: Net income attributable to non-controlling interests	—			—			3,722			—			3,722
Net income attributable to Select Medical Corporation	$	114,250		$	125,147		$	10,591		$	(135,738	)	$	114,250

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2012

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	114,250		$	125,147		$	14,313		$	(135,738	)(a)	$	117,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,255			37,952			6,957			—			47,164
Provision for bad debts	—			27,199			4,404			—			31,603
Loss on early retirement of debt	6,064			—			—			—			6,064
Loss (gain) from disposal of assets	—			(3,501		)	17			—			(3,484		)
Non-cash stock compensation expense	3,990			—			—			—			3,990
Amortization of debt discount	1,123			—			—			—			1,123
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(124,504		)	(11,234		)	—			135,738		(a)	—
Intercompany	73,693			(65,471		)	(8,222		)	—			—
Accounts receivable	—			7,296			(17,803		)	—			(10,507		)
Other current assets	1,182			(2,141		)	(890		)	—			(1,849		)
Other assets	3,488			(4,652		)	142			—			(1,022		)
Accounts payable	418			(5,842		)	1,326			—			(4,098		)
Due to third-party payors	—			(10,928		)	11,288			—			360
Accrued expenses	3,870			(1,912		)	998			—			2,956
Income and deferred taxes	14,481			—			—			—			14,481
Net cash provided by operating activities	100,310			91,913			12,530			—			204,753
Investing activities
Purchases of property and equipment	(3,617		)	(31,978		)	(9,593		)	—			(45,188		)
Proceeds from sale of assets	—			16,511			—			—			16,511
Investment in business, net of distributions	—			(9,899		)	—			—			(9,899		)
Acquisition of businesses, net of cash acquired	—			(1,547		)	—			—			(1,547		)
Net cash used in investing activities	(3,617		)	(26,913		)	(9,593		)	—			(40,123		)
Financing activities
Borrowings on revolving credit facility	365,000			—			—			—			365,000
Payments on revolving credit facility	(405,000		)	—			—			—			(405,000		)
Borrowings on 2011 credit facility term loans, net of discount	266,750			—			—			—			266,750
Payments on 2011 credit facility term loans	(7,063		)	—			—			—			(7,063		)
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(278,495		)	—			—			—			(278,495		)
Borrowings of other debt	5,557			—			278			—			5,835
Principal payments on other debt	(6,667		)	(322		)	(428		)	—			(7,417		)
Debt issuance costs	(4,236		)	—			—			—			(4,236		)
Dividends paid to Holdings	(57,467		)	—			—			—			(57,467		)
Equity investment by Holdings	1,104			—			—			—			1,104
Repayment of bank overdrafts	(3,011		)	—			—			—			(3,011		)
Intercompany debt reallocation	60,477			(61,143		)	666			—			—
Distributions to non-controlling interests	—			—			(2,997		)	—			(2,997		)
Net cash used in financing activities	(63,051		)	(61,465		)	(2,481		)	—			(126,997		)
Net increase in cash and cash equivalents	33,642			3,535			456			—			37,633
Cash and cash equivalents at beginning of period	11,427			—			616			—			12,043
Cash and cash equivalents at end of period	$	45,069		$	3,535		$	1,072		$	—		$	49,676

(a)  Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	11,427		$	—		$	616		$	—		$	12,043
Accounts receivable, net	—			369,321			44,422			—			413,743
Current deferred tax asset	11,415			3,221			3,669			—			18,305
Prepaid income taxes	9,497			—			—			—			9,497
Other current assets	6,340			19,407			4,075			—			29,822
Total Current Assets	38,679			391,949			52,782			—			483,410
Property and equipment, net	14,641			440,736			54,651			—			510,028
Investment in affiliates	2,751,776			83,772			—			(2,835,548		)(a) (b)	—
Goodwill	—			1,631,716			—			—			1,631,716
Other identifiable intangibles	—			72,123			—			—			72,123
Assets held for sale	2,742			—			—			—			2,742
Other assets	28,386			41,480			853			—			70,719
Total Assets	$	2,836,224		$	2,661,776		$	108,286		$	(2,835,548	)	$	2,770,738
Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	16,609		$	—		$	—		$	—		$	16,609
Current portion of long-term debt and notes payable	8,853			390			1,605			—			10,848
Accounts payable	7,353			76,207			12,058			—			95,618
Intercompany accounts	975,809			(880,537		)	(95,272		)	—			—
Accrued payroll	229			82,518			141			—			82,888
Accrued vacation	3,703			41,305			6,242			—			51,250
Accrued interest	11,843			137			—			—			11,980
Accrued restructuring	—			5,027			—			—			5,027
Accrued other	47,829			51,086			7,401			—			106,316
Due to third party payors	—			13,633			(8,107		)	—			5,526
Total Current Liabilities	1,072,228			(610,234		)	(75,932		)	—			386,062
Long-term debt, net of current portion	733,328			425,315			60,007			—			1,218,650
Non-current deferred tax liability	(2,509		)	75,750			8,787			—			82,028
Other non-current liabilities	46,555			17,970			380			—			64,905
Total Liabilities	1,849,602			(91,199		)	(6,758		)	—			1,751,645
Stockholder’s Equity:
Common stock	0			—			—			—			0
Capital in excess of par	848,844			—			—			—			848,844
Retained earnings	137,778			627,120			23,154			(650,274		)(b)	137,778
Subsidiary investment	—			2,125,855			59,419			(2,185,274		)(a)	—
Total Select Medical Corporation Stockholder’s Equity	986,622			2,752,975			82,573			(2,835,548		)	986,622
Non-controlling interest	—			—			32,471			—			32,471
Total Equity	986,622			2,752,975			115,044			(2,835,548		)	1,019,093
Total Liabilities and Equity	$	2,836,224		$	2,661,776		$	108,286		$	(2,835,548	)	$	2,770,738

(a)  Elimination of investments in consolidated subsidiaries.

(b)  Elimination of investments in consolidated subsidiaries’ earnings.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	16		$	603,737		$	90,378		$	—		$	694,131
Costs and expenses:
Cost of services	430			502,576			78,823			—			581,829
General and administrative	14,804			171			—			—			14,975
Bad debt expense	—			10,219			1,490			—			11,709
Depreciation and amortization	641			14,484			2,420			—			17,545
Total costs and expenses	15,875			527,450			82,733			—			626,058
Income (loss) from operations	(15,859		)	76,287			7,645			—			68,073
Other income and expense:
Intercompany interest and royalty fees	(659		)	655			4			—			—
Intercompany management fees	18,698			(14,320		)	(4,378		)	—			—
Equity in earnings of unconsolidated subsidiaries	—			1,633			20			—			1,653
Interest income	36			16			67			—			119
Interest expense	(12,556		)	(7,874		)	(1,096		)	—			(21,526		)
Income (loss) from operations before income taxes	(10,340		)	56,397			2,262			—			48,319
Income tax expense (benefit)	(1,502		)	21,215			530			—			20,243
Equity in earnings of subsidiaries	36,129			1,761			—			(37,890		)(a)	—
Net income	27,291			36,943			1,732			(37,890		)	28,076
Less: Net income attributable to non-controlling interests	—			—			785			—			785
Net income attributable to Select Medical Corporation	$	27,291		$	36,943		$	947		$	(37,890	)	$	27,291

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Nine Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Net operating revenues	$	102		$	1,809,552		$	276,412		$	—		$	2,086,066
Costs and expenses:
Cost of services	1,262			1,476,857			230,792			—			1,708,911
General and administrative	47,298			358			—			—			47,656
Bad debt expense	—			35,128			4,874			—			40,002
Depreciation and amortization	1,941			43,939			6,886			—			52,766
Total costs and expenses	50,501			1,556,282			242,552			—			1,849,335
Income (loss) from operations	(50,399		)	253,270			33,860			—			236,731
Other income and expense:
Intercompany interest and royalty fees	(2,654		)	2,635			19			—			—
Intercompany management fees	86,561			(73,451		)	(13,110		)	—			—
Loss on early retirement of debt	(20,385		)	—			—			—			(20,385		)
Equity in earnings of unconsolidated subsidiaries	—			1,285			44			—			1,329
Interest income	101			117			68			—			286
Interest expense	(28,932		)	(27,193		)	(3,757		)	—			(59,882		)
Income (loss) from operations before income taxes	(15,708		)	156,663			17,124			—			158,079
Income tax expense (benefit)	(214		)	65,259			809			—			65,854
Equity in earnings of subsidiaries	103,281			12,342			—			(115,623		)(a)	—
Net income	87,787			103,746			16,315			(115,623		)	92,225
Less: Net income attributable to non-controlling interests	—			—			4,438			—			4,438
Net income attributable to Select Medical Corporation	$	87,787		$	103,746		$	11,877		$	(115,623	)	$	87,787

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Nine Months Ended September 30, 2011

(unaudited)

	Select Medical Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Operating activities
Net income	$	87,787		$	103,746		$	16,315		$	(115,623	)(a)	$	92,225
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,941			43,939			6,886			—			52,766
Provision for bad debts	—			35,128			4,874			—			40,002
Loss on early retirement of debt	20,385			—			—			—			20,385
Loss (gain) from disposal of assets	13			(5,233		)	38			—			(5,182		)
Non-cash stock compensation expense	2,698			—			—			—			2,698
Amortization of debt discount	412			—			—			—			412
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(103,281		)	(12,342		)	—			115,623		(a)	—
Intercompany	60,188			(49,269		)	(10,919		)	—			—
Accounts receivable	—			(73,437		)	(8,029		)	—			(81,466		)
Other current assets	(455		)	412			283			—			240
Other assets	(8,306		)	8,826			203			—			723
Accounts payable	1,622			10,102			2,284			—			14,008
Due to third-party payors	—			2,710			(3,760		)	—			(1,050		)
Accrued expenses	(4,455		)	701			104			—			(3,650		)
Income and deferred taxes	34,723			—			—			—			34,723
Net cash provided by operating activities	93,272			65,283			8,279			—			166,834
Investing activities
Purchases of property and equipment	(2,384		)	(26,342		)	(3,368		)	—			(32,094		)
Investment in business	—			(13,514		)	—			—			(13,514		)
Acquisition of businesses, net of cash acquired	—			1,921			—			—			1,921
Proceeds from sale of assets	—			7,879			—			—			7,879
Net cash used in investing activities	(2,384		)	(30,056		)	(3,368		)	—			(35,808		)
Financing activities
Borrowings on revolving credit facility	595,000			—			—			—			595,000
Payments on revolving credit facility	(570,000		)	—			—			—			(570,000		)
Borrowings on 2011 credit facility term loans, net of discount	841,500			—			—			—			841,500
Payments on 2011 credit facility term loans	(2,125		)	—			—			—			(2,125		)
Payments on 2005 credit facility term loans, net of premium	(484,633		)	—			—			—			(484,633		)
Repurchase of 7 5/8% senior subordinated notes, net of premiums	(273,941		)	—			—			—			(273,941		)
Borrowings of other debt	5,496			—			—			—			5,496
Principal payments on other debt	(4,326		)	(650		)	(870		)	—			(5,846		)
Debt issuance costs	(18,556		)	—			—			—			(18,556		)
Repayments of bank overdrafts	(4,174		)	—			—			—			(4,174		)
Equity investment by Holdings	169			—			—			—			169
Dividends paid to Holdings	(204,561		)	—			—			—			(204,561		)
Intercompany debt reallocation	38,082			(37,564		)	(518		)	—			—
Distributions to non-controlling interests	—			—			(3,507		)	—			(3,507		)
Net cash used in financing activities	(82,069		)	(38,214		)	(4,895		)	—			(125,178		)
Net increase (decrease) in cash and cash equivalents	8,819			(2,987		)	16			—			5,848
Cash and cash equivalents at beginning of period	149			3,567			649			—			4,365
Cash and cash equivalents at end of period	$	8,968		$	580		$	665		$	—		$	10,213

(a)  Elimination of equity in earnings of consolidated subsidiaries.

XML

Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net operating revenues	$ 713,669	$ 694,131	$ 2,207,883	$ 2,086,066
Costs and expenses:
Cost of services	598,984	581,829	1,823,272	1,708,911
General and administrative	17,130	14,975	49,908	47,656
Bad debt expense	11,199	11,709	31,603	40,002
Depreciation and amortization	15,537	17,545	47,164	52,766
Total costs and expenses	642,850	626,058	1,951,947	1,849,335
Income from operations	70,819	68,073	255,936	236,731
Other income and expense:
Loss on early retirement of debt	(6,064)		(6,064)	(31,018)
Equity in earnings of unconsolidated subsidiaries	1,167	1,653	6,384	1,329
Interest income		119		286
Interest expense	(24,575)	(24,134)	(72,295)	(75,094)
Income before income taxes	41,347	45,711	183,961	132,234
Income tax expense	16,189	19,330	71,415	56,809
Net income	25,158	26,381	112,546	75,425
Less: Net income attributable to non-controlling interests	1,048	785	3,722	4,438
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	24,110	25,596	108,824	70,987
Income per common share:
Basic (in dollars per share)	$ 0.17	$ 0.17	$ 0.77	$ 0.46
Diluted (in dollars per share)	$ 0.17	$ 0.17	$ 0.77	$ 0.46
Select
Net operating revenues	713,669	694,131	2,207,883	2,086,066
Costs and expenses:
Cost of services	598,984	581,829	1,823,272	1,708,911
General and administrative	17,130	14,975	49,908	47,656
Bad debt expense	11,199	11,709	31,603	40,002
Depreciation and amortization	15,537	17,545	47,164	52,766
Total costs and expenses	642,850	626,058	1,951,947	1,849,335
Income from operations	70,819	68,073	255,936	236,731
Other income and expense:
Loss on early retirement of debt	(6,064)		(6,064)	(20,385)
Equity in earnings of unconsolidated subsidiaries	1,167	1,653	6,384	1,329
Interest income		119		286
Interest expense	(21,740)	(21,526)	(63,947)	(59,882)
Income before income taxes	44,182	48,319	192,309	158,079
Income tax expense	17,181	20,243	74,337	65,854
Net income	27,001	28,076	117,972	92,225
Less: Net income attributable to non-controlling interests	1,048	785	3,722	4,438
Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$ 25,953	$ 27,291	$ 114,250	$ 87,787

XML

Indebtedness

9 Months Ended

Sep. 30, 2012

Indebtedness

Indebtedness

5. Indebtedness

The components of long-term debt and notes payable are shown in the following tables:

	Holdings				Select
	December 31, 2011		September 30, 2012		December 31, 2011		September 30, 2012
	(in thousands)				(in thousands)
7 5/8 % senior subordinated notes	$	345,000	$	70,000	$	345,000	$	70,000
Senior secured credit facilities:
Revolving loan	40,000		—		40,000		—
Term loans (1)	837,974		1,098,784		837,974		1,098,784
Senior floating rate notes	167,300		167,300		—		—
Other debt	6,524		5,549		6,524		5,549
Total debt	1,396,798		1,341,633		1,229,498		1,174,333
Less: current maturities	10,848		11,084		10,848		11,084
Total long-term debt	$	1,385,950	$	1,330,549	$	1,218,650	$	1,163,249

(1)Includes unamortized discount of $7.8 million and $14.9 million at December 31, 2011 and September 30, 2012, respectively.

On August 13, 2012, Select, Holdings and the subsidiaries of Select named therein entered into an Additional Credit Extension Amendment (the “Extension Amendment”) to Select’s senior secured credit facility with a group of lenders and JPMorgan Chase Bank, N.A. as administrative agent.  Pursuant to the terms and conditions of the Extension Amendment, the lenders extended Series A Tranche B Term Loans in the aggregate principal amount of $275.0 million to Select at the same interest rate and with the same term as applies to other Tranche B Term Loan amounts borrowed by Select under the senior secured credit facility.  On September 12, 2012, Select used the proceeds of the Series A Tranche B Term Loans (other than amounts used for fees and expenses) and cash on hand to redeem an aggregate of $275.0 million principal amount of Select’s outstanding 7 5/8% senior subordinated notes due 2015 at a redemption price of 101.271% of the principal amount.  Select recognized a loss on early retirement of debt of $6.1 million for the three and nine months ended September 30, 2012 in connection with the redemption of the senior subordinated notes, which included the write-off of unamortized deferred financing costs and call premiums.

Maturities of Long-Term Debt and Notes Payable

Maturities of the Company’s long-term debt for the period from October 1, 2012 through December 31, 2012 and the years after 2012 are approximately as follows and are presented net of the discount on the senior secured credit facilities’ term loans:

	Holdings		Select
	(in thousands)		(in thousands)
October 1, 2012 – December 31, 2012	$	4,173	$	4,173
2013	9,652		9,652
2014	9,136		9,136
2015	246,345		79,045
2016	8,684		8,684
2017 and beyond	1,063,643		1,063,643

XML

Restructuring Reserves

9 Months Ended

Sep. 30, 2012

Restructuring Reserves

Restructuring Reserves

4.  Restructuring Reserves

In connection with the acquisition of substantially all of the outpatient rehabilitation division of HealthSouth Corporation, the Company recorded an estimated liability of $18.7 million in 2007 for business restructuring which was accounted for as additional purchase price. This reserve primarily included costs associated with workforce reductions and lease termination costs in accordance with the Company’s restructuring plan of which only lease termination costs remain.

In connection with the acquisition of all the issued and outstanding equity securities of Regency Hospital Company, L.L.C. (“Regency”), an operator of long term acute care hospitals, the Company recorded an estimated liability of $4.3 million in 2010 for business restructuring related to lease termination costs.

The following summarizes the Company’s restructuring activity:

	Lease Termination Costs
	(in thousands)
Balance as of December 31, 2011	$	5,027
Amounts paid in 2012	(1,169		)
Accretion expense	202
Revision of estimate	(2,045		)
Balance as of September 30, 2012	$	2,015

The Company expects to pay out the remaining lease termination costs through 2014 for the acquisition of the outpatient rehabilitation division of HealthSouth Corporation and through 2015 for the Regency acquisition.

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2012

Segment Information

Schedule of selected financial data for the Company's reportable segments

	Three Months Ended September 30, 2011
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	521,085	$	173,030	$	16		$	694,131
Adjusted EBITDA	81,570		19,435		(14,469		)	86,536
Total assets:
Select Medical Corporation	2,191,493		468,551		89,568			2,749,612
Select Medical Holdings Corporation	2,191,493		468,551		91,066			2,751,110
Capital expenditures	4,957		3,160		281			8,398

	Three Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	531,409	$	182,246	$	14		$	713,669
Adjusted EBITDA	83,659		20,354		(16,266		)	87,747
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	12,281		3,073		1,900			17,254

	Nine Months Ended September 30, 2011
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	1,561,270	$	524,694	$	102		$	2,086,066
Adjusted EBITDA	273,004		65,308		(46,117		)	292,195
Total assets:
Select Medical Corporation	2,191,493		468,551		89,568			2,749,612
Select Medical Holdings Corporation	2,191,493		468,551		91,066			2,751,110
Capital expenditures	21,574		8,142		2,378			32,094

	Nine Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	1,641,577	$	566,195	$	111		$	2,207,883
Adjusted EBITDA	285,779		68,669		(47,358		)	307,090
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	31,963		9,786		3,439			45,188

Schedule of reconciliation of Adjusted EBITDA to income before income taxes

	Three Months Ended September 30, 2011
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	81,570		$	19,435		$	(14,469	)
Depreciation and amortization	(12,828		)	(4,003		)	(714		)
Stock compensation expense	—			—			(918		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	68,742		$	15,432		$	(16,101	)	$	68,073		$	68,073
Equity in earnings of unconsolidated subsidiaries										1,653			1,653
Interest expense, net										(24,015		)	(21,407		)
Income before income taxes										$	45,711		$	48,319

	Three Months Ended September 30, 2012
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	83,659		$	20,354		$	(16,266	)
Depreciation and amortization	(11,553		)	(3,152		)	(832		)
Stock compensation expense	—			—			(1,391		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	72,106		$	17,202		$	(18,489	)	$	70,819		$	70,819
Loss on early retirement of debt										(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries										1,167			1,167
Interest expense, net										(24,575		)	(21,740		)
Income before income taxes										$	41,347		$	44,182

	Nine Months Ended September 30, 2011
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	273,004		$	65,308		$	(46,117	)
Depreciation and amortization	(37,921		)	(12,689		)	(2,156		)
Stock compensation expense	—			—			(2,698		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	235,083		$	52,619		$	(50,971	)	$	236,731		$	236,731
Loss on early retirement of debt										(31,018		)	(20,385		)
Equity in earnings of unconsolidated subsidiaries										1,329			1,329
Interest expense, net										(74,808		)	(59,596		)
Income before income taxes										$	132,234		$	158,079

	Nine Months Ended September 30, 2012
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	285,779		$	68,669		$	(47,358	)
Depreciation and amortization	(34,875		)	(10,034		)	(2,255		)
Stock compensation expense	—			—			(3,990		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	250,904		$	58,635		$	(53,603	)	$	255,936		$	255,936
Loss on early retirement of debt										(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries										6,384			6,384
Interest expense, net										(72,295		)	(63,947		)
Income before income taxes										$	183,961		$	192,309

XML

Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2012

Accounting Policies

Use of Estimates

Use of Estimates

        The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2012-02, “Intangibles — Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment,” (“Update 2012-02”). In accordance with Update 2012-02, an entity has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. If the entity determines that it is more likely than not that the fair value of the indefinite-lived intangible asset is less than the carrying value, the entity will be required to perform the quantitative impairment test. Update 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. However, early adoption is permitted. Update 2012-02 will not have a material impact on the Company’s consolidated financial statements.

In June 2011, the FASB issued ASU 2011-05, “Comprehensive Income (Topic 220) — Presentation of Comprehensive Income” (“Update 2011-05”) that improves the comparability, consistency and transparency of financial reporting and increases the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders’ equity. Update 2011-05 requires that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. Under either method, adjustments must be displayed for items that are reclassified from other comprehensive income (“OCI”) to net income, in both net income and OCI. Update 2011-05 does not change the current option for presenting components of OCI gross or net of the effect of income taxes, provided that such tax effects are presented in the statement in which OCI is presented or disclosed in the notes to the financial statements. Additionally, Update 2011-05 does not affect the calculation or reporting of earnings per share. Update 2011-05 was effective for fiscal years, and interim periods within those years, beginning after December 15, 2011 and is to be applied retrospectively. The Company adopted Update 2011-05 on January 1, 2012.  Update 2011-05 had no effect on the Company’s presentation of other comprehensive income for the three and nine months ended September 30, 2011 and 2012 because the Company did not have any items of other comprehensive income during these periods.

XML

Income per Common Share

9 Months Ended

Sep. 30, 2012

Income per Common Share

Income per Common Share

8.  Income per Common Share

The Company applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings. Effective January 1, 2009 the Financial Accounting Standards Board (“FASB”) clarified that share based payment awards that have not yet vested meet the definition of a participating security provided the right to receive the dividend is non-forfeitable and non-contingent. Participating securities are defined as securities that participate in dividends with common stock according to a predetermined formula. These participating securities should be included in the computation of basic earnings per share under the two class method. Based upon the clarification made by FASB, the Company concluded that its non-vested restricted stock awards meet the definition of a participating security and should be included in the Company’s computation of basic earnings per share.

The following table sets forth for the periods indicated the calculation of net income per share in the Company’s consolidated statement of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted earnings per share, respectively:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2011		2012		2011		2012
	(in thousands, except per share data)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	25,596	$	24,110	$	70,987	$	108,824
Less: Earnings allocated to unvested restricted stockholders	278		407		763		1,759
Net income available to common stockholders	$	25,318	$	23,703	$	70,224	$	107,065
Denominator:
Weighted average shares — basic	151,470		137,551		152,299		139,138
Effect of dilutive securities:
Stock options	206		337		223		266
Weighted average shares — diluted	151,676		137,888		152,522		139,404
Basic income per common share	$	0.17	$	0.17	$	0.46	$	0.77
Diluted income per common share	$	0.17	$	0.17	$	0.46	$	0.77

The following share amounts are shown here for informational and comparative purposes only since their inclusion would be anti-dilutive:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2011	2012	2011	2012
	(in thousands)
Stock options	2,437	78	2,412	1,683

XML

Fair Value

9 Months Ended

Sep. 30, 2012

Fair Value

Fair Value

6.  Fair Value

Financial instruments include cash and cash equivalents, notes payable and long-term debt.  The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.

The carrying value of Select’s senior secured credit facility was $878.0 million and $1,098.8 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of Select’s senior secured credit facility was $823.3 million and $1,104.3 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of Select’s senior secured credit facility was based on quoted market prices for this debt in the syndicated loan market.

The carrying value of Select’s 7 5/8% senior subordinated notes was $345.0 million and $70.0 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of Select’s 7 5/8% senior subordinated notes was $326.4 million and $70.9 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of this registered debt was based on quoted market prices.

The carrying value of Holdings’ senior floating rate notes was $167.3 million at both December 31, 2011 and September 30, 2012.  The fair value of Holdings’ senior floating rate notes was $143.9 million and $167.3 million at December 31, 2011 and September 30, 2012, respectively.  The fair value of this registered debt was based on quoted market prices.

The Company considers the inputs in the valuation process of its debt instruments to be Level 2 in the fair value hierarchy.  Level 2 in the fair value hierarchy is defined as inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.  These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

XML

Segment Information

9 Months Ended

Sep. 30, 2012

Segment Information

Segment Information

7.  Segment Information

The Company’s reportable segments consist of (i) specialty hospitals and (ii) outpatient rehabilitation. All other represents amounts associated with corporate activities and non-healthcare related services. The outpatient rehabilitation reportable segment has two operating segments: outpatient rehabilitation clinics and contract therapy. These operating segments are aggregated for reporting purposes as they have common economic characteristics and provide a similar service to a similar patient base. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, equity in earnings (losses) of unconsolidated subsidiaries and other income (expense).

The following tables summarize selected financial data for the Company’s reportable segments for the three and nine months ended September 30, 2011 and 2012.  The segment results of Holdings are identical to those of Select with the exception of total assets:

	Three Months Ended September 30, 2011
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	521,085	$	173,030	$	16		$	694,131
Adjusted EBITDA	81,570		19,435		(14,469		)	86,536
Total assets:
Select Medical Corporation	2,191,493		468,551		89,568			2,749,612
Select Medical Holdings Corporation	2,191,493		468,551		91,066			2,751,110
Capital expenditures	4,957		3,160		281			8,398

	Three Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	531,409	$	182,246	$	14		$	713,669
Adjusted EBITDA	83,659		20,354		(16,266		)	87,747
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	12,281		3,073		1,900			17,254

	Nine Months Ended September 30, 2011
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	1,561,270	$	524,694	$	102		$	2,086,066
Adjusted EBITDA	273,004		65,308		(46,117		)	292,195
Total assets:
Select Medical Corporation	2,191,493		468,551		89,568			2,749,612
Select Medical Holdings Corporation	2,191,493		468,551		91,066			2,751,110
Capital expenditures	21,574		8,142		2,378			32,094

	Nine Months Ended September 30, 2012
	Specialty Hospitals		Outpatient Rehabilitation		All Other			Total
	(in thousands)
Net operating revenue	$	1,641,577	$	566,195	$	111		$	2,207,883
Adjusted EBITDA	285,779		68,669		(47,358		)	307,090
Total assets:
Select Medical Corporation	2,165,248		431,310		184,120			2,780,678
Select Medical Holdings Corporation	2,165,248		431,310		185,250			2,781,808
Capital expenditures	31,963		9,786		3,439			45,188

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended September 30, 2011
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	81,570		$	19,435		$	(14,469	)
Depreciation and amortization	(12,828		)	(4,003		)	(714		)
Stock compensation expense	—			—			(918		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	68,742		$	15,432		$	(16,101	)	$	68,073		$	68,073
Equity in earnings of unconsolidated subsidiaries										1,653			1,653
Interest expense, net										(24,015		)	(21,407		)
Income before income taxes										$	45,711		$	48,319

	Three Months Ended September 30, 2012
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	83,659		$	20,354		$	(16,266	)
Depreciation and amortization	(11,553		)	(3,152		)	(832		)
Stock compensation expense	—			—			(1,391		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	72,106		$	17,202		$	(18,489	)	$	70,819		$	70,819
Loss on early retirement of debt										(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries										1,167			1,167
Interest expense, net										(24,575		)	(21,740		)
Income before income taxes										$	41,347		$	44,182

	Nine Months Ended September 30, 2011
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	273,004		$	65,308		$	(46,117	)
Depreciation and amortization	(37,921		)	(12,689		)	(2,156		)
Stock compensation expense	—			—			(2,698		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	235,083		$	52,619		$	(50,971	)	$	236,731		$	236,731
Loss on early retirement of debt										(31,018		)	(20,385		)
Equity in earnings of unconsolidated subsidiaries										1,329			1,329
Interest expense, net										(74,808		)	(59,596		)
Income before income taxes										$	132,234		$	158,079

	Nine Months Ended September 30, 2012
	(in thousands)
	Specialty Hospitals			Outpatient Rehabilitation			All Other
Adjusted EBITDA	$	285,779		$	68,669		$	(47,358	)
Depreciation and amortization	(34,875		)	(10,034		)	(2,255		)
Stock compensation expense	—			—			(3,990		)
										Select Medical Holdings Corporation			Select Medical Corporation
Income (loss) from operations	$	250,904		$	58,635		$	(53,603	)	$	255,936		$	255,936
Loss on early retirement of debt										(6,064		)	(6,064		)
Equity in earnings of unconsolidated subsidiaries										6,384			6,384
Interest expense, net										(72,295		)	(63,947		)
Income before income taxes										$	183,961		$	192,309

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies

Commitments and Contingencies

9. Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”) or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations and liquidity.

To address claims arising out of the operations of the Company’s specialty hospitals and outpatient rehabilitation facilities, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

During April 2012, the Company’s long term acute care hospital in Evansville, Indiana (“SSH - Evansville”) received two subpoenas from the Office of Attorney General for the State of Indiana. One subpoena demanded certain patient medical records of SSH - Evansville. The second subpoena demanded reports and documents related to SSH - Evansville for various periods beginning in 2006, including certain financial, statistical, billing and quality reports; certain policies and procedures, joint venture board meeting minutes, and documents related to certain complaints and internal investigations. SSH — Evansville subsequently received a Request for Information or Assistance from the Office of Inspector General of the U.S. Department of Health and Human Services (Indianapolis, Indiana Field Office) covering the period beginning in 2007 seeking substantially the same records demanded by the Indiana Attorney General’s Office, additional patient medical records of SSH - Evansville and additional documents and information of SSH - Evansville, including documents concerning SSH - Evansville’s relationships with its joint venture partner and seven other identified persons and entities. During May 2012, the Evansville (Indiana) Police Department executed a search warrant at SSH - Evansville purporting to seek evidence pertaining to the crime of theft. At the Company’s request, the Vanderburgh (Indiana) Superior Court ordered the release of the probable cause affidavit supporting that search warrant. According to the affidavit, confidential informants, some of whom are purportedly current or former employees of SSH-Evansville, alleged, among other things, that a physician on the medical staff at SSH-Evansville improperly manipulated patient diagnoses to raise the diagnosis related group (DRG) and lengths-of-stay to enhance reimbursement and, on one occasion, discontinued treatments to a patient based on financial motivation and without regard to the patient’s end of life instructions resulting in the patient’s death, and that a second physician on the medical staff at SSH-Evansville performed bronchoscopes that were medically unnecessary and resulted in at least two patient deaths. The affidavit also makes allegations that imply that the Company may not have provided complete or accurate documents called for in the Indiana Attorney General’s Office subpoenas which were received during April 2012. In August 2012, the Company received a subpoena from the Office of Inspector General of the U.S. Department of Health and Human Services (Chicago Regional Office) (“OIG — Chicago”) demanding additional documents covering the period beginning in March 2007 relating to the Company and SSH — Evansville, including contracts with SSH — Evansville’s joint venture partner, contracts and other documents relating to financial relationships with physicians practicing at SSH —Evansville, records of payments to and hours worked by physicians practicing at SSH — Evansville, documents relating to actual or expected physician referrals and admissions to SSH — Evansville, documents relating to billing for services furnished by the Company’s long term acute care hospitals (“LTCHs”), such as government program guidance and staff training materials, information relating to case manager duties and responsibilities at the Company’s LTCHs, reports on patient admissions, discharges, DRG, length-of-stay and transfers at SSH — Evansville, and documents relating to criteria used by the Company or SSH — Evansville for patient admissions, discharges and eligibility for service. In October 2012, the Company received an additional subpoena from OIG — Chicago seeking the medical records of 19 patients treated at SSH — Evansville between 2008 and 2012.  The Company has produced and will continue to produce documents in response to, and intends to fully cooperate with, these governmental investigations. At this time, the Company is unable to predict the timing and outcome of this matter.

Construction Commitments

At September 30, 2012, the Company had outstanding commitments under construction contracts related to new construction, improvements and renovations at the Company’s long term acute care properties and inpatient rehabilitation facilities totaling approximately $10.8 million.

XML

Income per Common Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Numerator:
Net income attributable to Select Medical Holdings Corporation (in dollars)	$ 24,110	$ 25,596	$ 108,824	$ 70,987
Less: Earnings allocated to unvested restricted stockholders (in dollars)	407	278	1,759	763
Net income available to common stockholders (in dollars)	$ 23,703	$ 25,318	$ 107,065	$ 70,224
Denominator:
Weighted average shares - basic	137,551	151,470	139,138	152,299
Effect of dilutive securities: Stock options (in shares)	337	206	266	223
Weighted average shares - diluted	137,888	151,676	139,404	152,522
Income per common share
Basic income per common share (in dollars per share)	$ 0.17	$ 0.17	$ 0.77	$ 0.46
Diluted income per common share (in dollars per share)	$ 0.17	$ 0.17	$ 0.77	$ 0.46
Anti-dilutive securities excluded from computation of earnings per share
Stock options (in shares)	78	2,437	1,683	2,412

XML

Restructuring Reserves (Tables)

9 Months Ended

Sep. 30, 2012

Restructuring Reserves

Schedule of Company's restructuring activity

	Lease Termination Costs
	(in thousands)
Balance as of December 31, 2011	$	5,027
Amounts paid in 2012	(1,169		)
Accretion expense	202
Revision of estimate	(2,045		)
Balance as of September 30, 2012	$	2,015

XML

Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified			9 Months Ended		9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012 Trademarks	Sep. 30, 2012 Certificates of need	Sep. 30, 2012 Accreditations	Sep. 30, 2012 Non-compete agreements
Amortized intangible assets:
Gross Carrying Amount						$ 25,909
Accumulated Amortization						(25,909)
Indefinite-lived intangible assets:
Gross Carrying Amount of Goodwill	1,633,106	1,631,716
Gross Carrying Amount	$ 1,704,889		$ 57,709	$ 11,914	$ 2,160
Weighted average time until next renewal			7 years 8 months 12 days		1 year 6 months

XML

Consolidated Statement of Changes in Equity and Income (USD $) In Thousands, unless otherwise specified	Total	Common Stock	Capital in Excess of Par	Retained Earnings	Non-controlling Interests	Select	Select Common Stock	Select Capital in Excess of Par	Select Retained Earnings	Select Non-controlling Interests
Balance at Dec. 31, 2011	$ 855,326	$ 145	$ 493,828	$ 328,882	$ 32,471	$ 1,019,093	$ 0	$ 848,844	$ 137,778	$ 32,471
Balance (in shares) at Dec. 31, 2011		145,268					0
Increase (Decrease) in Stockholders' Equity
Net income	112,546			108,824	3,722	117,972			114,250	3,722
Issuance and vesting of restricted stock	3,085	0	3,085
Issuance and vesting of restricted stock (in shares)		232
Exercise of stock options	1,104	0	1,104
Exercise of stock options (in shares)		217
Stock option expense	905		905
Repurchase of common shares	(46,790)	(5)	(27,150)	(19,635)
Repurchase of common shares (in shares)		(5,726)
Federal tax benefit of losses contributed by Holdings						2,922		2,922
Additional investment by Holdings						1,104		1,104
Net change in dividends payable to Holdings						5,240			5,240
Dividends declared and paid to Holdings						(57,467)			(57,467)
Distributions to non-controlling interests	(2,997)				(2,997)	(2,997)				(2,997)
Purchase of non-controlling interests	(477)		(414)		(63)	(477)		(414)		(63)
Other	16				16	16				16
Contribution related to restricted stock awards and stock option issuances by Holdings						3,990		3,990
Balance at Sep. 30, 2012	922,718	140	471,358	418,071	33,149	1,089,396	0	856,446	199,801	33,149
Balance (in shares) at Sep. 30, 2012		139,991					0
Balance at Jun. 30, 2012
Increase (Decrease) in Stockholders' Equity
Net income	25,158					27,001
Balance at Sep. 30, 2012	$ 922,718					$ 1,089,396	$ 0
Balance (in shares) at Sep. 30, 2012							0

XML

Intangible Assets

9 Months Ended

Sep. 30, 2012

Intangible Assets

Intangible Assets

3.  Intangible Assets

The Company’s intangible assets consist of the following:

	As of September 30, 2012
	Gross Carrying Amount		Accumulated Amortization
	(in thousands)
Amortized intangible assets:
Non-compete agreements	$	25,909	$	(25,909	)
Indefinite-lived intangible assets:
Goodwill	$	1,633,106
Trademarks	57,709
Certificates of need	11,914
Accreditations	2,160
Total	$	1,704,889

The Company’s accreditations and trademarks have renewal terms. The costs to renew these intangibles are expensed as incurred. At September 30, 2012, the accreditations and trademarks have a weighted average time until next renewal of approximately 1.5 years and 7.7 years, respectively.

Amortization expense for the Company’s intangible assets with finite lives follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2011		2012		2011		2012
	(in thousands)				(in thousands)
Amortization expense	$	328	$	—	$	981	$	340

Amortization expense for the Company’s intangible assets primarily relates to the amortization of the value associated with the non-compete agreement entered into in connection with the acquisition of the outpatient rehabilitation division of HealthSouth Corporation. The useful life of the outpatient rehabilitation division of HealthSouth Corporation’s non-compete was five years.

The changes in the carrying amount of goodwill for the Company’s reportable segments for the nine months ended September 30, 2012 are as follows:

	Specialty Hospitals			Outpatient Rehabilitation		Total
	(in thousands)
Balance as of December 31, 2011	$	1,333,553		$	298,163	$	1,631,716
Goodwill acquired during the period	—			1,723		1,723
Other	(333		)	—		(333		)
Balance as of September 30, 2012	$	1,333,220		$	299,886	$	1,633,106

XML

Intangible Assets (Details 2) (Non-compete agreements, Outpatient rehabilitation division of HealthSouth Corporation, USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Non-compete agreements | Outpatient rehabilitation division of HealthSouth Corporation
Finite-lived intangible assets
Amortization expense	$ 328	$ 340	$ 981
Useful life		5 years

XML

Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select's 7 5/8% Senior Subordinated Notes (Details 2) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Dec. 31, 2010
Current Assets:
Cash and cash equivalents	$ 49,676	$ 12,043	$ 10,213	$ 4,365
Accounts receivable, net	392,647	413,743
Current deferred tax asset	17,978	18,305
Prepaid income taxes	1,410	9,497
Other current assets	31,620	29,822
Total Current Assets	493,331	483,410
Property and equipment, net	494,625	510,028
Goodwill	1,633,106	1,631,716
Other identifiable intangibles	71,783	72,123
Assets held for sale	2,742	2,742
Other assets	86,221	72,128
Total Assets	2,781,808	2,772,147	2,751,110
Current Liabilities:
Bank overdrafts	13,598	16,609
Current portion of long-term debt and notes payable	11,084	10,848
Accounts payable	91,520	95,618
Intercompany accounts		0
Accrued payroll	83,683	82,888
Accrued vacation	53,210	51,250
Accrued interest	13,921	15,096
Accrued restructuring	2,015	5,027
Accrued other	99,004	101,076
Due to third party payors	5,886	5,526
Total Current Liabilities	373,921	383,938
Long-term debt, net of current portion	1,330,549	1,385,950
Non-current deferred tax liability	84,118	82,028
Other non-current liabilities	70,502	64,905
Total Liabilities	1,859,090	1,916,821
Stockholder's Equity:
Common stock	140	145
Capital in excess of par	471,358	493,828
Retained earnings	418,071	328,882
Subsidiary investment		0
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	889,569	822,855
Non-controlling interest	33,149	32,471
Total Equity	922,718	855,326
Total Liabilities and Equity	2,781,808	2,772,147
Select Medical Corporation
Current Assets:
Cash and cash equivalents	49,676	12,043	10,213	4,365
Accounts receivable, net	392,647	413,743
Current deferred tax asset	17,978	18,305
Prepaid income taxes	1,410	9,497
Other current assets	31,620	29,822
Total Current Assets	493,331	483,410
Property and equipment, net	494,625	510,028
Goodwill	1,633,106	1,631,716
Other identifiable intangibles	71,783	72,123
Assets held for sale	2,742	2,742
Other assets	85,091	70,719
Total Assets	2,780,678	2,770,738	2,749,612
Current Liabilities:
Bank overdrafts	13,598	16,609
Current portion of long-term debt and notes payable	11,084	10,848
Accounts payable	91,520	95,618
Accrued payroll	83,683	82,888
Accrued vacation	53,210	51,250
Accrued interest	13,413	11,980
Accrued restructuring	2,015	5,027
Accrued other	99,004	106,316
Due to third party payors	5,886	5,526
Total Current Liabilities	373,413	386,062
Long-term debt, net of current portion	1,163,249	1,218,650
Non-current deferred tax liability	84,118	82,028
Other non-current liabilities	70,502	64,905
Total Liabilities	1,691,282	1,751,645
Stockholder's Equity:
Common stock	0
Capital in excess of par	856,446	848,844
Retained earnings	199,801	137,778
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	1,056,247	986,622
Non-controlling interest	33,149	32,471
Total Equity	1,089,396	1,019,093
Total Liabilities and Equity	2,780,678	2,770,738
Select Medical Corporation | Select Medical Corporation (Parent Company Only)
Current Assets:
Cash and cash equivalents	45,069	11,427	8,968	149
Current deferred tax asset	11,673	11,415
Prepaid income taxes	1,410	9,497
Other current assets	5,158	6,340
Total Current Assets	63,310	38,679
Property and equipment, net	15,823	14,641
Investment in affiliates	2,889,285	2,751,776
Assets held for sale	2,742	2,742
Other assets	24,898	28,386
Total Assets	2,996,058	2,836,224
Current Liabilities:
Bank overdrafts	13,598	16,609
Current portion of long-term debt and notes payable	9,062	8,853
Accounts payable	7,771	7,353
Intercompany accounts	1,058,973	975,809
Accrued payroll	72	229
Accrued vacation	4,120	3,703
Accrued interest	12,504	11,843
Accrued other	50,778	47,829
Total Current Liabilities	1,156,878	1,072,228
Long-term debt, net of current portion	736,945	733,328
Non-current deferred tax liability	(4,715)	(2,509)
Other non-current liabilities	50,703	46,555
Total Liabilities	1,939,811	1,849,602
Stockholder's Equity:
Capital in excess of par	856,446	848,844
Retained earnings	199,801	137,778
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	1,056,247	986,622
Total Equity	1,056,247	986,622
Total Liabilities and Equity	2,996,058	2,836,224
Select Medical Corporation | Subsidiary Guarantors
Current Assets:
Cash and cash equivalents	3,535		580	3,567
Accounts receivable, net	334,826	369,321
Current deferred tax asset	2,698	3,221
Other current assets	21,497	19,407
Total Current Assets	362,556	391,949
Property and equipment, net	421,493	440,736
Investment in affiliates	80,859	83,772
Goodwill	1,633,106	1,631,716
Other identifiable intangibles	71,783	72,123
Other assets	59,482	41,480
Total Assets	2,629,279	2,661,776
Current Liabilities:
Current portion of long-term debt and notes payable	585	390
Accounts payable	70,365	76,207
Intercompany accounts	(963,967)	(880,537)
Accrued payroll	83,293	82,518
Accrued vacation	42,565	41,305
Accrued interest	909	137
Accrued restructuring	2,015	5,027
Accrued other	40,287	51,086
Due to third party payors	2,705	13,633
Total Current Liabilities	(721,243)	(610,234)
Long-term debt, net of current portion	364,287	425,315
Non-current deferred tax liability	80,258	75,750
Other non-current liabilities	19,546	17,970
Total Liabilities	(257,152)	(91,199)
Stockholder's Equity:
Retained earnings	752,267	627,120
Subsidiary investment	2,134,164	2,125,855
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	2,886,431	2,752,975
Total Equity	2,886,431	2,752,975
Total Liabilities and Equity	2,629,279	2,661,776
Select Medical Corporation | Non-Guarantor Subsidiaries
Current Assets:
Cash and cash equivalents	1,072	616	665	649
Accounts receivable, net	57,821	44,422
Current deferred tax asset	3,607	3,669
Other current assets	4,965	4,075
Total Current Assets	67,465	52,782
Property and equipment, net	57,309	54,651
Other assets	711	853
Total Assets	125,485	108,286
Current Liabilities:
Current portion of long-term debt and notes payable	1,437	1,605
Accounts payable	13,384	12,058
Intercompany accounts	(95,006)	(95,272)
Accrued payroll	318	141
Accrued vacation	6,525	6,242
Accrued other	7,939	7,401
Due to third party payors	3,181	(8,107)
Total Current Liabilities	(62,222)	(75,932)
Long-term debt, net of current portion	62,017	60,007
Non-current deferred tax liability	8,575	8,787
Other non-current liabilities	253	380
Total Liabilities	8,623	(6,758)
Stockholder's Equity:
Retained earnings	24,428	23,154
Subsidiary investment	59,285	59,419
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	83,713	82,573
Non-controlling interest	33,149	32,471
Total Equity	116,862	115,044
Total Liabilities and Equity	125,485	108,286
Select Medical Corporation | Eliminations
Current Assets:
Investment in affiliates	(2,970,144)	(2,835,548)
Total Assets	(2,970,144)	(2,835,548)
Stockholder's Equity:
Retained earnings	(776,695)	(650,274)
Subsidiary investment	(2,193,449)	(2,185,274)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders' Equity	(2,970,144)	(2,835,548)
Total Equity	(2,970,144)	(2,835,548)
Total Liabilities and Equity	$ (2,970,144)	$ (2,835,548)

XML

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2012

Intangible Assets

Schedule of intangible assets

	As of September 30, 2012
	Gross Carrying Amount		Accumulated Amortization
	(in thousands)
Amortized intangible assets:
Non-compete agreements	$	25,909	$	(25,909	)
Indefinite-lived intangible assets:
Goodwill	$	1,633,106
Trademarks	57,709
Certificates of need	11,914
Accreditations	2,160
Total	$	1,704,889

Schedule of amortization expenses for the Company's intangible assets with finite lives

	Three Months Ended September 30,				Nine Months Ended September 30,
	2011		2012		2011		2012
	(in thousands)				(in thousands)
Amortization expense	$	328	$	—	$	981	$	340

Schedule of changes in the carrying amount of goodwill for the company's reportable segments

	Specialty Hospitals			Outpatient Rehabilitation		Total
	(in thousands)
Balance as of December 31, 2011	$	1,333,553		$	298,163	$	1,631,716
Goodwill acquired during the period	—			1,723		1,723
Other	(333		)	—		(333		)
Balance as of September 30, 2012	$	1,333,220		$	299,886	$	1,633,106